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 INFLAMMATION AND CANCER 
 
In the 19th century, for the first time Rudolf Virchow hypothesized the existence of a causal 
link between inflammation and cancer1. This idea came up when he observed that tumor 
biopsies were highly infiltrated by leukocytes and that sites of chronic inflammation frequently 
represented the setting of tumor growth and development2.  
Virchow’s hypothesis was neglected until the last decades, when the growing number of 
experimental, epidemiological and clinical evidence has demonstrated that inflammation fuels 
tumor onset, growth, and progression. Consistently, the chronic use of non-steroidal anti-
inflammatory drugs (NSAIDs, e.g. aspirin), reduces incidence and mortality of many cancers3,4 
and  inhibition of specific inflammatory cytokines, such as interleukin 1β (IL-1β), significantly 
lowers the risk of lung cancer development, as demonstrated by the Canakinumab Anti-
inflammatory Thrombosis Outcomes Study (CANTOS)5. 
The existence of a functional link between inflammation and cancer is widely recognized, 
however, the molecular mechanisms underlying the tumor promoting functions of inflammation 
are still largely unknown. Therefore, dissecting these mechanisms, represents a fundamental 
step towards the development of new strategies for cancer prevention and treatment6. 
Tissue damages, due to physical or ischemic injury, exposure to toxins, exogenous or 
endogenous infections, trigger the inflammatory process, which involves a well-coordinated 
reaction of the innate and adaptive immune system, that promotes damage repair allowing for 
full or at least partial reconstitution of tissue integrity and functions7. The first line of defense 
is represented by the innate immune cells, including neutrophils, macrophages, mast cells, 
dendritic cells and natural killer cells, that initiate the inflammatory response by releasing 
cytokines, chemokines, matrix-remodeling proteases and reactive oxygen and nitrogen 
species2,6. Acute inflammation is usually a self-limiting process, whereas, chronic 
inflammation, due to a failure of mechanisms required for resolving the inflammatory response, 
generates a permissive microenvironment that facilitates and contributes to cancer development 
and progression1. 
Although in established tumors inflammation and cancer are two coexisting processes, in the 
initial phases of tumor onset, the link between inflammation and cancer can emerge through the 
contribution of two different pathways: the intrinsic pathway, driven by genetic alterations that 
lead to both neoplastic transformation and inflammation, and the extrinsic pathway is triggered 
by infection or irritant agents that initially cause chronic inflammation, and subsequently  
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neoplastic transformation6. Both pathways, converge and promote the activation of 
transcription factors, principally nuclear factor-κB (NF-κB), signal transducer of transcription 
(STAT3) and hypoxia-inducible factor (HIF1α), that induce the expression of genes encoding 
cytokines, chemokines, anti-apoptotic molecules and cyclins, promoting inflammation as well 
as survival and proliferation of neoplastic cells2 (Fig.1).  
 
 
Figure 1. The Extrinsic and Intrinsic Pathways drive the inflammatory process8. There are two pathways correlated with 
inflammation and cancer: the extrinsic and intrinsic pathways. The first one is related to genetic events (e.g. oncogenes), 
whereas the second one, the chronic inflammation is due to infections or irritants. Both pathways converge in a single way, 




1.1.1.1 The Intrinsic Pathways of cancer-related Inflammation. 
Genetic alterations of different tumor-suppressor genes (e.g. p53, VHL, TGFβ, Apc) and 
oncogenes (e.g. RET, RAS and MYC) have been found associated with both neoplastic 
transformation and the activation of the inflammatory response9.  
For example, p53 is the most important tumor suppressors factor, that in response to various 
cellular stresses, (e.g. DNA damage, hypoxia, and nutrient deprivation) and modulates the 
expression of genes regulating the cell cycle, apoptosis, and DNA repair10–12. Additionally, p53 
acts as an antagonist for the nuclear factor-kB (NF-kB)13,14, therefore limiting inflammation, 
guaranteeing cellular homeostasis and avoiding cell transformation. Instead of, in the context 
of chronic inflammation, the constitutive activation of NF-kB induces the production of 
inflammatory cytokines that impair p53 activity, increasing the risk of cancer development15–
17.  
On the other hand, both in vitro and in vivo studies have reported that expression of various p53 
mutants correlated with increased NF-kB expression18–20.  
Different in vitro experiments have reported that, tumor cells harboring mutant p53 promote 
inflammatory responses through different mechanisms, including: enhancement of NF-kB 
transcriptional activity in response to the cytokine Tumor necrosis factor  (TNF-α)20, repression 
of secreted interleukin-1 receptor antagonist (sIL-1Ra)21, promotion of NF-kB-dependent 
chemokines (e.g. CXCL5, CXCL8, and CXCL12)22 and increased of cytokine and chemokine 
expression in response to TLR3 (Toll-like-receptor 3)ligands23. Accordingly, in vivo, in a 
chemical model of colorectal cancer (CRC), loss of p53 in intestinal epithelial cells (IEC) 
results in increased NF-kB-dependent inflammatory microenvironment supporting epithelial-
mesenchymal transition (EMT) and colonic tumor progression24. 
Overall, these studies indicate that p53 mutants heighten the response of tumor cells to 
microenvironmental cues, thereby supporting cancer-related inflammation.  
Moreover, these observations have been confirmed in human premalignant and malignant 
lesions25, (e.g. in head and neck and in non–small cell lung cancers), where in many cases, p53 
mutants correlate with constitutive activation of NF-kB and a reduced apoptosis26.  
In conclusion, loss of tumor suppressor p53 inhibits proper DNA repair and accelerate DNA 
damage, that in turn fuels inflammation27, establishing a feed-forward loop that enhances tumor 
development28,29.  
Moreover, activation of different oncogenes increases the production of many inflammatory 
mediators that support the recruitment of myeloid cells30. For example, K-Ras oncogenic 
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signaling regulates the expression of different cytokines (IL-8, IL-1a and IL-1β) and 
chemokines (e.g. CCL2, CXCL1, CXCL3)31, that drive the accumulation of inflammatory 
cells35 leading to the construction of a chronic and “smoldering” state of inflammation that 
promotes neoangiogenesis and tumor growth32. 
 
1.1.1.2 The extrinsic pathway of cancer-related inflammation. 
It has been estimated that up to 25% of cancers are sustained by chronic inflammation6 and 
infections.  
In fact, different pathogens including virus 
(e.g. human papilloma virus, Hepatitis B 
and C virus), bacteria (Helicobacter 
pylori) and parasites (e.g. Schistosoma 
haematobium Clonorchis sinensis and 
Opisthorchis viverrini) are causally linked 
to cancers, that selectively arise in 
chronically infected organs (Panel 1)33.  
Beyond pathogens, commensal microbial species could exert different pro-tumoral activities. 
Indeed, in different types of cancer, (e.g. colon cancer34, pancreatic cancer 35, hepatocellular 
carcinoma36, lung cancer37,38), it has been reported that commensal microorganisms, by 
translocation through the protective tissue barrier (e.g. intestinal epithelial barrier), adherence 
to cancer cells and release of metabolites, are able to promote inflammation and sustain tumor 
growth. At the same time, when travelling with tumors cells to the distant metastatic sites, they 
participate in the sustenance of the inflammatory process and metastasis diffusion30.  
In CRC, different studies have suggested the pro-tumorigenic role of Fusobacterium, indeed, it 
promotes the initial phase of CRC development producing bacteria-derived virulence factors 
(e.g. FadA, Fap2, RaD), that impair colonic epithelial cell junctions, favoring its translocation, 
and the recruitment and activation of inflammatory cells, building up an inflammatory 
microenvironment, that fosters neoplastic transformation39. Further important pro-tumorigenic 
species enriched in CRC in tumor bearers, are represented by Streptococcus gallolyticus, 
Bacteroides fragilis, Escherichia coli, and Enterococcus faecalis34.  
 In liver cancer, gut microbial components reach the liver via the portal circulation and enhance 
inflammation, fibrosis, and carcinogenesis. However, translocation of intestinal bacteria, 
triggers inflammatory responses through Toll-like receptors, contributing to liver fibrosis and 
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cirrhosis, that are responsible for the high rate of HCC development36. Whereas, in lung cancer, 
Jin and colleagues have discovered that exists a crosstalk between microbiota and immune cells, 
able to regulate tumor development. Local microbiota promotes inflammation and tumor cell 
proliferation by stimulating Myd88-dependent IL-1β and IL-23 production and by inducing 
proliferation and activation of inflammatory γδ T cells37.   
Cancer can be also associated with chronic inflammatory conditions due to autoimmune 
disorders and exposure to different physical (radiation), mechanical and chemical harmful 
environmental cues. It has been recognized that patients suffering of inflammatory bowel 
diseases (IBDs), both ulcerative colitis and Crohn’s disease have approximately, a 3 fold higher 
risk of developing CRC than general population. Of note, risk increases according to the length 
and severity of the disease. For ulcerative colitis the percentage of patients that develop cancer 
range from 2% after 10 years to 18% after 30 years. For Crohn disease, around 8% of patients 
develop cancer after 30 years40–42.  
Lung exposure of chemical irritants, such as tobacco-derived products and asbestos fibers fuel 
chronic inflammation and increase the risk of lung cancer and malignant mesothelioma, 
respectively43,44.  
The persistent accumulation and activation of inflammatory cells promote cancer development, 
trough the production of inflammatory mediators, that augment mutation rates and favor the 
proliferation and the survival of mutated cells.  
In addition, Reactive Oxygen Species (ROS) and Nitrogen Species (RNS) are crucial factors 
able to induce DNA damage and genomic instability. Elevated ROS levels accompanied with 
down-regulation of cellular antioxidant enzyme systems, are essential to maintain tumorigenic cell 
signaling, sustaining tumor cell proliferation, survival, autophagy, and metastasis45, through the 







1.1.1.3 The molecular mediators of cancer-related inflammation  
The intrinsic and extrinsic pathways share many crucial molecular players including 
transcription factors (NF-κB, HIF1α and STAT3), cytokines (e.g. IL1β, IL6, TNF, IL-23), 
chemokines (CCL2, CXCL8) and pro-angiogenic factors (VEGF)8.  
NF-κB represents a crucial molecular lynchpin that connects inflammation to tumorigenesis, 
indeed this transcription factor is a master regulator of the expression of inflammatory 
cytokines, as well as genes that regulate cell proliferation, survival, adhesion and 
angiogenesis1,6,47.  
Inflammation is usually associated with hypoxia in different pathological conditions, in 
particular inflammatory diseases, since numerous studies reported an extensive crosstalk 
between NF‐κB (inflammation) and HIF (hypoxia)48. HIF-1α is an essential transcriptional 
factor in the hypoxic tumor environment. In this setting, HIF regulates changes in glycolysis, 
nutrient uptake, angiogenesis, apoptosis, and cell migration, contributing to tumor survival and 
metastasis. Several studies have demonstrated that HIF-1 expression is elevated in different 
types of solid tumor (e.g. colon, lung and breast cancers) and correlated with a poor prognosis 
49,50. Constitutive activation of the transcriptional factor STAT3 promotes tumor cells 
proliferation, survival, angiogenesis and invasion, by activating both inflammatory pro-
oncogenic pathways and immune suppressive programs51–53.  
(Cytokines also contribute to cancer-related inflammation, by favoring leukocyte recruitment, 
neo-angiogenesis, tumor cell 
proliferation, invasion and 
metastatization (Panel 2)1,54. As well 
know, IL-6 exterts both a direct effect on 
tumor cells, (e.g. affecting proliferation 
and survival, activating genes ancoding 
for antiapoptotic and proliferative 
proteins) and  on myeloid cells, 
promoting their differentiation toward a 
suppressor phenotype45. In addition, IL-
6 induces VEGF expression that consequently promotes tumor angiogenesis 6 and also it 




IL-1β is another important cytokine that is often overexpressed in variuos types of cancer, (such 
as colon, lung, breast, head cancers) and that negatively correlate with patients’ prognosis8. 
Mechanistically, IL-1β increases the expression of pro-inflammatory, pro-angiogenic and pro-
metastatic genes, (e.g. IL-6, IL-8, VEGF, TGFβ and MMPs), promoting tumor progression and 
resistence to therapy45. 
Tumor initiation and progression is also sustained by chemokines (CCL2, CCL5, CCL17, 
CLL22, CXCL12, CXCL8), soluble molecules released by both tumor and stromal cells that 





Tumor-Associated Macrophages (TAMs) 
Undoubtedly, Tumor-Associated Macrophages (TAMs) are the major population of 
inflammatory cells that accumulate in solid tumors where they can reach up to 50% of the tumor 
mass55. Despite their potential cytotoxic activities, in many cases TAMs cooperate with tumors 
to promote their own development, growth and malignant progression. Understanding the 
mechanisms driving TAMs accumulation and functional activation pave the way for the 
development of new strategies that alone or in association with conventional radio/chemio-
therapy and/or immunotherapy open promises for cancer patients56–58. 
1.1.2 Origin of TAMs  
Although the recruitment of cells of the monocyte-macrophage lineage represents one of the 
hallmarks of cancer-related inflammation55, over the last years, the discovery that many tissue 
resident macrophages (TRM) are a self-maintaining population of embryonic origin has brought 
into question of TAMs’ ontogeny and its functional relevance. 
Nowadays, several preclinical studies have pointed out the dual origin of TAMs (Fig.2) but, to 
what extent the developmental diversity might integrate with the functional activity is still under 
debate. TAMs are a heterogeneous population of cells that originate from both newly recruited 
monocytes and TRM. 
In many cancer types, the most of TAMs derive from circulating monocytes (Ly6C+ CCR2+); 
that are generated from adult bone marrow hematopoietic stem cells. These inflammatory 
monocytes are recruited to the tumor tissue, by chemokines (e.g. CCL2, CXCL12, CCL18, 
CCL20), cytokines, complement components and CSF-1. Along with these chemoattractants, 
the activation of the integrins α4β1 and αLβ2, drives the extravasation of monocytes in tumor 
tissue where they undergo Notch-dependent differentiation in Ly6C-
CD11c+MHCII+CD11bloVcam1+ TAMs58–61 . This population of monocytes-derived TAMs 
variable coexist with a population of TRM that in some organs, such as liver, brain, epidermis, 
lungs peritoneum and heart, mainly derive from embryonic progenitors62–65. So far, different 
markers have been exploited to distinguish TRM (CX3CR1hi, MERTK, CD64, Siglec1, F4/80) 
from bone-marrow-derived macrophages (instead of Integrin α4, L-selectin, Ly6c, and Nr4a1)58 
and to explore their relative impact on disease progression  
For example, in a mouse model of lung cancer, it has been demonstrated that both TRMs and 
monocytes-derived TAMs participate in tumor promotion, however tissue-resident interstitial 
macrophages specifically support tumor growth, while monocyte-derived TAMs contribute to 
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tumor remodeling and spreading66. In contrast in a genetic murine model of breast cancer, only 
monocytes derived TAMs appear to express tumor promoting activities. Indeed, inhibition of 
monocytes-derived TAM accumulation resulted in T cells activation and decreased tumor 
growth, whereas TRM depletion was inconsequential67. In glioblastoma monocytes-derived 
TAMs constituted approximately 85% of the total population, with TRM accounting for the 
approximately 15% remaining68. 
At the opposite, recent studies have indicated that TRM (CD163+ Tim4+) from omentum are 
the key driver in the invasive progression of metastatic ovarian cancer69 
Overall these studies suggest that the contribution of TRM and monocytes-derived TAMs 
depend on tumor origin. Certainly, dissecting the cross-talk between developmental origin and 
functional heterogeneity is an outstanding issue that the advent of single-cell based approaches 
will likely help to figure out. 
 
 
Figure 2. The dual origin of TAMs: from the circulating monocytes in the blood or for tissue resident 









1.1.3 Functional states of TAMs  
Several experimental studies suggest that, the transition from early neoplastic events 
(elimination phase) towards advanced tumor stages (escape phase) is associated with a 
functional switch of TAMs’ polarized activation71 
At the first phase of tumor development, TAMs express an antitumor-(M1-like) phenotype, 
therefore they produce high level of inflammatory cytokines (e.g. TNF α) and effector 
molecules (e.g. ROS and RNS) capable to kill tumor cells both directly and through tissue 
destructive reactions, centered on the vessel wall (hemorrhagic necrosis)55,70,72.  
M1-like-TAMs also support the activation of anti-tumor T cell responses. Indeed, they are 
powerful antigen presenting cells through the expression of high levels of major 
histocompatibility complex class II (MHCII) and B7 molecules and the production of 
inflammatory cytokines, such as IL-12. They also produce chemokines, such as CXCL9, 
CXCL10, CXCL11, that drive the recruitment and activation of T-cells55,70,72.  
Unfortunately, during tumor progression, different TME changes, including hypoxia, excessive 
production of cellular metabolites (e.g. lactate) and immunosuppressive conditions, promote an 
alternatively activated or M2-like phenotype73. Various cytokines and signals expressed by 
different cell types (tumor cells, fibroblast, eosinophils, basophils, Th2 T cells and B cells) 
drive M2-like TAM activation55,72–74. Among these, IL10, prostaglandin E2 (PGE2), TGFβ, 
IL6, CCL2, MCSF and migration-stimulating factor (MSF) were reported to induce M2-like 
polarization74.  
Owing to their M2-skewed phenotype, TAMs exert several pro-tumoral functions, inducing cell 
proliferation and survival, (through the production of EGF, FGF, PDGF), promoting immune 
suppression, (by releasing immune-suppressive molecules, such as IL-0 and TGFβ), enhancing 
angiogenesis, tumor cell migration and metastatization64 (Fig.3).  
In 80% of human cancer studies, high number of ΤΑΜs that largely express an M2-skewed 
phenotype are associated with poor prognosis, especially in glioblastoma and lymphoma, renal 
cell carcinoma and breast, pancreatic, head and neck cancers58. 
As demonstrated by in vivo studies and clinical evidence, blockade of M2 phenotype and 




Figure 3. Different states of TAMs polarization55. A gradual switch of macrophages polarization, from M1-like phenotype to 
M2-like phenotype takes place during tumor progression. During tumor elimination phase M1-like TAMs exert cytotoxic and 





















1.1.3.1 Epigenetic Modifications control macrophages activation 
The regulation of macrophage activation status is highly controlled by epigenetic modifications, 
that include DNA methylation and histone modifications77. 
DNA methylation mediates gene silencing by adding a methyl group to the 5’-carbon of the 
cytosine in promoter-associated CpG islands78. DNA methyltransferases (e.g. DMT1 and 
DNMT3b) are implicated in M1 polarization; in detail, DMT1 increases the levels of TNFα and 
IL-6, through the silencing of SOCs179, whereas DNMT3b downregulates the expression of 
ARG1 and CD20680. Although their impact on macrophages polarization is clear, the role of 
DNA methyltransferases in TAMs remains poorly understood77. 
Histone modifications include different types of post-translational modifications, but  
methylation and acetylation are the most important modifications that occur in macrophages 77. 
Histone acetylation, mediated by histone acetyltransferases (HAT), is associated with the 
activation of transcription, whereas histone deacetylation, mediated by and histone deacetylases 
(HDACs), is associated with transcriptional repression77.  
HDACs have an ambivalent effect in TAMs, studies have demonstrated that, in prostate cancer, 
Pan HDAC inhibits M2-functions in TAMs; blocking the secretion of VEGF and IL-10 it’s able 
to prevent EMT process 81. In contrast, murine models of breast, lung and pancreatic cancer 
have showed that, HDAC activity promotes tumor growth by increase TAMs NO production 
82, and its inhibition is able to restore TAM phagocytic activity, promoting the reduction of 
tumor burden and the metastasis diffusion83. 
On the other hand, histone methyltransferases (HMT) and histone demethylases (HDM), that 
respectively catalyze histone methylation and demethylation, are involved in the regulation of 
macrophages polarization, in particular, DNMT3B and DMMT1 promote M1 phenotype, 
preventing M2 markers expression79, whereas PRMT1, HMT, SMYD3 positively regulate M2 
polarization78.  
Although in macrophages, the effect of histone modifications was studied, on TAMs it is yet to 




1.1.4 Function of TAMs in the Tumor Microenvironment (TME) 
TAMs can promote tumor progression and dissemination by numerous ways: producing growth 
factors for tumor cells, secreting immunosuppressive mediators, promoting angiogenesis and 
release proteases that remodel the extracellular matrix in favor of cancer dissemination (Fig.4). 
 
 
Figure 4. Pro-tumoral activities of Tumor Associated Macrophages (TAMs)60. TAMs represent the major population of 
myeloid cells recruited in tumor site. They promote and sustain tumor cells by producing growth factor (e.g. PDGF, EGF, VEGF) 
and creating an immunosuppressive tumor microenvironment (TME). Furthermore, TAMs promote angiogenesis and 
lymphangiogenesis that favor cells invasion and metastasis.  
1.1.4.1 TAMs favor Immunosuppression 
In tumor, TAMs contribute to the establishment of an immunosuppressive environment, which 
is in turn associated with cancer immune escape (Fig.4).  
M2-likeTAMs present a secretory profile characterized by low levels of inflammatory and 
immunostimulatory cytokines (e.g. IL-12, IL18, IL-1β, TNFα and IFNγ) and high expression 
of pro-restorative and immunosuppressive cytokines (e.g. IL10, TGFβ and PGE2), that inhibit 
cytotoxic and adaptive immune responses. In detail, TGF-β reduces dendritic cells migration 
and maturation, downregulates MHC-II surface expression on macrophages, triggers exhausted 
NK-cell phenotype inhibiting their cytolytic activity and suppresses Th1 differentiation in favor 
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of Treg expansion84,85. In the same time, the release of PGE2 inhibits IFNγ production and 
compromises NK cells functions86. 
Furthermore, the release of chemokines, such as CCL17, CCL18 and CCL22, contributes to 
drive the selective recruitment of T-cell subsets lacking cytotoxic activity56,72, and CCL2 
production enhances the migration to the tumor site of CCR2+monocytes, where they acquire 
an M2-like phenotype.  
In addition, TAMs express immune checkpoint ligands, such as programmed cell death ligand 
1 (PD-L1), PD-L2, B7H4 and CTLA4 ligands B7-1, B7-2, which upon binding to the immune-
checkpoint receptors, they trigger T cell cycle arrest, anergy, and apoptosis56,72. Several studies 
showed that, PD-L1, PD-L2 and B7-H4 are overexpressed on TAMs in hepatocellular 
carcinoma, glioblastoma and pancreatic cancer, ovarian carcinoma72,87.  
In the same time, the expression of major histocompatibility complex in TAMs results 
completely deregulated, on one side, TAMs express low MHC class II and on the other, the 
expression of MHC class I molecules is completely unbalanced.   
The non-classical MHC-I molecules, HLA-G and -E co-operate to induce anergy in the TME, 
indeed HLA-E on the surface of the TAMs binds the inhibitory receptor CD94/NKG2A 
expressed by NK cells and cytotoxic T lymphocytes, inhibiting their activity and protecting 
TAMs from the cytolysis. Whereas HLA-G inhibits IFNγ secretion, NK and CD8T cells 
cytotoxicity and induces tolerogenic dendritic cells, enable to promote T cells activation 88,89.  
Another mechanism, by which TAMs directly inhibit T cell cytotoxicity is through the enzyme 
indoleamine 2,3 dioxygenase (IDO), that induces a significant depletion of the amino-acid 
tryptophan (Trp), that is essential for T cells proliferation, differentiation and activation 90,91. In 
addition, TAMs lead to T cells suppression, by locally depleting L-arginine, thought the 
activation the enzyme Arginase 1 (ARG1)73,92.    
If in the primary tumor, TAMs induce T cells apoptosis, through the release of NO93, in the 
metastatic niches, metastasis-associated macrophage precursors (MAMPCs) suppress the 
cytotoxic activity of CD8+ T cells through a ROS–mediated mechanism94. 
The role of TAMs in immunomodulation also includes their capacity to inhibit phagocytosis, 
indeed, they can promote tumor immune evasion through expression of signal regulatory 
protein α (SIRPα). SIRPα is a cell-surface protein, mainly expressed on myeloid cells, 
(including macrophages and dendritic cells), that is the receptor for CD47, a cell surface protein, 
that typically protects normal cells from phagocytosis. The overexpressed CD47 receptors on 
tumor cells interact with SIRPα and deliver the “do not eat me” signals to TAMs, hence, playing 
a crucial role in the instauration of a phagocytosis resistance mechanism and in the promotion 
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of tumor escape. Blockade of the CD47-SIRPα signal has been shown to stimulate 
phagocytosis, leading to tumor cell elimination 95–97. 
Besides, another interesting pathway involved in the resistance of phagocytosis is the leukocyte 
immunoglobulin-like receptor B (LILRB: 1 and 2), negative regulators of myeloid cell 
activation. Cancer cells express MHC-I molecules on their surface, that interact with LILRBs 
on macrophage and inhibit phagocytosis clearance 95,97. Especially, studies have demonstrated 
that LILRB1 expression is particularly abundant on TAMs and blocking the MHC class I–
LILRB1 signaling axis might sensitize tumors to macrophage attack, making these cells more 
vulnerable to phagocytic clearance98. Furthermore, LILRB2 inhibition markedly downregulates 
multiple gene targets involved in M2-like phenotype, enhancing pro-inflammatory responses 
in TAMs and restoring antitumor immunity99.  
 
 
Figure 4. Different pathways involved in TAMs immunosuppressive activity100. TAMs have a key role in immunosuppression, 
producing cytokines, chemokines and immunosuppressive metabolites, expressing inhibitory receptor for T cells, inhibiting 
their phagocytic activity. 
22 
 
1.1.4.2 TAMs induce Angiogenesis and Lymphangiogenesis 
In solid tumors many areas of hypoxia are present, neoangiogenesis facilitates oxygenation and 
nutrients delivery to neoplastic cells, contributing to tumor growth101. Hypoxia-inducible-
factors are the principal transcription factors activated by low oxygen tension. In particular, 
HIF1α, which is expressed in TAMs, drives the expression of a variety of pro-angiogenic genes. 
TAMs, preferentially accumulate in hypoxic regions, are involved in the production and release 
of potent proangiogenic cytokines (VEGF, TNFa, IL8), growth factors (platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF), macrophage colony– stimulating factor, 
(CSF-1/M-CSF), MMPs (MMP2, MMP9, MMP12) and other molecules, able to potentiate 
tumor invasiveness, through the initiation of new blood or lymphatic vessels102,103.  
This correlation between TAMs and the formation of a new tumor vasculature is clearly 
demonstrated in different types of human cancers, (such as melanoma, B-cell non-Hodgkin's 
lymphoma, mucoepidermoid carcinoma of salivary glands, pulmonary adenocarcinoma, 
glioma, and leiomyosarcoma and breast and gastric cancer)104, and in experimental mouse 
tumor models, the genetic or pharmacological depletion of macrophages has undoubtedly 
confirmed that TAMs are the principal inducers of the ‘‘angiogenic switch’’70.  
In particular, both in mice and in human, a specific subpopulation of TAMs (Tie2+) is able to 
interact with mural pericytes and regulate the vascular structure 105. Tie2+ TAMs are attracted 
into the tumors by endothelial cell-derived cytokines angiopoietin-2 (ANG-2), which interacts 
with their TIE receptors, and CXCL12 that respectively was linked by their CXCR4 receptors. 
Tie2+ TAMs are essential to increase the vascular density and favor metastasis dissemination 
106,107, through the release of high levels of MMP9, VEGF-A, COX-2, and Wnt5a106. Several 
studies have demonstrated that, a genetic deletion of TIE2 blocks ANGPT2- TIE2 signaling 
pathway in TAMs, decreasing angiogenic interaction107.  
TAMs not only can regulate metastasis dissemination by angiogenesis, but also promote 
lymphangiogenesis. Since in human breast cancer, higher numbers of TAM are associated with 
lymphatic microvessel density, lymph node metastasis or lymph vessel invasion. TAMs support 
tumor lymphangiogenesis, by secreting high levels of VEGF and MMPs, promoting tumor 








Figure 5.  Molecular pathways involved in TAMs promoting angiogenesis55.  
 
1.1.4.3 TAMs promote tumor cells invasion and metastasis 
Cancer is a systemic disease, indeed during their progression, neoplastic cells acquire 
distinctive ability to leave the primary tumor site and reach distant sites where they settle down 
and grow103, and the metastatic process represents the most critical phase of the disease, leading 
up to 90% of cancer deaths108. This process is driven not only by the intrinsic alterations in 
tumor cells, but also by the implicated cross-talk between cancer cells and their altered TME 
components, especially TAMs, that contribute to tumor invasiveness and worse prognosis1.  
The metastatic process is a multistep sequence that includes invasion of the basement 
membrane and cell migration, intravasation into the vasculature or lymphatic system, survival 
in the circulatory system, extravasation and adaption and growth in the metastatic sites109 and 
TAMs are crucially implicated in all the different steps of this process (Fig.6).  
TAMs favor the first step of tumor invasion by releasing cytokines, such as TGFβ, IL1β, IL8, 
TNFα, that trigger epithelial-mesenchymal transition (EMT), a process in which epithelial 
cancer cells shift to gain a mesenchymal phenotype: cells acquire fibroblast properties by 
augmenting their motility and their ability to penetrate surrounded matrix110.  In vitro and in 
vivo studies have revealed an abundance of TAM infiltrate in the EMT hotspots in tumor site111, 
where they participate to enhance the expression of mesenchymal markers like vimentin, snail 
and N-cadherin and repress E-cadherin levels in tumor cells97,111,112.  
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Moreover, TAMs participate in extracellular matrix (ECM) degradation and cell-ECM 
interaction, focal events in metastasis dissemination97. They release numerous proteolytic 
enzymes, including matrix metalloproteases (MMP-2, MMP-9), plasmin, urokinase-type 
plasminogen activator (uPA), osteonectin, and cathepsins, thus permitting the degradation of 
the basal membrane and surrounding connective tissues, to facilitate tumor cell invasion and 
migration97,113.  
Cell migration is sustained by cells-ECM interaction and it is guarantee by TAM-derived 
secreted protein acidic and rich in cysteine (SPARC), a matricellular protein that favors the 
interactions between tumor cells-fibronectin and vitronectin, promoting rapid transolcation into 
blood vessels114,115.  
Next, macrophages assist the entry of tumor cells into the blood and lymphatic vessels116,where 
they acquire the capacity to survive and disseminate in the body117. TAMs not only promote 
the entrance of tumor cells into the circulation by a positive feedback loop, consisting of tumor 
cell-produced CSF-1 and TAM-produced EGF118, but also protect them by NK cytotoxic 
activity119. 
Finally, in the later phase, TAMs both assist tumor cells extravasation and prepare sites for 
tumor cells growth in the pre-metastatic niches (PMNs). TAMs are accumulated in selected 
distant tissues in response to tumor-derived factors (such as CCL2, CSF-1, VEGF, PLGF, TNF-
α, TGF-β, tissue inhibitor of metallopeptidase (TIMP)-1, and exosomes), where they facilitate 
the homing of circulating tumor cells (CTCs) and generate a permissive TME, for cancer cell 
seeding120. 
 
Figure 6. TAMs favor metastatic process97. TAMs assist in all steps of metastasis instauration, starting from tumor cells 




1.1.5 TAMs as a therapeutic target  
Owing to the importance of TAM activities for tumor development and progression, new 
therapeutic strategies targeting TAMs are widely investigated121. Different approaches are 
under evaluation, such as reduction of the number of TAMs on tumor site by their selective 
killing, inhibition of their recruitment and TAM re-education, in order to restore their 
tumoricidal activity55,70,121 (Fig.7-8). 
 
Figure 7. Different strategies to target TAMs70. TAMs targeted approaches include inhibition of TAM recruitment and 
localization, re-polarization /re-programing (either or) of their phenotype, TAM depletion induce their elimination or 








1.1.5.1 Inhibition of monocytes recruitment into the tumor and TAMs 
neutralization.  
The accumulation of macrophages in tumors is due to the continuous recruitment of monocytes 
from the circulation, in response to chemo-attractants produced by tumor cells. The pivotal 
orchestrators of monocytes migration are the tumor-derived factors (TDFs): CCL2, CXCL12 
and CSF-155.  
Studied have shown that high levels of CCL2 in tumor, as well in serum, are associated with 
poor prognosis in different types of tumors122. 
In several preclinical model (e.g. melanoma, prostate, breast, lung and liver cancers) 
neutralization of CCL2/CCR2 axis, using anti-CCL2 antibodies or CCR2 inhibitors, has 
demonstrated a suppression in TAM accumulation and a consequent reduction of tumor growth 
and metastasis122–124. Moreover, in a mouse model of ovarian cancer, CCL2 inhibition has 
improved the effect of paclitaxel and carboplatin therapies125.  
On this basis, several CCL2-neutralising antibodies are now in clinical trial, and in particular, 
preliminary clinical studies in solid tumors have shown that carlumab (a human immunoglobin 
G1κ antibody, that binds to CCL2), causes efficient deflection of macrophages and delay in 
tumor regrowth after chemotherapy126.  
Currently, CCR2 antagonists are in clinical trials as monotherapy in patients with metastatic 
cancers, or in combination with chemotherapy (FOLFIRINOX) in advanced pancreatic 
adenocarcinomas. Patients treated with only chemotherapy did not show an objective response, 
in contrast, in combination therapy group, half of patients had an objective tumor response, and 
the majority of those patients achieved local tumor control127.  
Moreover, accumulating evidence has demonstrated the essential role of CXCL12-CCR4 axis 
in tumor progression, in fact, CXCL12 mediates recruitment and retention of CXCR4+ bone 
marrow–derived cells to the neoangiogenic niches, supporting vascularization and tumor 
growth128. 
Nowadays, Mozobil® (also known as plerixafor, and AMD3100) is emerging as CXCR4 
receptor antagonist, that disrupts the CXCL12-CXCR4 axis, mobilizing hematopoietic stem 
cells to the peripheral blood and preventing their accumulation in the tumor site. Since, it is 
under evaluation in different trials (NCT02179970, NCT03277209) in patients with solid 
tumors and patients with acute myeloid leukemia55.  
CSF-1 is abundantly produced in several tumors and is essential for macrophages 
differentiation. Its neutralization through monoclonal antibodies, antisense oligonucleotides, or 
kinase inhibitors gave promising results in different preclinical studies, including acute myeloid 
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leukemia, melanoma mammary carcinoma, and glioblastoma 129–131; therefore, blocking CSF-
1R is under evaluation in phase I/II clinical trials with different types of advanced solid 
tumors132. 
In murine model of breast, prostate and cervical tumors, anti-CSF-1R dependent TAM 
depletion correlate with an expansion of tumor infiltrating cytotoxic CD8 T cells and an 
improved therapeutic response55 
An interesting example is represented by CSF-1R targeting anti-body, RG7155, that has 
demonstrated an important clinical activity in diffuse-type giant-cell tumor patients, due to an 
important reduction of TAMs and a consequent increase of CD8+/CD4+ T cells ratio133. 
Another interesting example is represented by the compound PLX3397, in different types of 
human cancer in combination with radiotherapy or chemotherapy or ICBs, it is able to enhance 
the efficacy of the treatment134–136. 
Another druggable target on TAMs is represented by the scavenging receptor CD163. In a 
melanoma mouse model, the researchers have conjugated CD163 antibody with a lipid carrier 
loaded with doxorubicin to target the selective depletion of CD163+ TAMs, obtaining a 
significant tumor regression137  
Prior to these innovative treatments, bisphosphonates have represented a wide used approach 
for TAM depletion138, due their ability to inhibit proliferation, migration of macrophages and 
induce their apoptosis139.  
In experimental models, the encapsulation of clorodronate in liposomes (Clodrolip) positively 
reduced macrophages tumor infiltration in bone metastasis from lung cancer and lung 
metastasis from breast cancer limiting metastasis diffusion140. Furthermore, different studies 
have demonstrated the activity of another bisphosphonate, the Zoledronic acid, which is able to 
reduce tumor burden in a mouse model of bone metastases from breast cancer55. 
Although bisphosphonates had promising results in vivo, the high toxicity and the inconsistent 
results in patients have limited their use in therapy141. 
Trabectedin is another important antineoplastic agent, that not only it is able to target tumor 
cells but also TAMs, mediating their apoptosis, through the activation of caspase 8 by TNF-






1.1.5.2 Reprogramming of TAMs toward an M1 phenotype 
Given the high plasticity of TAMs, rewiring their activation towards the M1 phenotype has 
emerged as an interesting therapeutic strategy142.  
Studying the molecular basis of TAMs, our group has demonstrated, that nuclear accumulation 
of p50 NF-κB inhibitor homodimers drives the expression of an M2 transcriptional program 
associated with tumor growth and progression. Since, in preclinical models of fibrosarcoma and 
melanoma, ablation of p50 restores M1 inflammatory responses and antitumor resistance, 
suggesting p50 as a potential target for TAM reprogramming143. 
Nowadays, several approaches, based on the re-education of TAMs in anti-tumor cells, have 
shown beneficial activities both in preclinical and in clinical studies.  
An interesting target for macrophage repolarization is represented by Toll-like receptors 
(TLRs), the innate immunity pattern recognition receptors, that upon engagement by their 
ligands, mediate the activation of M1-like functional polarization of macrophages.  
In this context, the endosomal TLRs (TLR3, TLR7, TLR8 and TLR9) represented interesting 
druggable targets for synthetic ligands.  
The activation of TLR3 by poly I:C is able to restore the cytotoxic activities of macrophages in 
a mouse model of colon cancer, increasing the production of the inflammatory cytokines IL6, 
IL12, TNFα, iNOS, enhancing the antigen uptake and improving T cell priming. Currently, the 
antitumor effect of Poly I:C is investigated in clinical trials, alone or in combination of ICBs 
therapy in different types of cancer144,145.  
TLR7/TLR8 activation is another attractive target for TAM repolarization. Indeed, Imiquimod, 
TLR7/TLR8 agonist, induces strong M1 activation, showing an antitumoral activity in different 
preclinical models, including basal cell carcinoma, melanoma and breast cancer skin 
metastases122. Furthermore, another imiquimob analogue represents a promising drug for TAM 
reprogramming, since intra-tumor injection of a TLR7/8 agonist 3M-052, induces macrophage 
repolarization and consequently tumor regression in a mouse model of subcutaneous 
melanoma146  
Currently, clinical trials on solid tumor are evaluating the combination of TLR7/8 agonists and 
chemotherapy or immune checkpoints. 
Furthermore, the therapeutic efficacy of the TLR9 agonist, Cytosine phosphate guanin (CpG) 
oligodeoxinucleotides, was reported by different preclinical studies, Guiducci and colleagues 
have demonstrated that the combination Cpg-ODN and IL10 antagonist promptly switched M2 
cells to an M1 phenotype, sustaining their cytotoxic activities147. 
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An attractive target to repolarize macrophages is the activating receptor CD40, expressed on 
the surface of APC cells, such as dendritic cells, monocytes, macrophages and B lymphocytes. 
Its activation mediates the expression of MHC molecules, the production of pro-inflammatory 
cytokines and promotion of T cell activation55. 
In various mouse model of cancer, agonistic anti-CD40 antibodies have shown to favor 
cytotoxic functions of TAMs, for example, in colon and breast cancer model their combination 
with ICBs led to a complete tumor rejection in about half of treated mice. Moreover, in murine 
model of colon, sarcoma and breast cancer, the combination of anti-CD40 plus anti-CSF-1R 
antibodies resulted in M1 macrophages repolarization, CD8 T cells activation and a significant 
anti-tumor effect148.  
Currently, different CD40 agonists are under evaluation in several clinical trials for solid 
tumors, either as a single agent, or in combination with conventional chemotherapy or 
immunotherapy55. 
In pancreatic cancer, the combination of CD40 agonist antibodies with gemcitabine resulted in 
tumor regression and in an increase of survival, due to the restoration of antitumor macrophages 
effect, in fact, they sustained antigen-presentation reestablishing immune surveillance149  
Another promising target to repolarize TAMs, is PI3Kγ, a kinase expressed primarily in 
myeloid cells, that controls the switch between immune stimulation to suppression76. PI3Kγ 
inhibition enhanced proinflammatory cytokines expression, cytotoxic T cells recruitment into 
tumor and consequently lead to tumor regression76. In vitro, inhibition of PI3Kγ, with Ibrutinib 
or with TG100-115, induces TAM expression of IL12 and a downregulation of TFGβ and 
ARG1. Moreover, the inhibition of PI3Kγ signaling in different mouse models, (e.g. head and 
neck SCC, lung, breast and PDAC), has suppressed tumor growth and enhanced anti-tumor 
immunity150.  
The macrophage receptor with collagenous structure (MARCO) is another attracting target. It 
is a scavenger receptor, mainly expressed by a subpopulation of TAMs with an M2-like 
immunosuppressive gene signature, both in murine tumor models and in human cancer.  
Anti-TAM antibodies directed against the scavenger receptor MARCO induce suppression of 
tumor growth and metastatic dissemination both in 4T1 mammary carcinoma model and B16 
melanoma mouse model122,151. Furthermore, MARCO represents a potential new immune target 
for anti‐TAM treatment in a subset of NSCLC patients152. 
The CD47 (on tumor cells)–SIRPα (on phagocytic cells) axis is involved in the regulation of 
phagocytosis. In the context of tumor, the overexpression of CD47 represents a phagocytosis 
resistance mechanism96. At the moment, there are two anti-CD47 mAbs (Hu5F9-G4 and 
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CC-90002) and one soluble recombinant SIRPα–crystallizable fragment (Fc) fusion protein 
(TTI-621). The pharmacological inhibition of CD47-SIRPα pathway, using a monoclonal 
antibody or soluble SIRPα-Fc construct can restore phagocytosis and killing of tumor cells by 
macrophages in various preclinical cancer models; at the moment, these pharmacological 
treatments are being tested in phase I clinical trials122,153. 
Another possibility to reprogram TAMs is represented by the class IIA HDAC inhibitors, that 
can selectively reprogram monocytes and macrophages in the tumor, enhancing their 
inflammatory properties as described in luminal B-type breast cancer model, where 
intraperitoneal injection of HDAC inhibitor TMP195 not only has increased monocytes 
infiltration, but also stimulated the differentiation into antitumoral macrophages154. 
1.1.5.3 TAMs as a delivery of therapeutics agents 
An emerging strategy to treat tumors, is to consider TAMs as a drug delivery system, taking 
advantage of their ability to target and migrate to the tumor sites, creating a live cell-mediated 
drug delivery system155,156.  
Macrophages loaded with drugs ex vivo, could be reintroduced into the circulation, where 
thanks to their tumor-homing capacity they unload the drug directly at tumor site, minimizing 
adverse effects157. Different studies have demonstrated that macrophages could be interesting 
carriers to improve antitumor efficacy, by conveying drug-containing nanoparticles (e.g. 
doxorubicin) or pro-drugs, toxic agents or oncolytic virus158–160.  
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Tumor Associated Macrophages (TAMs) are the major population of leucocytes infiltrating 
tumors and the master regulators of cancer-related inflammation. Despite, their potential anti-
tumor activity, TAMs acquire an M2-skewed phenotype endowed of many tumor-promoting 
activities, including suppression of adaptive immunity and induction of angiogenesis, tumor 
cells proliferation, survival and migration. Beyond contributing to tumorigenesis, TAMs can 
profoundly affect the response to anti-cancer therapies, either impairing or enhancing the 
efficacy of anti-cancer strategies. Accumulating clinical studies have confirmed TAMs as 
prognostic indicators of cancer progression and as attractive targets for the development of new 
therapeutic approaches.  
Our study is focused on TAMs with the dual aim: 1) identification of new important molecules 
driving TAM pro-tumoral functions 2) gathering information regarding the impact of TAMs on 
anti-tumor activity of EPZ-6438, a new epigenetic modulator that is under clinical evaluation  
1) To identify new molecular players of TAM pro-tumoral activities, we analyzed the 
alterations of the phospho-proteoma of TAMs isolated from murine MN/MCA1 
fibrosarcoma, as compared to resting (ctr), M1 (IFNγ/LPS for 30 min) and M2 (IL-4 for 8h) 
polarized macrophages. We originally found the phosphorylation of Tripartite motif-
containing 28 (TRIM28) at Ser473 (TRIM28 S473p) in both M1-polarized PECs and TAMs. 
TRIM28 is a member of the Kruppel-Associated-Box Proteins that participates in the 
dynamic organization of chromatin and is involved in multiple cellular activities. To get 
insights the triggers and the molecular mechanisms driving TRIM28 S473p in macrophages, 
we analyzed different inflammatory signals, including cytokines (IFNγ, TNFα, IL-1β, IL-6), 
microbial products (TLR ligands) and selected molecules of their signaling cascades. In the 
attempt to identify potential tumor-derived signals controlling TRIM28 S473p in TAMs, we 
also tested immunoregulatory molecules (IL-10, PGE2), that we have found enriched in 
fibrosarcoma.  We next explored in vivo, the functional relevance of myeloid TRIM28 in 
different contexts of cancer related inflammation. We generated mice lacking the protein 
TRIM28 in myeloid cells (TRIM28LysM-Cre) and we used these mice to evaluate whether the 
total absence of TRIM28 could affect TAM activity in both fibrosarcoma model and in 
colitis-associated cancer (CAC) model.  To get insights into the effects of lack of TRIM28 
on LPS-induced inflammatory gene expression, we generated mRNA sequencing (mRNA-
seq) data sets of WT(TRIM28LysM-Cre) and TRIM28 KO (TRIM28flox/flox) PECs under both 
untreated condition (Ctr) and following the treatment with 10ng/ml LPS for 4 hours to induce 
M1-polarized activation or for 20 hours to induce an LPS-tolerant phenotype.  
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TRIM28 acts as an oncogenic driver in different cancer types, including colorectal cancer 
(CRC). So far, phosphorylation of TRIM28 on serine 473 (S473) has been found associated 
with DNA repair mechanisms and epigenetic stability. Given that, we have found that both 
TLR ligands and inflammatory cytokines can induced TRIM28 S473p, we explored the 
impact of inflammation on TRIM28-dependent DNA damage response and consequent 
susceptibility of intestinal epithelial cells (IECs) to undergo neoplastic transformation. We 
treated TRIM28Villin-Cre and TRIM28flox/flox mice with AOM /DSS and we analyzed 
inflammatory response and tumor development. Next, to dissect the mechanisms whereby 
TRIM28 in IECs influence inflammation-driven CRC development, we analyzed the 
transcriptional profile of IECs/tumor cells and lamina propria immune cells by single cell 
RNAseq approach. This is a state-of-the-art NGS approach that allows to improve the 
characterization of heterogeneous cell populations and thus the resolution of complex 
biological systems. We analyzed both the tumor lesions and the colon of AOM/DSS-treated 
mice 9 days (colitis) after the first DSS administration, when the mutant cells due to AOM 
treatment likely start the selection operated by immune cells.  
2) Malignant Pleural Mesothelioma (MPM) is a highly aggressive cancer with long latency 
period and dismal prognosis. Recently, EPZ-6438 (tazemetostat) has entered in clinical trials 
due to the anti-proliferative effects reported on MPM cells. We set up a reliable 3D MPM-
monocytes spheroid model to investigate the impact of TAMs on MPM cell responsiveness 
to EPZ-6438. We initially confirmed the anti-proliferative effects of EZH2 inhibitor in MPM 
spheroids, then we evaluated both monocytes recruitment into the tumor spheroids and their 
functional differentiation towards a TAMs-like phenotype (Mo-TAMs). We performed gene 
expression analysis by RT-PCR and we tested Mo-TAMs activity by evaluating tumor cell 
proliferation and spreading. Next, we analyzed the effect of prolonged EPZ-6438 treatment 
on monocytes recruitment into MSTO spheroids as well as on Mo-TAMs gene expression. 
We analyzed the functional impact of Mo-TAM on the anti-tumor effects due to EZH2 
inhibition in MPM cells. Finally, we tested the susceptibility of MPM cells to the cytotoxic 
activity of M1-polarized monocytes in order to evaluate the potential synergistic effect of 
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Tumor-associated macrophages (TAMs) are key components of the inflammatory tumor 
microenvironment (TME) supporting tumor development, growth and progression. Over the 
last years, the therapeutic value of macrophage-targeting approaches has been successfully 
proven in small cohorts of cancer patients. This evidence supports new studies to gather the 
molecular pathways underlying the pro-tumoral activities of TAMs. 
To identify new molecular players of TAM pro-tumoral activities we analyzed the alterations 
of the phospho-proteoma of TAMs isolated from murine MN/MCA1 fibrosarcoma, as 
compared to resting (ctr), M1 (IFNγ/LPS, 30 min) and M2 (IL-4, 8 hours) polarized 
macrophages. We originally found the phosphorylation of Tripartite motif-containing 28 
(TRIM28) at Ser473 (TRIM28 S473p) in both M1-polarized PECs and TAMs. TRIM28 is a 
member of the Kruppel-Associated-Box Proteins that participates in the dynamic organization 
of chromatin and is involved in multiple cellular activities.  
We found that different pro-inflammatory signals, including cytokines (TNFα, IL-1, IL-6) and 
microbial products (ligands of TLR4, 2 and 5) induce a transient TRIM28 S473p, via the 
MyD88-p38 dependent pathway, whereas selected immunomodulatory mediators (IL-10, 
PGE2) trigger a mild, but long-lasting TRIM28 S473p.   
We explored in vivo, the functional relevance of myeloid TRIM28 by studying mice the lack 
the protein in myeloid cells (TRIM28LysM-Cre) and we found that the total absence of TRIM28 
in myeloid cells does not affect the pro-tumoral activities of TAMs in fibrosarcoma model nor 
tumor multiplicity in colitis-associated cancer (CAC) model but exacerbated colitis. 
Accordingly, RNA-seq analysis indicates that TRIM28 modulates macrophage response to both 
short and prolonged LPS treatment by affecting the expression of selected gene transcriptional 
programs associated to activation of adaptive immunity, cell metabolism and oxidative stress 
response, including DNA damage response. Noteworthy, lack of TRIM28 in intestinal 
epithelial cells (IECs) confers resistance to CAC, using a single cell RNAseq approach we 
provide data suggesting that TRIM28 in IEC impact on immune cells composition during the 
transition from colitis to cancer along with mild effects on the expansion of neoplastic cells 
with an EMThigh gene signature and accumulation of Goblet and Paneth cells under colitis stage. 
Overall, these results identify TRIM28 as a new molecular target at the crossroads between 




Although the existence of a functional link between chronic inflammation and cancer has been 
suggested in the 19th century, the importance of inflammation in the pathogenesis of cancer 
has only been proven in the last two decades1–3. Nowadays, it has been estimated that up to 
20% of all human cancers are causally associated with chronic inflammation4.   
Several studies have shed light on the molecular and cellular inflammatory circuits that support 
tumor development. Myeloid cells are an important source of reactive oxygen species (ROS) 
and reactive nitrogen intermediates (RNI)-that favor DNA mutations5.  Several inflammatory 
cytokines (e.g., IL-6, IL-1, IL-23, IL-17A) can directly promote neoplastic cells survival, 
proliferation and genomic instability, through the activation of the transcription factors NF-B 
and STAT36,7, as well as the inhibition of p53 activity8,9. 
Nevertheless, inflammatory response, supported by innate immune cells, is also crucial for the 
activation of an adaptive immune response (e.g., IL-12, IFNγ) capable to eliminate nascent 
tumors2. Although immune cells continuously recognize and destroy nascent tumor cells, the 
genetically unstable neoplastic cells are able to evade immune surveillance by selecting new 
variants of transformed cells, characterized by their loss of antigenicity and immunogenicity, 
consequently generating an immunosuppressive microenvironment that is fundamental for 
tumor formation and advancement (immuno-editing)1,3.  
Tumor associated macrophages (TAMs) represent the major component of the tumor 
microenvironment (TME) and the crucial orchestrator of tumor-promoting inflammation10.  
Macrophages are characterized by high heterogeneity and plasticity, namely the capacity to 
express different programs of polarized activation in response to the dynamic change of 
microenvironmental signals. Macrophage plasticity, in vivo, emerges as a continuum of 
different functional states of polarized activation, ranging from the pro-inflammatory and anti-
tumor M1-phenotype to the immunosuppressive and pro-healing M2- phenotype11.  
Cytokines such as IFN-γ and tumor necrosis factor-α (TNF-α), predominantly secreted by Th1 
cells, activate macrophages towards a classic M1 phenotype, instead, Th2 (IL-4) and 
immunosuppressive (IL-10) cytokines promote the expression of alternative M2-skewed 
programs12–14.  Despite their potential cytotoxic activities, in many established cancers, the most 
of macrophages acquire an M2-skewed phenotype devoid of cytotoxic activity and endowed of 
immunosuppressive and pro-healing properties15–17.  
Therefore, a growing number of clinical studies have confirmed TAMs as prognostic indicators 
of cancer progression17,18 and as promising therapeutic targets10. Indeed, over the last years, the 
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therapeutic value of macrophage-targeting approaches has been successfully proven in small 
cohorts of cancer patients. This evidence supports new studies to gather the molecular players 
underlying the pro-tumoral activities of TAMs. 
In agreement with previous findings in established tumors19, we have recently reported that 
progressive nuclear accumulation of p50 NF-κB in macrophages during intestinal tumor 
development drives tumor-promoting reprogramming of colorectal cancer–associated 
inflammation20. Here we started by the analysis of the alterations of the phospho-proteoma of 
TAMs isolated from murine MN/MCA1 fibrosarcoma to find new molecular players of TAMs 
pro-tumoral activities.  
We identified Tripartite motif containing 28 (TRIM28) TRIM28, a pleiotropic protein that 
participates in the dynamic organization of chromatin and regulates numerous different 
processes including gene expression, DNA repair, pluripotency, proliferation, differentiation 












Materials and Methods  
Mice 
Wild type mice (C57BL6J) mice were purchase from Charles River Laboratories (Calco, Italy), 
B6.Cg-Tg(Vil1-cre)997Gum/J (Villin-Cre) mice and B6.129P2-Lyz2tm1(cre)Ifo/J (LysM-Cre) 
mice were from Jackson Laboratories (Bar Harbor, Maine, USA), and TRIM28flox/flox mice, (on 
a C57BL6J background strain), were from the laboratory of Professor G. Carl Huber 
(University of Michigan Medical School, Dept. of Cell & Developmental Biology). 
TRIM28 flox/flox mice were crossed with LysM-Cre mice or with Villin-Cre mice, to generate 
mice with specific deletion of TRIM28 in macrophages (MϕΔTRIM28) or in intestinal epithelial 
cells (IEC) of the small and large intestines (IECΔTRIM28).  
Myd88 knock-out mice were from Professor Francesca Granucci, (University of Milano-
Bicocca, Milan, Italy). 
In all experiments male mice with 8-10 weeks of age were used.   
Mice are maintained in transparent cages of plexiglas with a litter of corn cobs de-dusted, to 
absorb droppings. Standard conditions of temperature (24±2°C), humidity (60±5%) and 
illumination (12 hours light, 12 hours dark) were applied. During experimental period, mice 
had free access to water and feed. They were monitored daily, and euthanized when displayed 
excessive discomfort. The study was designed in compliance with: Italian Governing Law 
(Legislative Decree 116 of Jan. 27, 1992); EU directives and guidelines (EEC Council Directive 
86/609, OJ L 358, 12/12/1986); Legislative Decree September 19, 1994, n. 626 (89/391/CEE, 
89/654/CEE, 89/655/CEE, 89/656/CEE, 90/269/CEE, 90/270/CEE, 90/394/CEE, 
90/679/CEE); the NIH Guide for the Care and Use of Laboratory Animals (1996 edition); The 
study was approved by the The Ethics Committee for Animal Experimentation - 
C.E.S.A.P.O. University of Piemonte Orientale " A. Avogadro " and  by Ministry of Health, 
Italy. 
Genotyping of mice was performed by PCR using the following primers, for LysM-Cre mice: 
P1 (common primer) 5′-CCC AGA AAT GCC AGA TTA CG-3′, P2 (mutant primer) 5’-CTT 
GGG CTG CCA GAA TTT CTC-3’ and P3 (WT primer) 5’-TTA CAG TCG GCC AGG CTG 
AC-3’. Thermic profile: 94° 3min (1 cycle), 94° 30s, 62° 1min, 72° 1min, 72° 2min (30 cycles) 
and 10° for the rest of time. Wild type mice give an amplicon of 350 bp, an additional product 
of 700bp indicates the presence of mutant (LysM-Cre) allele.  
For Villin-Cre mice: IMR1878: 5’-GTG TGG GAC AGA GAA CAA ACC-3’, IMR1879: 5’-
ACA TCT TCA GGT TCT GCG GG-3’, IMR8744: 5’-CAA ATG TTG CTT GTC TGG TG-
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3’ and IMR8745: 5’-GTC AGT CGA GTG CAC AGT TT-3’. Thermic profile: 94° 3min (1 
cycle), 94° 30s, 64° 1min, 72° 1,5min, 72° 3min (35 cycles) and 10° for the rest of time.  PCR 
gives rise to an amplicon of 200 bp as internal control and of 1100bp if the transgene (Villin-
Cre) is present.  For TRIM28flox/flox mice: YD208 (WT primer) 5’-GGA ATG GTT CAT TGG 
TG-3’, VR211 (Flox primer) 5’-ACC TTG GCC CAT TTA TTG ATA AAG-3’ and TV210 
(Flox primer): 5’-GCG AGC ACG AAT CAA GGT CAG-3’. Thermic profile: 94° 3min (1 
cycle), 94° 30s, 55° 30s, 72° 1 min, 72° 7min (30 cycles) and 10° for the rest of time.  A PCR 
product of 152 bp is representative of WT DNA, while a 180bp amplicon identifies the 
TRIM28flox/flox allele.  
Purification of Peritoneal Exudate Macrophages (PECs)  
WT C57BL6J, TRIM28LysM-Cre and TRIM28flox/flox mice were injected intra-peritoneum (i.p.) 
with 1ml of 3% (wt/vol) thioglycollate medium. 5 days after injection, mice were sacrificed and 
PECs were collected by washing the peritoneal cavity with saline solution. PECs were 
centrifuged at 1200 rpm, 4°, 8 min; the supernatant was discarded and the cells were re-
suspended in saline solution. Cells were pelleted again (1000rpm, 4°C, 10 min), resuspended 
in RPMI 1640 supplemented with 1% L-Glutamine and 1% penicillin-streptomycin 
(incomplete RPMI) and counted with Turk solution. PECs were seeded in plates (8x106 cells in 
100 mm Petri dish) and incubated at 37°C and 5% of CO2. After 1h, cells were vigorously 
washed with saline to eliminate non-adherent cells. Macrophages were cultured in RPMI 1640 
supplemented with 1% L-Glutamine and 1% penicillin-streptomycin and 10% of FBS 
(complete RPMI).  After at least 1h of recover, PECs were stimulated as following indicated.  
Purification of Tumor Associated Macrophages (TAMs) 
TAMs were purified from murine solid tumor fibrosarcoma. Tumor cells were injected intra-
muscle (i.m.) at a concentration of 105 cell/mice in the left leg, 21 days later tumors reached a 
volume of about 2 cm3, mice were euthanized and tumors were harvested. Each tumor was cut 
in small pieces (avoid necrotic zone and blood vessels) and washed with saline solution. To get 
a single cell suspension, tumor pieces were put in a bottle containing a PBS solution with 
0,125% trypsin endotoxin-free, (20-40 ml/tumor) and incubated at 37°C for 30-40min, in a 
stirring way. Next, FBS (1/5 of the total volume) was added to inactivate trypsin, cell 
suspension was filtered with a sterile gauge and centrifuged at 1000 rpm, 10 min. Cells were 
re-suspended in incomplete RPMI 1640, diluted with 10% Trypan Blue (diluted 1:10, Sigma) 
and counted.  Cell suspension was seeded in incomplete RPMI (20x106 cells in 100 mm Petri 
dish), and incubated at 37°C, 5% of CO2, for 1 hour. Then, cells were vigorously washed with 
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saline, in order to eliminate non-adherent cells, and complete RPMI medium was added. After 
1 hour in incubator for recovering, TAMs were treated as following described. 
Isolation of Human Monocytes 
Monocytes were obtained from buffy coats of healthy donors. Blood was washed once with 
saline at 1000 rpm to remove plasma and platelets, and then centrifuged on Ficoll (GE Health 
Care) at 2200, RT, 30 min (brake free).  Peripheral blood mononuclear cells were collected at 
the interface. Then, after two washes with saline, monocytes were purified by fractionation on 
a one-step discontinuous Percoll (GE Health Care) gradient.  Cells obtained from Ficoll 
gradient were washed twice in saline and suspended in isoosmotic complete RPMI 1640 
medium. The Percoll solution was prepared by mixing 9.25 parts of concentrated Percoll and 
0.75 parts of PBS; (the osmolarity of this solution was adjusted to 285 mOsm). Cell suspension 
was carefully layered on the top of the 46% Percoll solution; tubes were centrifuged at 2000 
rpm, RT, 30 min. Monocytes were recovered at the interface, washed twice in saline and 
resuspended at 5*106 cells/ml in RPMI 1640 medium supplemented with 1% FBS, plated and 
left 1 hour in incubator, after they were washed with saline and cultured in complete medium 
until treatment. 
Cell culture and reagents 
PECs and TAMs were cultured in RPMI 1640 (Lonza), with 10% foetal bovine serum (Lonza), 
L-Glutamine (2mM, Lonza), and penicillin-streptomycin (100U/ml, Lonza).  
Lipopolysaccharide from Salmonella abortus equi S-form (LPS, 10ng/ml), PAM3CSK4 
(2μg/ml), Flagellin (100ng/ml), Loxoribine (100μM) and Poly I-C (10μg/ml) were purchased 
from Enzo Life Sciences. Oligodeoxynucleotide with CpG1826 (1μg/ml) sequence (5’-
tccatgagcttcctgagctt-3), was produced by MWG-biotech (M-Medical s.r.l.).   
Cytokines (IL-1, IL-4, IL-6, IL-10, IFNγ, PGE2 and TNFα, 20ng/ml) were acquired from 
Peprotech.  
Wortmannin (100nM), a PI3Ks inhibitor, and p38 MAPK inhibitor (SB202190, 10μM) were 







PHOSPHOPROTEOMIC ANALYSIS OF TAMs AND POLARIZED PECs 
The phospho-proteoma of TAMs isolated from murine fibrosarcoma (MN/MCA1) was 
analysed in comparison to naïve (untreated), classic (M1) and alternative (M2) polarized 
macrophages (PECs).  
To get M1 polarized PECs, cells were stimulated with LPS (100ng/ml) and IFNγ (200U/ml) for 
30 minutes, whereas for M2 activation, PECs were treated with IL-4 (20ng/ml) for 8 hours. 
Protein extraction 
After the indicated treatments, cells were washed twice with ice-cold PBS 1X, then lysed with 
300µL/Petri of Lysis Buffer (25mM Tris-HCl, pH8; 75mM NaCl; 2,5mM EGTA, pH 8; 
0,75mM MgCl2; 10% Glycerol [vol/vol]; 1% Tryton X-100 [vol/vol]; 50mM NaF, 10mM 
NaPP, 10mM Na3VO4; 100µg/ml PMSF, Cocktail α-protease 1X). After 20 minutes of 
incubation on ice the cell lysates were collected in eppendorf and centrifuged (at 4°C, 13000 
rpm, 20 min) to eliminate cell debrises. Supernatants (protein extracts) were transferred in new 
tube and stored at -80°C. Protein extracts were quantified with Comassie brilliant blue assay 
kit (Thermo Scientific). 300μg of each protein extracts were precipitated with 6 volume of 
acetone, and incubated o.n. at -20°C. After this period, the samples were centrifuged at 13000 
rpm, 10 min; the supernatant was discarded and the pellet was air dried for 30 minutes. At the 
end, samples were stored at -80°C. 
Phosphorylation maps 
To generate the phosphorylation map of the different samples we took advantage of the iTRAQ 
technique (Isobaric tags for relative and absolute quantitation). This method was based on the 
covalent labelling of the N-terminus and sidechain amines of peptides from protein digestions 
with tags of varying mass. Our reagent, the 4-plex iTRAQ, could be used to label all peptides 
from 4 different samples/treatments. These samples were then pooled and fractionated by nano 
liquid chromatography. From all fractions, phosphopeptides were enriched on TiO2 beads in 
the presence of 2,5-dihydrobenzoic acid and analyzed by tandem mass spectrometry (MS/MS). 
The relative abundance (ratio) of the peptides was defined by measuring the low molecular 
mass reporter ions generated by the fragmentation of the attached tag. Next, fragmentation data 
were in silico analyzed to identify the labelled phospho-peptides, hence the corresponding 
proteins. Next, by using the Ingenuity Pathways Analysis (IPA) software maps of protein-
protein interaction was created.  
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Immunostaining and Confocal Microscopy Analysis  
Cryostat tumor sections (from murine fibrosarcoma) of 8 μm were fixed in PFA 4% for 15 min. 
Endogenous peroxidises were blocked with 2-3% H2O2 (40%) in H2O, for 5 minutes. 
Unspecific binding sites were blocked with BSA 2% + Triton 100X 0,1%, in PBS+/+ Tween20 
(0,05%), for 1hour. Immunostaining was carried out with rat anti-mouse CD3 (#A0452, 
DAKO), rat anti-mouse F4/80 (clone CI:A3-1, AbD Serotec), rat anti-mouse Ly6G (clone 1A8 
BD),  rabbit anti-mouse KAP1 (clone: 10484, Abcam, 1:500) and rabbit anti-mouse P-KAP1 
(clone: EPR5249, Epitomics, 1:700), for 1 hour. Goat anti-rat AlexaFluor 488 conjugated and 
donkey anti-rabbit AlexaFluor 647 conjugated were used as secondary antibodies. 
Nuclei were stained with DAPI (4',6-diamidino-2-phenylindole) (#D1306, Life Technologies) 
and then mounted with ProLong Antifade Gold Reagent (P-36931, Life Technologies). Slides 
were analyzed with Olympus Fluoview FV1000 laser scanning confocal microscope with 60X 
(N.A.0.4).  
FACS ANALYSIS 
5x105 and 1x106 cells were used for staining extra- and intra-cellular antigens respectively. 
Staining was performed in FACS buffer at 4°C for 20 minutes, with the following antibodies: 
FITC anti-mouse LY6C (clone 1A8, Miltenyi), PE anti-mouse Ly6G (clone1G7-10G, Miltenyi), 
APC anti-mouse CD11b (clone M1/70, Biolegend), and PerCP-Cy5.5 anti-mouse CD45 (clone 
30-F11, Biolegend), Alexa488 anti mouse CD8a (clone 53-6.7, Biolegend), PE anti-mouse CD4 
(clone GK 1.5, Biolegend) and APC anti-mouse INF-γ/Isotype (clone XMG 1.2, Biolegend)  
FITC anti-mouse CD11b (clone M1/70, Pharmigen), PE anti-mouse F4/80 (clone BM8, 
Biolegend ), APC anti-mouse Ki-67 (clone 16A8, Biolegend).  
For intracellular staining (INF-γ, Ki-67) Cytofix/Cytoperm and PermWash staining kit 
(Pharmigen) were used according to the manufacturer’s protocol. Cells were detected using the 
BD FACS Canto cytofluorimeter and analyzed with Flowjo Software.  
Western Blot (WB) Analysis 
30 μg total of proteins were separated on 7.5% SDS-PAGE under reducing conditions and 
transferred onto nitrocellulose membrane. Membrane was incubated at RT, with 5% nonfat dry milk 
(Applichem) or 5%BSA (Sigma) in TBST (50mM Tris, 150mM NaCl, 0,1% Tween) to saturate 
non-specific binding sites. After 1 hour of blocking, membrane was incubated with the primary 
antibody solution at 4°C, o.n. Next, the membrane was washed with TBST for 10 minutes at 
RT (three times) and incubated with the HRP-conjugated secondary antibodies solution. After 
1 hour at RT, membrane was washed three times for 10 minutes with TBST.  Finally, 
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chemiluminescence substrate (ECL, Biorad) was added and signals were detected at trans-
illuminator Chemidoc (Biorad). 
List of primary antibodies and conditions of use: pTRIM28 Ser 473, (Clone: EPR5249, 
EPITOMICS), dilution 1:50000, 5% BSA, 4°C, o/n; TRIM28 (ab 10484, Abcam), diluition 
1:1000, 5% milk, 4°C, o/n; p-AKT (Cell Signaling), dilution 1:1000, 5% BSA, 4°C, o/n; IKB-
α,  dilution 1:1000), 5% milk, 4°C, o/n; : p-STAT6 (Cell Signaling) dilution 1:1000, in BSA 
5%, o/n, 4°C;  Actin (Sigma-Aldrich), dilution 1:10000, 5% milk, RT, 1 hour. 
List secondary antibodies: Goat- α-Rabbit-HRP-coniugated (7074S, Cell Signaling) and Goat- 
α-Mouse-HRP-coniugated (7076S, Cell Signaling); dilution 1:5000, RT, 1 hour.  
Total RNA extraction  
RNA was extracted according to the manufacturer’s instructions of RNeasy Mini Kit (Qiagen).   
RNA was quantified by using Nanodrop spectrophotometer. RNA quality was assessed as 
260/280 and 260/230 OD ratio >1.5. 2 μg of RNA was reverse transcribed by the Script 
Advanced icDNA Synthesis Kit (Biorad), and then 4ul of diluted CDNA (ratio 1:5) was used 
as a template for SYBER Green Master Mix (Biorad) and detected by the CFX96 Real-Time 
System (BioRad). All samples were run in triplicate. Expression data were normalized to Actin 
housekeeping mRNA and were analyzed by the 2−(ΔCt) method. Results are expressed or as 
2−(ΔCt) or as fold upregulation respect to the control cell population. The sequences of gene-
specific were designed by using https://www.ncbi.nlm.nih.gov/tools/primer-blast/. The primers 
are synthetized by Sigma-Aldrich and their list is reported in Supplementary Table S1. 
RNAseq 
Peritoneal macrophages (PEC) were isolated from TRIM28LysM-Cre and TRIM28flox/flox mice after 
5 day of i.p. injection with 1ml of 3% thioglycolate solution (ref). Cells were left untreated, 
activated by 4 hour of LPS (100ng/ml ) (ditta) treatment (LPS) or tolerized by (L/L) by 20 hours 
of LPS treatment.For each condition, experiments were performed in duplicate, for a total of 
12 samples. Total RNA was extracted RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions RNA quality was assessed on an Agilent 4200 TapeStation, 
obtaining a mean RNA integrity number (RIN) of 6.4 (max: 7.4, min 4.9). Libraries were 
prepared starting from 500 ng of total RNA with the SMARTer® Stranded Total RNA Sample 
Prep Kit - HI Mammalian Clontech-Takara), following the manufacturer’s instructions. 
Libraries were sequenced as 76-bp paired-end reads on a NextSeq550 platform (Illumina). 
Reads were mapped to the UCSC mm10 reference genome and to the Mus 
Musculus transcriptome [Illumina’s iGenomes reference 
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annotation,  http://support.illumina.com/sequencing/sequencing_software/igenome.html] with 
Star v.2.7.1a21, and gene count tables generated using htseq v.0.11.222. Quality control (QC) 
was performed on raw data (.fastq files) using FastQC v.0.11.823, and on aligned data (.bam 
files) using RSeQC v.2.6.424. The final QC report was generated with MultiQC v.1.725, by 
aggregating the results and statistics obtained with multiple tools (FastQC, STAR, htseq, 
RSeQC). Differential gene expression was performed using pairwise comparisons between 
experimental groups with the DeSeq2 Bioconductor package26, using a Wald test to assess 
statistical significance of the observed fold change differences. Differentially expressed (DE) 
genes were selected using a false discovery rate (FDR) of ≤0.01, and a log2 fold change of ≥1 
or ≤ -1. Gene set enrichment analyses were performed using the TopGo Bioconductor package 
[https://bioconductor.org/packages/release/bioc/html/topGO.html] as well as Metascape 27 with 
default parameters, independently on upregulated and downregulated genes.  
MN/MCA1 Fibrosarcoma 
TRIM28LysM-Cre and TRIM28flox/flox were injected intra-muscle in the left hind limb with 105 
MN/MCA1 cells. Starting from the 14th day, tumor growth was monitored three times a week 
by measuring tumor volume with a calliper. Since MN/MCA1 fibrosarcoma metastasise to the 
lungs, when tumor reached a volume of about 2.5 cm (about 21th day), mice were sacrificed, 
tumors were weighted and lung metastases were counted.  To isolate TAMs, tumors were 
disaggregated as described above. Further, tumors and spleens were analysed for the 
composition of infiltrated immune cells by Fluorescence-activated cell sorting (FACS) analysis.  
To this aim, each tumor was disaggregated at 37°C, for 20 minutes in a solution of 0,5mg/ml 
collagenase, in incomplete RPMI. Next, the collagenase activity was blocked by adding EDTA 
to a final concentration of 10mM. Tumors pieces were smashed by pipetting up and down with 
a Pasteur pipette. Next, cell suspension was diluted with 10-20 ml of PBS 1X and filtered 
through a sterile gauge.  Cell suspension was filtered again on a 70µm cell strainer and 
centrifuged at 1000 rpm, for 10 minutes. Cells were re-suspended in FACS buffer (HBSS with 
1% FBS) and counted. 
Spleens were smashed on a 70µm cell strainer in complete RPMI, and centrifuge at 1200 rpm, 
for 8 minutes. To eliminate erythrocytes, cells were resuspended with ACK buffer lysis (Lonza) 
(2ml/spleen) and kept at RT for 5 minutes. Cells were centrifuged (at 1200 rpm, for 8 minutes), 
re-suspended in FACS buffer and counted. To evaluate the level of INF-γ produced by CD4 
and CD8 cells, 1x106 splenocytes were re-suspended in complete RPMI medium and activated 
with PMA+Ionomycin for 4 hours. 
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Dextran Sodium Sulphate (DSS) - induced acute colitis 
To induce acute colitis, 8- to 10-week-old mice (TRIM28LysM-Cre, TRIM28Villin-Cre and TRIM28 
flox/flox littermates), were treated with1.5% dextran sodium sulphate (DSS, MP Biomedicals, 
molecular mass: 40 kDa) in drinking water for 5 days, followed by 2 weeks of tap water. To 
evaluate colitis mice were daily monitored for body weight. Mice were euthanized if they 
showed signs (visible rectal bleeding or a 25-30% decreased of initial body weight) of excessive 
discomfort. Mice were sacrificed or at day 8, (acute phase of colitis) or at 18th day, (recovery). 
Colon were harvested and measured. The extent of colon shortening reflects the degree of 
inflammation.   
Azoxymethane (AOM)/DSS AOM-CRC model  
To recapitulate IBD-associated CRC, 10- to 12-week-old mice were injected intra-peritoneal 
(i.p.) with a single dose (10 mg/kg of body weight) of the mutagenic agent azoxymethane 
(Sigma). Five days later, mice received water with 1.2-1.5% dextran sodium sulfate for 5 days, 
separated by 16 days of tap water. This cycle of DSS treatment was repeated two more times. 
After 3 months of AOM/DSS treatment, mice develop multiple colonic tumors. During DSS 
treatment, the clinical course of colitis was evaluated by monitoring mice body weight28.   
AOM-CRC model  
To reproduce sporadic CRC, mice were i.p. injected with AOM (10mg/kg of body weight), 
once a week for 6 weeks. After 6 months mice developed multiple visible colonic polyps29.  
At the time of harvest, mice were euthanized, colons were resected, flushed with saline solution, 
opened longitudinally, and macroscopically evaluated for tumor numbers.   
Single-Cell RNA-Seq  
Sample preparation 
Single-cells RNAseq was performed on 8895  Intestinal Epithelial Cells  (IECs, Epcam+-CD45-
/+) and on 32944  immune cells (Epcam--CD45+) derived from the entire colon tissues or the 
tumor lesions of 2 mouse strains (TRIM28VillinCre and TRIM28flox/flox mice). For each strain, 2 
different conditions were analyzed: the acute phase of colitis (at the 1st DSS cycle) and during 
tumor development 3 weeks after the last cycle of DSS. For each condition, experiments were 
performed in duplicate, for a total of 12 samples. 
Colon were longitudinally cut and washed with PBS to remove feces and debris. Colon tissues 
(in 1st analysis) or tumors (in 2nd analysis) were sliced into small fragments roughly 2 mm long. 
and incubated under rotation (speed 35-40) in HBSS (w/o Ca2+/Mg2+) containing 5% FBS, 10 
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mmol/L HEPES, 2.5 mmol/L EDTA for 20 minutes at 37°C (twice). Tissues were collected and 
washed in HBSS medium containing 5mM CaCl2 and then finely minced and incubated under 
rotation in HBSS containing 5% FBS, 10 mmol/L HEPES, 5mM CaCl2,  dispase/collagenase (1 
mg/mL; Roche), collagenase IV (250 μg/mL; Serva), and DNAse (40 μg/mL; Roche) for 20 
minutes at 37°C.  
The single cell suspension was then passed through a through a 100-μm and 70-μm cell strainers 
and centrifuged 1450rpm, 4°, 6 min. 
10 million cells/group were stained in 0.5% FBS, HBSS solution with anti-mouse CD45 (FITC, 
clone 30-F11, Biolegend), anti-Epcam (ApC-eFluor 780, Clone G88, Invitrogen), in the 
presence of LIVE/DEAD (Pacific Blue, Invitrogen) to evaluate cell viability. CD45+ cells and 
Epcam+ cells were collected after sorting (BD FACSAria™ Fusion sorter). Cells were 
resuspended in 1ml PBS plus 0.04% BSA and washed two times by centrifugation at 450 rcf 
for 7min. After the second wash cells were resuspended in 30 ul and counted with an automatic 
cell counter (Countess II, Thermo Fisher) to get a precise estimation of total number of cells 
recovered.    
Afterwards cells, mixed following this ratio 70% CD45+-Epcam- cells + 30% Epcam+- CD45+/- 
cells, for each sample were loaded into one channel of the Single Cell Chip A using the Single 
Cell 3’ v2 single cell reagent kit (10X Genomics) for Gel bead Emulsion generation into the 
Chromium system. Following capture and lysis, cDNA was synthesized and amplified for 14 
cycles following the manufacturer’s protocol (10X Genomics). 50 ng of the amplified cDNA 
were then used for each sample to construct Illumina sequencing libraries. Sequencing was 
performed on the NextSeq500 Illumina sequencing platform following 10x Genomics 
instruction for reads generation. A sequencing depth of at least ~ 50.000 reads/cell was obtained 
for each sample. 
Data pre-processing and integration 
Reads, derived from raw sequencing data, were aligned to the mm10 mouse genome with Cell 
Ranger v3.0.130 and count matrices were loaded with Seurat R package v3.0.1. Ribosomial 
genes and cells having less than 200 or more than 3000 expressed genes were removed. Data 
normalization was performed by applying the NormalizeData Seurat function (method = 
LogNormalize). Then, the “SCT” normalization31 was performed on each sample, obtaining an 
integrated dataset consisting of 41,839 cells. A principal component analysis (PCA) was 
performed on the top variable features and the first 20 principal components (PCs) were selected 
for downstream analysis. The FindClusters Seurat function was used with different resolution 
values to identify cell clusters and their stability was assessed with the clustree R package 
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v.0.432. A final clustering resolution of 0.1 was chosen, giving rise to a total of 11 clusters. 
Cluster marker genes were obtained using the FindAllMarkers Seurat function (FDR < 0.05). 
Reclustering of epithelial and immune cells was performed by repeating the same analysis to 
different subset of the whole dataset. Reclustering of epithelial cells was obtained considering 
the subsets of cells belonging to clusters number 3, 5, 8 and 10 (8,895 cells) and a clustering 
resolution of 0.4 was chosen. Reclustering of immune cells was obtained considering the 
subsets of cells belonging to the remaining clusters (32,944 cells) and a clustering resolution of 
1.0 was selected.  
To determine the cells frequency shift between experimental conditions the number of cells 
belonging to each cluster has been divided into the experimental groups, obtaining a table where 
each column corresponds to an experimental group and each row correspond to a cluster. Cells 
frequency were then obtained by using the prop.table R function (margin = 2). Both reclustering 
was considered separately. For epithelial cells, clusters 6, 8 and 9 were excluded from the 
counting process. 
Statistical analysis 
Statistical evaluation of the differential analysis was performed by one-way ANOVA and 
unpaired Student's t-test. (GraphPad Prism software). significance level was set at *p < 0.05, 






Tripartite motif-containing 28 (TRIM28) protein is new target of the inflammatory kinase 
signaling shared by TAMs and M1-polarized macrophages  
Mass spectrometry-based phosphoproteomics is a powerful methodology for the study of kinase 
signaling, an essential process for cellular activity33. To investigate the molecular pathways 
underlying the TAMs pro-tumoral activities we analyzed the alterations of the phospho-
proteoma of TAMs isolated from murine MN/MCA1 fibrosarcoma, as compared to resting 
(ctr), M1 (IFNγ/LPS, 30min) and M2 (IL-4, 8 hours) polarized macrophages (Fig. 1A top).  The 
protein extracts were labeled with the 4-plex isobaric tags for relative and absolute quantitation 
(iTRAQ), then the combined and dried digests were subjected to phospho-peptide enrichment 
using Magnetic Titanium Dioxide Phosphopeptide Enrichment Kit and subsequently prepared 
for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The relative 
abundance (ratio) of the peptides was defined by measuring the low molecular mass reporter 
ions generated by the fragmentation of the attached tag. Next, in silico analysis of the 
fragmentation data for peptide scoring, protein identification, and quantification were 
performed using MaxQuant software34. The results, representative of two biological replicates, 
showed a list of 24 proteins with the higher different levels of phosphorylation among the 
distinct populations of analyzed macrophages.  
In particular, Tripartite motif-containing 28 (TRIM28) emerged as the protein with the highest 
levels of phosphorylation on Ser473 (S473p) in M1-polarized PECs and TAMs (Fig.1 A down 
and Supplementary Fig.1 A-C). 
TRIM28, also known as KRAB (Kruppel-associated box)-associated protein (KAP1) or 
transcription intermediary factor 1β (TIF1β) is a member of the Kruppel-Associated-Box 
Proteins that participates in the dynamic organization of chromatin and is involved in multiple 
aspects of cellular physiology, including immunology, cancer biology, virology and embryo 
development 35,36.  
TRIM28 biological activity is mainly regulated by post-translational modifications including 
sumoylation, ubiquitination and phosphorylation.  
Western-blot analysis of a new set of biological samples confirmed high levels of TRIM28 
S473p in both M1-polarized PECs and TAMs, along with a similar amount of total TRIM28 
protein in all samples (Fig. 1B). Taken together, these results indicate that TRIM28 S473p is 
triggered in both M1-polarized PECs and TAMs, without any significant alteration of the total 
amount of protein. 
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To ascertain in vivo, the phosphorylation of  TRIM28 S473 in TAMs, MN/MCA1 tumor 
sections were immunostained with anti-F4/80 along with anti-TRIM28 or anti-
PhosphoTRIM28(Ser473) antibodies. Confocal microscopy analysis confirmed that almost all 
TAMs (F4/80+ cells) express TRIM28 in its Ser473 phosphorylated form. Furthermore, we 
observed a significant amount of TRIM28 S473p in T-cells (CD3+) and proliferating (Ki67+) 
cells, which largely represent tumor cells.  Overall, these results suggest that TRIM28 could 
play a role in tumor development by modulating both neoplastic cells activities and cancer-






Figure 1. High levels of pTRIM28 Ser473 in M1-polarized macrophages and TAMs. (A top) Scheme of sample preparation for 
phosphoproteoma analysis: TAMs isolated from murine MN/MCA1 fibrosarcoma were compared to resting (CTR), M1 
(IFNγ/LPS, 30 min) and M2 (IL-4, 8 hours) polarized macrophages. (A down) Selected proteins list defining the 
phosphoproteoma of TAMs as compared to naïve (CTR), M1 and M2-polarized macrophages.  (B) Validation of the results of 
phospho-maps by Western Blot. PECs were left untreated (CTR) or stimulated with INFγ+LPS, for 30’ (M1-polarized activation) 
or IL-4 for 8 hours (M2-polarized activation). TAMs were isolated from MN-MCA1 fibrosarcoma. Total proteins extracts were 
analyzed by Western blot for TRIM28 S473p and TRIM28. Actin was used as loading control. (C) Confocal microscopy analysis 
of TRIM28 (red) and pTRIM28 (red) in TAMs (F4/80+ cells, green), T-cells (CD3+ cells, green) and proliferative tumors cells (Ki-
67+ cells, green). The cell nuclei were counterstained with DAPI (blue). Magnification 60X. 
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Selected inflammatory cytokines and bacterial products trigger phosphorylation of TRIM28 
at serine 473 residue through the MyD88/p38 dependent pathway  
So far, phosphorylation on serine 473 (S473) has been reported in both physiological condition, 
such as during the late S phase of cell cycle, and in different stress setting including DNA 
damage37, metabolic stress38, viral infection39 and T cell receptor activation40,41. Our results 
provide the first evidence that the combination of LPS and IFN triggers TRIM28 S473p in 
macrophages. To go insight the characterization of the inflammatory signals that could induce 
TRIM28 S473p, PECs were treated with both TLR ligands and inflammatory cytokines.  Albeit 
we didn’t observe any significant phosphorylation of TRIM28 in response to IFN we 
confirmed TRIM28 S473p upon LPS treatment (Data not shown). Moreover, Western blot 
analysis showed that TNFα, IL-1, and IL-6 activate phosphorylation of TRIM28 at Ser473 
(Fig. 2A). Although cytokines were less potent than LPS, we observed a similar kinetic of 
TRIM28 S473p in response to all the M1-inducing signals (Fig. 2A), indicating that TRIM28 
S473p is an early and transient event of the signaling cascade induced by both bacterial products 
and inflammatory cytokines. Beyond LPS (TLR4), we observed that either 2μg/ml PAM3CSK4 
(TLR2) or 100ng/ml Flagellin (TLR5), were able to trigger high levels of TRIM28 S473p, 
whereas 10μg/ml Poly-IC (TLR3), 100μM Loxoribine (TLR7) and 1μg/ml CpG1826 (TLR9) 
didn’t induce TRIM28 S473p (Fig. 2B). Activation of all TLRs was confirmed by IκBα 
degradation (Fig. 2B), therefore we can conclude that TRIM28 S473p is new molecular event 
of the plasma membrane TLR signaling cascade.  
To go insight the molecular mechanisms driving TRIM28 S473 phosphorylation, we initially 
analyzed the impact of the adaptor protein MyD88, the first crucial molecule of the transduction 
pathway for all TLRs, except TLR3. PECs isolated from WT and Myd88 Knock-Out (Myd88-
/-) mice were treated with LPS for 15, 30 and 60 minutes and analyzed for TRIM28 S473p. WB 
showed that LPS-induced TRIM28 S473p was totally abrogated in Myd88-/- PECs, (Fig. 2C), 
thus demonstrating that phosphorylation of TRIM28 is under the control of the Myd88-
dependent pathway. 
TLR engagement activates different intracellular signaling pathways, including 
Phosphatidylinositol-3 kinase (PI3K)/ Akt pathway. Since in response to distinct DNA damage 
stimuli, PI3K-related kinases members ATM (ataxia telangiectasia mutated)/ATR (ataxia 
telangiectasia and Rad3 xrelated) induce TRIM28 S473p42, we evaluated whether the PI3K/Akt 
signaling pathway could be involved in MyD88-dependent phosphorylation of TRIM28 at 
S473. To address this hypothesis, PECs were treated or not with an irreversible nonselective 
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inhibitor of the PI3K-related kinases members (Wortmannin, 100nM) for 1 hour. Next, medium 
was changed and cells were activated with LPS or PAM3CSK4 for 30 minutes, to induce 
TRIM28 S473p. WB analysis showed that both TLR agonists induced similar levels of TRIM28 
S473p in cells pre-treated or not with Wortmannin (Fig. 2D). To confirm that Wortmannin 
blocks PI3K/Akt activation, we evaluated the levels of pAkt. As expected, pre-treatment of 
Wortmannin abrogated both LPS and PAM3CSK4 induced phosphorylation of Akt (Fig.2D). 
Therefore, we can conclude that TLR4 and TLR2-dependent TRIM28 S473p is independent on 
PI3K/Akt pathway. 
Different studies have reported that TRIM28 S473p can be triggered by p38 MAPK43. In 
colorectal cancer cells, peroxide-induced p38 MAPK triggers phosphorylation of TRIM28 at 
S473, this event is associated with a more efficient DNA repair and tumor cell survival under 
oxidative stress conditions43. Infection of human lung epithelial cells by highly pathogenic 
avian influenza virus (HPAIV) strains result in PKR-mediated sensing of viral RNA and p38-
MSK1-dependent TRIM28 S473 phosphorylation an event that leads to exacerbated 
inflammation and tissue damage44. The p38 MAK is also a key regulator of TLR-induced 
inflammatory gene expression45,46. Based on this evidence, we explored whether TLR 
dependent activation of p38 could control TRIM28 Ser473p in murine macrophages. PECs 
were preincubated with p38 inhibitor (SB 202190, 10 μM) for 30 minutes, and subsequently 
treated with LPS and PAM3CSK4 for 30 minutes. Western blot analysis demonstrates that p38 
inhibition restrained both TLR2 and TLR4-induced TRIM28 S473p (Figure 2E) thus 
confirming p38 MAPK as a key kinase for the phosphorylation of TRIM28 at S473 under 
inflammatory condition 
Collectively these results demonstrate that TRIM28 S473p is induced by different pro-
inflammatory signals, including cytokines and microbial products, suggesting TRIM28 as a 











Selectively immunoregulatory M2-like signals induce TRIM28 (Ser473) phosphorylation. 
To evaluate TRIM28 S473p in M2-skewed activation, PECs were treated with IL-4 for 0,5, 1, 
2, 4 and 8 hours. According with phospho-proteomic analysis, we did not detect any TRIM28 
S473p after 8 hours of IL-4 stimulation and we confirmed these results at earlier time points. 
(We used LPS treatment as positive control of TRIM28 S473p and Stat6 phosphorylation as 
read out of IL-4 treatment) (Fig. 2F). In the attempt to identify potential tumor-derived signals 
controlling TRIM28 S473p in TAMs, we tested immunoregulatory molecules (IL-10, PGE2) 
that we had found enriched in fibrosarcoma model19,47. WB analysis of IL-10 or PGE2 
stimulated PECs showed that both immunomodulatory stimuli were able to induce TRIM 
S473p, with a lower potency than LPS but with a long lasting effect (Fig. 2G).  
Finally, we evaluated whether bacterial products and cytokines were able to trigger 
phosphorylation of TRIM28 at S473 also in human monocytes. WB analysis confirmed 
TRIM28 S473p in human monocytes treated with LPS, TNF and IL-10 for 30 minutes, 








Figure 2. Both inflammatory cytokines and microbial products trigger TRIM28 S473p in PECs. (A) PECs were treated with 
TNFα (20ng/ml), IL-1b (20ng/ml), IL-6 (20ng/ml) and LPS (100ng/ml) for 30, 60, 120 minutes and were analysed for p-
TRIM28 (ser473) levels by WB. Actin was used as sample loading control. (B) PECs were treated with 100ng/ml of LPS 
(TLR4), 2mg/ml of PAM3CSK4 (TLR2), 1mg/ml of CpG1826 (TLR9), 10mg/ml of PolyI-C (TLR3), 100ng/mL of Flagellin (TLR5) and 
100mM of Loxoribine (TLR7) for 30 minutes and were analysed by WB for p-TRIM28(Ser473) and KAP1 levels. To verify TLR 
activation, membrane was immunoblotted with an anti-IκBα antibody.  Actin was used as sample loading control.  
LPS, PAM3CSK4 and Flagellin require Myd88 and p38 MAPK activation to induce TRIM28 Ser473p. (C) PECs from wild type 
(WT) and Myd88-/- mice were stimulated with LPS (100ng/ml) for 15, 30, 60 minutes and analysed for TRIM28 S473p by 
Western blot. (D) PECs were treated or not with Wortmannin, (100nM) for 1 hour. Next, medium was changed and cells were 
activated with LPS (100ng/ml) or PAM3CSK4 (2mg/ml) for 30 minutes. Protein extracts were analysed by Western blot. 
Membrane was immunoblotted with anti-pTRIM28 (Ser473) and anti-pAkt antibodies. Actin was used as sample loading 
control. (E) PECs were treated or not with p38 inhibitor (SB202190, 100μM), for 1 hour. Next, cells were activated with LPS 
(100ng/ml), PAM3CSK4 (2mg/ml) for 30 minutes. Protein extracts were analysed by Western blot. Membrane was 
immunoblotted with anti-pTRIM28 (Ser473) and anti-TRIM28 antibodies. Actin was used as sample loading control. 
pTRIM28 are induced by selected immunoregulatory signals:(E) PECs were treated with IL-4 (20ng/ml) for 0,5, 1, 2, 4 and 8 
hours. PECs activated with LPS (100ng/ml), were used as positive control of TRIM28 S473p. Protein extracts were analysed 
by WB for TRIM28 S473p. To verify IL-4 stimulation, membrane was followed immunoblotted with anti-pSTAT6 antibody. The 
band (*) detected in the LPS lane represents membrane bound anti-pTRIM28(Ser473) antibody. (F) Immunoblot analysis of 
TRIM28 S473p in IL-10 (20ng/ml) and PGE2 (10μM) treated PECs. Actin was used as sample loading control. 
Inflammatory signals induce TRIM28 Ser473p in human monocytes:(G) Monocytes were isolated from peripheral blood of 
healthy donors (buffy-coat) and were stimulated with LPS (100ng/ml), TNFα (20ng/ml) and IL-10 (20ng/ml), for 30 minutes. 




Lack of TRIM28 in myeloid cells worsens DSS-induced colitis. 
To explore, in vivo, the functional relevance of myeloid TRIM28 in the context of cancer-
related inflammation, we took advantage of TRIM28flox/flox mice to generate mice that lacks 
TRIM28 in myeloid cells (TRIM28LysM-Cre).   
We initially evaluated the impact of TRIM28 on TAMs activities in the fibrosarcoma model. 
TRIM28LysM-Cre and TRIM28flox/flox mice were injected with MN/MCA1 cells and monitored for 
fibrosarcoma growth and progression. Both tumor growth curve and lung metastasis formation 
were similar in the two groups of mice (Fig. 3A). Furthermore, FACS analysis of both primary 
tumor and spleen showed a similar expansion of myeloid cells (TAMs, M- and PMN-MDSC) 
in tumor bearing mice (Fig. 3B) and RT-PCR analysis of TAMs indicated a mild deregulation 
of few M1-skewed genes (TNFα, IL-1β, IL-6, IL-23) along with an enhanced expression of 
CCL22 in TRIM28 KO TAMs (Fig. 3C). Collectively these results indicate that the total 
absence of TRIM28 in myeloid cells does not affect the pro-tumoral activities of TAMs in 
fibrosarcoma model.   
Next, we investigated the effect of myeloid TRIM28 in model of inflammation-driven cancer.  
Lack of TRIM28 in T cells has been found associated with both increased inflammation in a T 
cell transfer model of colitis48 as well as in spontaneous development of autoimmunity41. 
However, the effect of TRIM28 in myeloid cells in inflammatory response has never been 
investigated.  We used a chemical model of acute colitis driven by the disruption of intestinal 
barrier integrity to evaluate the inflammatory response mounted by TRIM28LysM-Cre and 
TRIM28flox/flox mice. Mice were treated with the colitogen agent DSS in drinking water, for 5 
days, followed by 2 weeks of regular water. To evaluate the clinical course of colitis, mice body 
weight was monitored daily and colon length was measured at the end of the experiment. The 
results showed that, TRIM28LysM-Cre mice showed a severe body weight loss and colon 
shortening as compared to TRIM28flox/flox (Fig. 3E, F). These results clearly demonstrated that 
myeloid-specific ablation of TRIM28, exacerbates DSS-induce colitis, thus supporting the 
analysis of CAC development in TRIM28LysM-Cre mice.  
To induce CAC, a single intra-peritoneal injection of the pro-carcinogen AOM (10mg/kg of 
body weight) was followed by three rounds of DSS treatment that induce a chronic state of 
inflammation enabling the development of multiple colonic polyps. In response to AOM/DSS 
treatment, TRIM28LysM-Cre, and TRIM28flox/flox were evaluated for both inflammatory response 
and development of neoplastic lesions. In keeping with acute model of colitis, lack of TRIM28 
in myeloid cells resulted in increased weight loss (Fig. 3H) and colon shortening (Fig. 3I). At 
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necroscopy, macroscopic evaluation of colons shown a similar number of tumor lesions 
TRIM28LysM-Cre, and TRIM28flox/flox indicating that, lack of TRIM28 in myeloid cells doesn’t 
alter tumor multiplicity (Fig.3L, M). Whether the increased inflammation developed by 
TRIM28LysM-Cre in response to AOM/DSS might affect tumor growth and progression is a 






Figure 3. TRIM28 in myeloid cells does not affect the pro-tumoral activities of TAMs in fibrosarcoma model. (A) TRIM28LysM-
Cre and TRIM28flox/flox mice were transplanted with 105 MN/MCA1 cells, starting from the 14th day, tumor growth was 
monitored three times a week by measuring tumor volume with a calliper. After euthanasia tumors were weighted and 
macroscopic lung metastases were counted (Data shown Mean ± SD and are representative of one of two independent 
experiments (*P<0.05 two-tailed t-test N=7). (B) FACS analysis of TAMs (F4/80+ cells), M-MDSC (CD11b+Ly6C+ cells) and 
PMN-MDSC (CD11b+Ly6C+ cells) accumulation in primary tumors and spleens of tumor bearing mice. Data from one 
representative experiment of 3 independent experiments (N= 5 TRIM28LysM-Cre mice, N=5 TRIM28flox/flox mice) Data shown are 
mean ± SEM. (C) RT-PCR analysis of TAMs derived from fibrosarcoma from TRIM28LysM-Cre and TRIM28flox/flox mice. TAMs were 
stimulated with INFγ+LPS (200U/ml INFγ+100ng/ml LPS, for 3 hours).  The expression of selected M1 (TNF-α, IL1-β, IL-6, IL-
12p35, IL-12p40, IL-23p19, CXCL9, CXCL10, iNOS) and M2 (IL-10, TGF-β, CD206, ArgI, CCL17, CCL22) genes were evaluated by 
qRT-PCR. Results are normalized on Actin mRNA levels and expressed as fold induction with respect to untreatd (ctr) TAMs. 
Data shown are means±SD; *P<0.05, two-tailed t-test, N=3 different biological samples.  
The impact of TRIM28 ablation in myeloid cells in DSS-acute colitis and CAC model.  
We took advantage of mice carrying a specific deletion of TRIM28 in myeloid cells (TRIM28-LysM-Cre mice to investigate its role 
in inflammation and cancer. (D) Scheme of DSS treatment in acute colitis model: to induce acute colitis, mice were treated 
with 1.2-1.5% of DSS in drinking water for 5 days, followed by 2 weeks of regular water. (E) Body weight loss was monitored 
every 2-3 days.  At day 18th mice were euthanized, (E) colons were resected and measured. Data shown are mean ± SEM, 
two-tailed t-test, **p<0.01. Data from one representative experiment of 2 independent experiments (N= 12 TRIM28LysM-Cre 
mice and N=12 TRIM28flox/flox mice for each experiment). (G) Scheme of the treatment of AOM/DSS model: to induce CRC, a 
single intra-peritoneal injection of AOM was followed by three rounds of treatment with DSS. Each round consisted of 5 days 
of 1.2% DSS in drinking water, followed by 16 days of regular water. (H) Graphics of body weight loss during treatment and 
(I) colon length after colon resection in TRIM28LysM-Cre and TRIM28flox/flox. (L) Representative images of CRC lesions, (M) colons 
were longitudinally opened and polyps were counted. Data shown are mean ±SEM, two-tailed t-test. Data from one 







TRIM28 modulates macrophage expression of LPS-induced transcriptional programs  
TRIM28 interacts with KRAB-zinc finger proteins to target specific genomic regions and 
modulates transcription through interactions with HP1 isoforms49. In addition of epigenetic 
control, TRIM28, HP1β, and HP1γ can directly regulate initiation and/or elongation of RNA 
polymerase II (Pol II)-dependent transcription50. Since we have observed that TRIM28LysMCre 
mice developed a more severe DSS-induced colitis, we evaluate the impact of lack of TRIM28 
on LPS-induced inflammatory gene expression. We generated mRNA sequencing (mRNA-seq) 
data sets of WT (TRIM28LysMCre) and TRIM28 KO (TRIM28flox/flox) PECs under both untreated 
condition (Ctr) and following the treatment with 100ng/ml LPS for 4 hours to induce M1-
polarized activation (LPS(4h)) or for 20 hours to induce an LPS-tolerant phenotype 
(LPS(18h))51.  
Data obtained with two biological replicates were highly correlated (r2>0.99) indicating high 
reproducibility between samples. Differential gene expression was performed using pairwise 
comparisons between the following experimental groups: WT_LPS (4h) vs WT_ctr, 
KO_LPS(4h) vs WT_ctr, KO_LPS(4h) vs KO_ctr and WT_LPS(18h) vs WT_ctr, 
KO_LPS(18h) vs WT_ctr, KO_LPS(18h) vs KO_ctr (Fig 4 A, D). To evaluate the effects of 
TRIM28 that are solely due to LPS treatment, we compared LPS treated TRIM28 KO to both 
KO_ctr and WT_ctr.  As summarized by Venn diagrams, upon short exposure to LPS, 2457 
(70.5%) genes are deregulated in both WT and TRIM28 KO PECs, indicated that the most of 
LPS-regulated genes are TRIM28 independent. However, 197 (5.7%) of genes are specifically 
deregulated in TRIM28 WT and 166 (4.8%) in TRIM28 KO only, overall indicating that 
TRIM28 regulates the expression of specific subset genes in response to LPS (Fig.4A). We 
focused on these LPS-regulated TRIM28 dependent genes. We analyzed the 197 genes that 
were specifically deregulated by LPS in WT PECs. Metascape analysis indicated a consistent 
enrichment of gene pathways involved in pyruvate metabolism, TCA cycle, nucleotide-excision 
repair (e.g. Nthl1, Pold1, Pole, Ercc8, Fan1, Fen1 genes) and DNA damage response (e.g. Cdk2, 
Fen1, Nthl1, Pold1, Pole, Eifak4, Pagr1a, Rps27l, Bbbc3 genes), suggesting that TRIM28 
modulates macrophage metabolism and repair of damaged DNA upon LPS exposure.   
In addition, lack of TRIM28 (TRIM28 KO PECs) modulated genes associated with cytokines 
secretion, including IL-6 production, corroborating the importance of TRIM28 in the regulation 
of LPS-induced inflammatory response (Fig.4B). 
Collectively, in comparison to ctr WT PECs, 4 hours of LPS activation triggers the upregulation 
of 1624 genes in WT and 1677 genes in TRIM28 KO PECs, whereas 1316 genes were 
downregulated in WT and 1337 genes in TRIM28 KO PECs (Supplementary Fig. A-D).  For 
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each comparison, a pathway enrichment analysis was performed using the Gene Ontology (GO) 
by TopGO. In both WT and TRIM28 KO PECs, 4 hours of LPS activation triggered an up-
regulation of pathways associated with immune cell activation and inflammation, however in 
WT PECs we observed a higher enrichment of pathways related to inflammatory cytokines 
production (e.g. IL-12) and MAPK activity whereas in TRIM28 PEC of those supporting 
mononuclear cell proliferation, leukocytes mediates cytotoxicity and inhibition of biosynthetic 
processes (Supplementary Fig.2 A, B). Among the genes that are downregulated by short LPS 
treatment, WT PECs showed a selective enrichment of pathways related to DNA methylation 
and double-strand break repair, whereas in TRIM28 KO PECs with leukocytes migration.  
(Supplementary Fig.2 C, D).  
In line with short LPS treatment, we observed 259 genes (8.7%) and 328 (11.1%) that are 
selectively regulated by prolonged LPS stimulation in WT and KO, respectively along with a 
large number of genes (1802, 60.8%) that are regulated by LPS in a TRIM28 independent 
manner (Fig. 4D). Metascape analysis of TRIM28 dependent genes showed that in WT,  LPS-
modulated genes are related to phagocytosis, antigen processing and presentation,  isoprenoid 
metabolism and   detoxification processes; whereas in KO came up genes associated with 
different metabolic pathways regulating proteins and amino acids catabolism, cholesterol 
biosynthesis and insulin-dependent metabolic processes  (Fig.4E, F). 
Overall, prolonged exposure to LPS was associated with 1168 upregulated and 1058 
downregulated genes in WT PECs; whereas in TRIM28 KO counterparts, 1276 genes are 
induced and 1114 genes are repressed by LPS treatment as compared to WT_ctr PECs. 
(Supplementary Fig.2 E-H).  
LPS tolerant WT PECs showed a selective enrichment of pathways associated with T cell 
activation and biosynthetic processes involving nucleobase-containing compounds and cellular 
nitrogen products.  In contrast in LPS tolerant TRIM28 KO PECs we observed an increase in 
the pathways that regulate the metabolism of organic cyclic compounds, the response to 
hormones, the induction of gene transcription and different cellular activity associated to virus 
sensitivity (e.g viral genome replication and type I interferons) (Supplementary Fig.2 E, F). 
Among the genes that are downregulated in LPS tolerant condition, WT PEC showed an 
enrichment of pathways related to response of oxidative stress, autophagy, IL-1 production and 
defense whereas in TRIM28 KO of those that are associated with the repression of gene 
expression (Supplementary Fig.2 G, H). 
Collectively these results indicate that TRIM28 modulate macrophage response to both short 
and prolonged LPS treatment by affecting the expression of selected gene transcriptional 
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programs associated to activation of adaptive immunity, modulation of multiple metabolic 






Figure 4. RNAseq analysis of “acute” and prolonged LPS treatment on PECs TRIM28_WT and TRIM28_KO.  Experimental 
scheme. (A, D) Ven diagram representation of acute and prolonged LPS treatment in PECs derived from TRIM28LysM-Cre and 
TRIM28flox/flox. PECs were stimulated with LPS (100ng/ml) for 4h or 18h, untreated PECs were left in complete medium 
throughout the entire experimental period. RNASeq of differential gene expressions was performed using pairwise 
comparisons between: WT_LPS (4h) vs WT_ctr, KO_LPS(4h) vs WT_ctr, KO_LPS(4h) vs KO_ctr and WT_LPS(18h) vs WT_ctr, 
KO_LPS(18h) vs WT_ctr, KO_LPS(18h) vs KO_ctr. DE genes were defined setting log2 fold change of ≥1 or ≤ -1 and FDR-
adjusted pvalue of ≤0.01. (B, C and E, F ) Gene set enrichment analyses performed by Metascape, with default parameters, 
independently on upregulated and downregulated genes (B,C) genes modulated by LPS_(4h) only in WT or KO mice (E, F) 
genes different modulated by LPS_(8h) only in WT or KO mice. 
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Lack of TRIM28 in intestinal epithelial cells (IECs) confer resistance to colitis-associated 
cancer (CAC).  
In non-immune cells, TRIM28 has been extensively studied in different cancers, in which, 
depending on the type, it can exert pro- or anti-tumoral functions52.  The tumor-suppressor 
activity of TRIM28 is related to the regulation of DNA repair mechanisms and epigenetic 
stability53, regulated by its phosphorylation of Ser473 and/or Ser824. Given that, we have found 
that both TLR ligands and inflammatory cytokines can induced TRIM28 S473p, we explored 
the impact of inflammation on TRIM28-dependent DNA damage response and consequent 
susceptibility of intestinal epithelial cells (IECs) to undergo neoplastic transformation.  
We initially analyzed the inflammatory response developed by TRIM28flox/flox and TRIM28Villin-
Cre mice in an acute model of DSS-induced colitis.  After a single round of DSS treatment, 
TRIM28Villin-Cre mice developed a more severe colitis as demonstrated by more pronounced 
reduction of body weight and colon length as compared to TRIM28floxflox mice (Fig. 5 B, C). 
Both TRIM28flox/flox and TRIM28Villin-Cre mice control mice showed a similar colon length and 
body weight (data not shown) ruling out any important effects of TRIM28 under physiological 
condition.   
Next, to explore the role of IECs- specific ablation of TRIM28 in CAC development, 
TRIM28flox/flox and TRIM28Villin-Cre mice were treated with azoxymethane (AOM) in 
combination with three rounds of DSS treatment. Albeit we confirmed an increased body 
weight loss in TRIM28Villin-Cre mice after the first DSS treatment, both mice groups showed 
similar flare up in response to the following rounds of DSS administration (Fig. 5E). In line 
with the body weight loss, at necroscopy, we observed a comparable colon shortening (Fig. 5F) 
However, macroscopic and histologic analysis of colons showed a drastic reduction of tumor 
lesions in TRIM28Villin-Cre mice (Fig. 5H). These results indicate that lack of TRIM28 in IECs 
enhances resistance against CAC development without affecting the overall degree of intestinal 
inflammation.   
In conclusion, our results showed that in preclinical models of CRC, the lack of TRIM28 in 
intestinal epithelial cells is fundamental to confer tumor resistance only in inflammation driven-








Figure 5. Study of the impact of TRIM28 ablation on IECs in DSS-induced colitis and chemically CRC models. We took 
advantage of mice carrying a specific deletion of TRIM28 in intestinal epithelial cells (TRIM28-VillinCre mice) to investigate its 
role in inflammation and cancer. (A) Scheme of DSS treatment in acute colitis model: to induce acute colitis, mice were treated 
with 1.2-1.5% of DSS in drinking water for 5 days, followed by 2 weeks of regular water. (B) Body weight loss was monitored 
every 2-3 days.  At day 18th mice were euthanized, (C) colons were resected and measured. Data shown are mean ± SEM, 
two-tailed t-test, **p<0.001. Data from one representative experiment of 2 independent experiments (N=10 TRIM28Villincre 
mice and N=10 TRIM28flox/flox mice for each experiment). (D) Scheme of the treatment of AOM/DSS model: to induce CRC, a 
single intra-peritoneal injection of AOM was followed by three rounds of treatment with DSS. Each round consisted of 5 days 
of 1.2% DSS in drinking water, followed by 16 days of regular water. (E) Graphics of body weight loss during treatment and 
(F) colon length after colon resection of TRIM2VillinCre and TRIM28flox/flox.(G) Representative images of CRC lesions, (H) colons 
were longitudinally opened and polyps were counted. Data shown are mean ±SEM, two-tailed t-test, N=7 (N= 8 TRIM28Villin 
Cre mice and N=8 TRIM28flox/flox mice for each experiment). (I) Scheme of the treatment of AOM model: mice were treated 
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intraperitoneal (ip) with 10mg/kg of AOM, once a week for 6 weeks; 24 weeks after the first AOM dose, colons of mice were 
harvested and tumors were counted.  (L) To analyze tumor development, colons were longitudinally opened and polyps were 
counted. (M) Representative images of CRC lesions. Data shown are mean ±SEM, two-tailed t-test. N=1 (N=15 TRIM28Villincre 
mice and N= 18 TRIM28flo/xflox mice) 
Single-Cell Transcriptome analysis of inflamed colon tissue and CRC lesions of TRIM28Villin-Cre 
and TRIM28flox/flox mice (AOM/DSS model). 
To dissect the mechanisms whereby TRIM28 in IECs supports inflammation-driven CRC 
development, we treated TRIM28Villin-Cre and TRIM28flox/flox mice with AOM /DSS and we 
analyzed the transcriptional profile of IECs/tumor cells and lamina propria immune cells by 
single cell RNAseq approach. This is an absolutely state-of-the-art NGS approach that allows 
to improve the characterization of heterogeneous cell populations and thus the resolution of 
complex biological systems54. 
Since we have observed that a tumor promoting inflammatory reprograming occurred during 
the transition from colitis to cancer20, we analyzed both the tumor lesions and the colon of 
AOM/DSS-treated mice 9 days (colitis) after the first DSS administration, when the mutant 
cells due to AOM treatment likely start the selection operated by immune cells.  
For colitis we profiled the transcriptome of approximately 1400 epithelia cells (Epcam+CD45-
) and 10800 immune cells (CD45+ Epcam-) of both TRIM28Villin-Cre and TRIM28flox/flox mice, 
whereas for CRC lesions we analyzed   2162 epithelia cells (Epcam+CD45+/-) and 6321 immune 
cells (CD45+ Epcam-) of TRIM28Villin-Cre and 3865 epithelia cells (Epcam+CD45+/-) and 4928 
immune cells (CD45+ Epcam-) of TRIM28flox/flox mice. 
The analyses of the immune and epithelial cells were performed independently.    
UMAP analysis and plotting identify 30 clusters of transcriptionally distinct cell types for the 
immune cells (CD45+ Epcam-cells) and 9 clusters for the epithelial cells (Epcam+CD45+/-cells).  
We annotated immune and epithelial cell clusters by taking advantage of cell-signatures 
reported in published studies55,56 or Database sets (e.g.MouseRNAseqData, 
HumanPrimaryCellAtlasData, BlueprintEncodeData) in combination with careful evaluation of 
marker genes. 
We identified 9 clusters of myeloid cells, including 2 clusters of neutrophils, 3 clusters of  
dendritic cells (cDC1, cDC2 and pDC), 1 cluster of monocytes and 2 clusters of macrophages 
including a population of CD14high IL1βhigh cellsand of M2 ApoehighC1qhigh cells). We also 
annotated 11 clusters of lymphoid cells, including population of CD8+, CD4+, NK, and γδ T 
cells, as well as 9 clusters of B cells including population of BCR activated B cells, 
CCL3+CCL4+ B cells, IgDhigh B cells, germinal center B cells, 2 populations of antigen 
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presenting B cells and 3 of Plasma B cells. Next, we evaluated the frequency of each cell cluster 
in colon (colitis) and tumors of TRIM28Villin-Cre and TRIM28flox/flox mice.   In tumor lesions of 
TRIM28Villin-Cre mice, we observed a trend towards an expansion of BCR activated B cells 
cluster.  Interestingly, different clinical studies have pointed out the high infiltration of B 
lymphocytes (CD20+) as  favorable prognostic indicators in terms of improved disease-specific 
survival57,58  and a lower risk of disease recurrence in metastatic colorectal cancer59.   
As compared to colitis, tumor lesions of both TRIM28flox/flox and TRIM28Villin-Cre mice showed 
a decreased frequency of the clusters related to NK (NK IL-22high), CD8 T cells (CD8 T cells 
and CD8 effector T + TGD cells) and γδ T cells (CD8 effector T + TGD cells). Of note, in the 
colon of TRIM28VillinCre mice, the clusters of NK IL-22high cells and early memory CD8 T cells 
tend to augment under “colitis” stage. In addition, the clusters of early memory CD8 T cells, 
CD4 effectors and TGD-Th2 T cells seem to be expanded in the tumor of TRIM28Villin-Cre mice. 
In contrast to lymphoid cell clusters, the results suggest a reduction of tumor associated myeloid 
clusters. In particular, monocytes, neutrophils and both CD14highIL1high and ApoehighC1qhigh 
macrophage clusters tend to be lower in CRC lesions of TRIM28Villin-Cre than in TRIM28flox/flox 
mice, whereas under “colitis” stage the population of colonic neutrophils seem to be expanded 
in absence of TRIM28. Overall, these observations warrant further studies to evaluate whether 
the tumor resistance in TRIM28Villin-Cre might be associated to the expansion of cytotoxic 
lymphoid cells along with the reduction of pro-tumoral myeloid cells.   
Among the 9 clusters of epithelial cells (Epcam+CD45+/- cells) we were able to identify 4 
clusters including populations of colonic cells, namely bottom Enterocytes, MUC3+ 
Enterocytes, Goblet and Paneth cells and stem cells. We also annotated as neoplastic cells the 
cluster enriched in epithelial-mesenchymal transition (EMT) genes and we found 2 clusters 
characterized by the high expression of Mitochondrial genes (cluster 1 and 5) that likely include 
populations of apoptotic cells. Finally,3 clusters have cell signature of fibroblasts and immune 
cells (mast cells and intraepithelial B and T cells). As expected, the cluster of neoplastic cells 
with a higher EMT signature selectively expanded in tumors, in particular in those of 
TRIM28flox/flox mice. In contrast the cluster of Goblet and Paneth cells is reduced during the 
transition from colitis to cancer, and seems to be lightly decreased in the colon of  TRIM28Villin-
Cre as compared to TRIM28flox/flox mice. These last observations suggest a potential impairment 
of Goblet and Paneth cells in TRIM28Villin-Cre as a pathogenic event contributing to increased 
intestinal inflammation.  
Collectively these results suggest that lack of TRIM28 in IECs impact on immune cells 
composition during the transition from colitis to cancer along with mild effects on the expansion 
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of neoplastic cells with an EMThigh gene signature and accumulation of Goblet and Paneth cells 














Figure 6. Single cell-RNAseq analysis of  immune cells infiltrate (CD45+, Epcam-cells) and Epithelial cells (Epcam+CD45- cells) 
of inflamed colon tissue and CRC lesions, during acute phase of DSS colitis and after  tumor development in AOM/DSS CRC 
model. (A) UMAP of integrated biological replicates identified 30 unique cell clusters for immune cells. Resolution 1.0. For 1st 
time point 10874 cells for TRIM28Villin-Cre mice and 10821 cells for TRIM28flox/flox mice were analyzed; for the 2nd analysis 6321 
cells for TRIM28Villin-Cre mice and 4928 cells for TRIM28flox/flox mice. (B) Distribution in terms of percentage of all immune cells 
across clusters 0–30 between TRIM28Villin-Cre  and  TRIM2 flox/flox  mice, in colitic colon tissue and tumors. (C) UMAP of integrated 
biological replicates identified 10 unique cell clusters for Epithelial cells (clusters 6,8 and 9 were excluded). Resolution 0.4 
was chosen. For 1st time point 1431 cells for TRIM28VillinCre mice and 1427 cells for TRIM28 flox/flox mice were analyzed; for the 
2nd analysis 2162 cells for TRIM28Villin-Cre mice and 3875 cells for TRIM28 flox/flox mice. (D) Distribution in terms of percentage 
of all epithelial cells across clusters 0–7 between TRIM28Villin-Cre  and TRIM28 flox/flox mice, in colitic colon tissue and tumors. 
Statistical comparisons were performed using one-way A-NOVA, significance level was set a *p<0.05. For each condition, 





Tumor Associated Macrophages (TAMs) are the major population of inflammatory cells 
infiltrating tumors, and the crucial orchestrators of tumor-promoting inflammation.  
Accumulating evidence indicates that TAMs-centred strategies may serve as promising 
candidates for cancer therapy. Understanding the molecular determinants underlying TAMs 
polarized activation represents a crucial challenge to identify new targets for more powerful 
therapeutic approaches.  
The biological activity of the majority of the proteins is regulated at the post-translational 
level60; in particular, the addition of phosphate groups to Serine, Tyrosine, Histidine and 
Threonine residues is a reversible modification that regulates several aspects of protein biology. 
Here we used mass spectrometry-based phosphoproteomics, a powerful methodology for the 
study of kinase signaling. To dissect the molecular pathways underlying the pro-tumoral 
activities of TAMs.   
Comparing the alterations of the phospho-proteoma of TAMs isolated from murine MN/MCA1 
fibrosarcoma, as compared to resting (ctr), M1 (IFNγ/LPS for 30 minutes) and M2 (IL-4 for 8 
hours) polarized macrophages we originally found the phosphorylation of Tripartite motif-
containing 28 (TRIM28) at Ser473 (TRIM28 S473p) in both M1-polarized PECs and TAMs.  
The tripartite motif containing protein 28 (TRIM28), also known as KRAB (Kruppel-associated 
box)- associated protein or transcription intermediary factor 1β (TIF1β) is a pleiotropic protein 
that participates in the dynamic organization of chromatin and regulates numerous different 
processes including gene expression, DNA repair, pluripotency, proliferation, differentiation 
and cell survival. TRIM28 biological activity is mainly regulated by post-translational 
modifications including sumoylation, ubiquitination and phosphorylation.  
So far, phosphorylation on serine 473 (S473) has been reported in both physiological condition, 
such as during the late S phase of cell cycle, and in different stress setting such as DNA 
damage37, metabolic stress38, viral infection39,61 and T cell receptor activation40,41. Our results 
provide the first evidence of TRIM28 S473p in macrophages activated by different 
inflammatory triggers.  
Confocal analyses of MN/MCA1 fibrosarcoma sections, confirmed TRIM28 S473p in TAMs 
and extended this observation to tumor cells, suggesting that TRIM28 could play a role in tumor 




Immunoregulatory molecules (IL-10, PGE2) that we have previously found enriched in 
fibrosarcoma, represent potential tumor-derived signals controlling TRIM28 S473p in TAMs. 
Indeed, we found that they were able to induce long-lasting TRIM28 S473p in PECs.  
Additionally, we found that several M1-inducing stimuli, including inflammatory cytokines 
(TNFα, IL-1β, IL-6) and plasma membrane toll-like receptor ligands (LPS, PAM3CSK4 and 
Flagellin) induce transient TRIM28 S473p in PECs 
Given that TLRs play a key role in the initiation of host defense against a wide range of threats 
and can contribute to the development and progression of inflammatory and autoimmune 
diseases and cancers62 we decided to investigate the molecular mechanisms driving TRIM28 
S473p upon plasma membrane TLRs engagement. We focused on the adaptor protein MyD88, 
which is the first crucial molecule of the transduction pathway for all TLRs, except TLR3, and 
we demonstrated that TRIM28 S473p is totally abrogated in Myd88-/- PECs, thus demonstrating 
that the Myd88-dependent pathway control TRIM28 S473p. 
Ligands of TLRs trigger several intracellular signaling pathways, such as the 
Phosphatidylinositol-3 kinase (PI3K) and the downstream serine/threonine kinases (Akts). 
Besides inflammation, PI3K/Akt dependent pathway plays an important role in the regulation 
of many cellular processes, including survival, proliferation, differentiation and metabolism63.  
Furthermore, several growth-factors induce the activation of this signaling pathway which are 
frequently altered in cancers64–66. Noteworthily, it was recently reported that the PI3K-related 
kinases members ATM (ataxia telangiectasia mutated)/ATR (ataxia telangiectasia and Rad3 
related) induce TRIM28 S473p in response to distinct DNA damage stimuli42. 
Therefore, we have hypothesized that PI3K/Akt signalling pathway could be involved in 
MyD88-dependent TRIM28 S473p induction. In contrast, our results reveal that TLR4- and 
TLR2-dependent TRIM28 S473p is independent of PI3K/Akt pathway. 
Another crucial protein in the MyD88-dependent pathway, is represented by p38, a member of 
the MAPKs signaling cascade, involved in the production of inflammatory mediators, including 
TNF-α and COX-267. P38 plays an essential role in regulating cellular processes, especially 
inflammation and it is activated downstream of MyD88 by stimulation of TLR2 and TLR446. 
In colorectal cancer cells, peroxide-induced p38 MAPK triggers phosphorylation of TRIM28 
at S473, this event is associated with a more efficient DNA repair and tumor cell survival under 
oxidative stress conditions68. Moreover, infection of human lung epithelial cells by highly 
pathogenic avian influenza virus (HPAIV) strains result in PKR-mediated sensing of viral RNA 
and p38-MSK1-dependent TRIM28 S473 phosphorylation an event that leads to exacerbated 
inflammation and tissue damage39. In summary, overall in vitro studies demonstrate that 
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TRIM28 S473p is induced by different pro-inflammatory signals, including cytokines and 
microbial products, suggesting TRIM28 as a novel regulator of M1-polarized activation.  
Finally, we confirmed TRIM28 phosphorylation in human monocytes treated with selected 
inflammatory stimuli. thus indicating that our finding could have translational perspectives. 
Although TRIM28 is involved in immune responses by controlling T cells69 and B cells70 
development, its function in macrophages differentiation is largely unknown. 
To establish the role of TRIM28 in macrophages and better characterized its impact on their 
activation, we analyzed the transcriptome of murine macrophages, derived from TRIM28LysMCre 
and TRIM28flox/flox mice, after acute and prolonged treatment with LPS, by RNA sequencing 
(RNAseq) technique. As expected, acute and prolonged exposition to LPS enhances the 
expression of different classes of genes; although the most of the induced are exclusively 
dependent by LPS approximately 10% of them are influenced by genotype. Collectively our 
data indicate that TRIM28 modulate macrophage response to both short and prolonged LPS 
treatment by affecting the expression of selected gene transcriptional programs associated to 
activation of adaptive immunity, modulation of multiple metabolic pathways and response to 
oxidative stress including DNA damage response.  
In future, we’re going to better characterize the pathways involved in the acute and prolonged 
inflammatory response, in order to dissect the impact of TRIM28 on macrophages phenotype 
and functional activation. TRIM28 can regulate gene transcription by, acting as a scaffold for 
different transcriptional factor. In the attempt scout potential TRIM28 dependent transcription 
factors, we are going to analyze the upstream regions of LPS-induced TRIM28-dependent 
genes for the the enrichment transcriptional binding motifs   
In vivo, to study the circuits involved in cancer-related inflammation, we focused on DSS-acute 
colitis model and DSS/AOM CAC model. Our data showed that in DSS-acute colitis model 
TRIM28LysM-Cre mice worsens intestinal inflammation in response to the treatment, but in 
contrast, despite the increased inflammatory response, lack of TRIM28 in myeloid cells seems 
not alter tumor multiplicity in AOM/DSS-induced CRC, in order to clarify this data, we’re 
going to perform histologically analysis on CRC lesions, evaluating the colitis and dysplasia 
grade, immune infiltrated, apoptosis, proliferation, stemness, DNA-damage and EMT process.  
Given that in non-immune cells, TRIM28 has been extensively studied in different cancers, in 
which, depending on the type, it can exert pro- or anti-tumoral functions we explored the impact 
of inflammation on TRIM28-dependent DNA damage response and consequent susceptibility 
of intestinal epithelial cells (IECs) to undergo neoplastic transformation. Taking advantage of 
mice lacking of TRIM28 in IECs and we discovered that IEC- specific ablation of TRIM28 
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worsens DSS-induced colitis and in AOM/DSS model, mice carrying IECs specific ablation of 
TRIM28 developed less number of tumor lesions, demonstrating that the ablation of TRIM28 
in IECs confers resistance against inflammation-driven tumor development under  
Our results suggest that TRIM28 modulates CRC development in both cell-specific and disease 
stage-specific dependent manner.  
This unexpected result obtained in TRIM28Villin-Cre brought us to perform the single cell 
transcriptome analysis of immune infiltrated and epithelial cells during the acute phase of 
colitis, that represents the elimination phase and when tumors were formed (escape phase), 
when CRC lesions were formed.  
These preliminary results gave us an overview of the cellular population expression in the 
inflammatory condition and during tumor development, defining the difference between the 
two phenotype. In particular, in acute colitis, in TRIM28Villin-Cre mice had an increase in the 
percentage of NK, CD8+ and CD4+ T cells, to confirm they higher inflammatory status as 
compare to TRIM28flox/flox mice. Whereas, in tumors TRIM28Villin-Cre mice have a higher 
expansion of B cells clusters, that could be related with a good prognostic value, as 
demonstrated by different clinical studies, in which patients whose tumors are highly infiltrated 
by B lymphocytes (CD20+) have a significantly improved disease-specific survival. The most 
interesting results emerged in the distribution of myeloid clusters, indeed, in TRIM28Villin-Cre 
mice the presence of the tumor infiltrating neutrophils (TANs) and TAMs was considerably 
decreased in CRC lesions, as well as a reduction of colon cells expressed EMT genes. 
Collectively these results suggest that lack of TRIM28 in IECs impact on immune cells 
composition during the transition from colitis to cancer along with mild effects on the expansion 
of neoplastic cells with an EMThigh gene signature and accumulation of Goblet and Paneth cells 
under colitis stage.  
Further analyses are essential to better understand the mechanism involved in TRIM28Villin-Cre 
protection.  
In conclusion, overall our in vitro and in vivo results bring us to consider TRIM28 as a novel 
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Supplementary Figure 1. Analyse of the phosphoproteoma of PECs and TAMs. Representative maps of CTR vs M1 PECs (A); 
CTR vs M2 PECs (B) and CTR PECs vs TAMs (C). Proteins with higher levels of phosphorylation are in red, proteins with lower 
levels of phosphorylation are in green. Maps of phosphorylated proteins were generated by using the Ingenuity Pathways 













Supplementary Figure 2. TopGO analysis of acute and prolonged LPS treatment on PECs TRIM28_WT and TRIM28_KO. 
Comparison of genes regulated by LPS in acute (LPS(4h)) and prolonged (LPS(18h)) exposition in KO mice using a different 
basal (CTR) condition, WT or KO mice. DE genes were defined setting log2FC <=-1 or >=1 and FDR-adjusted pvalue <=0.01 (B-
O) Gene set enrichment analyses performed by TopGo Bioconductor package for the following comparisons:  WT_LPS(4h) vs 
WT_CTR, KO_LPS(4h) vs WT_CTR or WT_LPS(18h) vs WT_CTR, KO_LPS(18h) vs WT_CTR of genes up-regulated by acute (A, B) 
or prolonged exposure to LPS (C, D)  or downregulated by LPS(4h) (E, F) or LPS(18h)(G, H).  DE genes were defined setting 




Supplementary Figure 3. Preliminary histological analysis of formalin-fixed, paraffin-embedded of colon swiss rolls sections 
from TRIM28Villin-Cre and TRIM28flox/flox mice after AOM/DSS treatment. Error bars, SEM. ***, P < 0.001 by two-tailed 
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Supplementary Table 1. Real-Time PCR primers list   
Gene Forward Reverse  
Forward  Reverse 
Actin  cccaaggccaaccgcgagaagat  gtcccggccagccaggtccag  
Arginase I  cagaagaatggaagagtcag  cagatatgcagggagtcacc  
CD206 tctttgcctttcccagtctcc tgacacccagcggaatttc 
CCL2  ccgtcattttctgcctcatcc  ccctatggccctcattctca  
CCL17  agtgctgcctggattacttcaaag  ctggacagtcagaaacacgatgg  
CCL22  taacatcatggctaccctgcg  tgtcttccacattggcacca  
CXCL9 tctcggacttcactccaacaca actccacactgctggaggaaga 
CXCL10  ccgtcattttctgcctcatcc ccctatggccctcattctca 
IL 1β  aagttgacggaccccaaaagat  tgttgatgtgctgctgcga  
IL 6  ggataccactcccaacagacct  gccattgcacaactcttttctc  
IL 10  ggttgccaagccttatcgga  acctgctccactgccttgct  
IL 12p35  ctatctgagctccgcctgaaag  ggccaagaccacctgactctta  
IL 12p40  ggaagcacggcagcagaata  aacttgagggagaagtaggaatgg  
IL 23p19  agccagttctgcttgcaaagg  ggaggttgtgaagttgctccatg  
i-NOS gccaccaacaatggcaaca cgtaccggatgagctgtgaatt 
KAP1  gctcgtccctgtacatt  aatccaccatagcgccgtc  
TGF- accaactattgcttcagcttcagctccac gatccacttccaacccaggtc 
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Malignant Pleural Mesothelioma (MPM) is a highly aggressive cancer with long latency period 
and dismal prognosis. Recently, EPZ-6438 (tazemetostat), an inhibitor of the histone 
methyltransferase EZH2, has entered in clinical trials due to the anti-proliferative effects 
reported on MPM cells. However, the direct and indirect effects of epigenetic reprograming on 
the tumor microenvironment (TME), is hitherto unexplored. Tumor Associated Macrophages 
(TAMs), expressing an M2-like phenotype are the major infiltrating immune cells supporting 
tumor growth and progression. To investigate the impact of TAMs on MPM cell responsiveness 
to EPZ-6438, we set up a reliable 3D MPM-monocytes spheroid model that recapitulates in 
vitro, both monocytes recruitment in tumor and their functional differentiation towards a TAM-
like phenotype (Mo-TAMs). Along with an increased expression of genes for M2 and 
immunosuppressive molecules, monocytes-recruiting chemokine and inhibitory immune 
checkpoints, Mo-TAMs promote tumor cell proliferation and spreading. Prolonged treatment 
of MSTO spheroids with EPZ-6438 enhances both the recruitment of Mo-TAMs and the 
expression of tumor promoting inflammatory genes overall suppressing the anti-proliferative 
effects due to EZH2 inhibition in MPM cells. Albeit M1-polarized monocytes exert a significant 
cytotoxic effect against MPM cell monolayer, they were not able to kill MPM cell in a 3D 
spheroid model. Overall, our findings indicate that TAMs are a driving force for MPM growth, 
progression and resistance to EPZ-6438, therefore the combination of pharmacological 
inhibition of EZH2 with strategies of either TAM depletion or inhibition of monocyte 






Malignant pleural Mesothelioma (MPM) is a rare and aggressive tumor that originates from 
mesothelial cells lining the pleural cavity. MPM has a strong causal link to the airborne 
exposure of asbestos fibers and a long latency period of outcome; therefore, the incidence of 
MPM is expected to rise in the following years, even though many developed countries have 
banned the use of asbestos in the late nineteenth century1–3. Based on cell morphology, MPM 
is classified in three major histologic subtypes associated with a different prevalence and 
prognosis4. Epithelioid MPM is the most common and favorable subtype; although patients’ 
median survival is only 13 months after the diagnosis5. The sarcomatoid is the rarest and the 
most aggressive subtype, it does not benefit of surgery and has a median survival of 4 months, 
despite chemotherapy6. The biphasic is characterized by a mixed population of square-shaped 
(epithelioid) with elongated and spindle-shaped (sarcomatoid) cells, it accounts for 10-15% of 
MPM cases and has an intermediate prognosis between the other two subtypes (median survival 
of 8 months) that might be linked to proportion of sarcomatoid component4.  
The long latency of tumor development along with the non-specific nature of the clinical 
symptoms, (e.g. pleural effusion, dyspnea and chest pain) hinder the diagnosis, therefore MPM 
is often detected at advanced stage, in elderly patients, lowering further the chance of 
treatment3,7. MPM cells are highly resistant to conventional chemotherapy or radiotherapy and 
surgery is rarely an option due to its complexity (extra-pleural pneumonectomy, or pleurectomy 
or decortication) and the health status of the patients8. Despite the poor therapeutic benefits, 
since 2003 chemotherapy based on pemetrexed and cisplatin has remained the cornerstone of 
treatment, with no approved second line treatments9. Identification of new therapeutic strategies 
is an urgent medical need.   
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 
2 (PRC2), that plays a key role in the trimethylation of lysine 27 on histone H3 (H3K27me3), 
leading to chromatin compaction and gene repression10. In addition of being a crucial regulator 
of cell lineage determination 11, EZH2 is involved in several biological activities (e.g cell cycle 
progression, autophagy, apoptosis, senescence and repair of damaged DNA) and acts as a 
crucial oncogenic driver in many different malignancies12.  EZH2 is frequently overexpressed 
in MPM, where it represents both a useful biomarker for discriminating MPM form reactive 
mesothelial hyperplasia13,14 and a promising prognostic and therapeutic target 15. Indeed, 
different studies have shown that high expression of EZH2 is associated with diminished patient 
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survival15,16 and its ablation or pharmacological inhibition significantly reduced proliferation, 
migration, clonogenicity, and tumorigenicity of MPM cells16,17. In addition to MPM, 
hyperactivation of EZH2 due to gain of function mutations or overexpression has been reported 
in different types of cancer, leading to the development of different EZH2 inhibitors12. Among 
these, tazemetostat/EPZ-6438 (Epizyme, Inc.) has been recently approved by FDA for patients 
with advanced epithelioid sarcoma18 and has also entered into clinical trials for diffuse large B-
cell lymphoma19, follicular lymphoma20 and relapsed or refractory MPM with BAP1 
inactivation21,22.  
Beyond the direct anti-proliferative effect on tumor cells, EPZ-6438-driven epigenetic 
reprogramming can both directly and indirectly affect the tumor microenvironment (TME). 
Accumulating evidence highlights the importance of EZH2 in survival and activity of both 
effector T cells23,24 and Treg 25,26, as well as in reducing T cell infiltration by inhibiting Th-1-
chemokine expression by ovarian and melanoma cancer cells27,28.  So far, the impact of EZH2 
inhibition on human tumor associated macrophages (TAMs) accumulation and functional 
activation is still largely unexplored.  
Macrophages play a key role in both MPM development and progression. In the attempt to clear 
asbestos fiber, “frustrated phagocytosis” triggers lung macrophages to release copious amount 
of reactive oxygen species (ROS) and inflammatory cytokines leading to an increased 
recruitment and activation of immune cells and consequent generation of a chronic 
inflammatory state, promoting malignant transformation29. Macrophages are highly plastic 
cells, despite they can be powerful inflammatory and effector cells (M1-polarized activation), 
local microenvironmental changes associated to tumor development and growth, re-program 
tumor associated macrophages (TAMs) towards an immunosuppressive M2-like phenotype, 
supporting immune escape30–32. Accordingly, in MPM patients, the number of stromal 
macrophages positively correlates with Tregs, and the amount of CD163+ TAMs negatively 
correlated with overall survival30,31. Ablation of macrophages in mice also delayed tumor 
growth in different MPM models30,33.  
In addition of being central orchestrators of immunosuppressive TME34, TAMs play a crucial 
role in dictating the efficacy of different therapies. Here we set up a 3D spheroid model based 
on the co-culture of human bi-phasic MSTO-211H cells and monocytes isolated from the 
peripheral blood of healthy donors to evaluate both the effects of EZH2-dependent epigenetic 




Materials and Methods 
Isolation and purification of human Monocytes 
Monocytes were isolated from buffy coats of healthy donors, using sequential Ficoll and Percoll 
density gradient centrifugations as previously described35.  
For gene expression or Western blot analysis, cells were seeded in incomplete RPMI medium 
and incubated at 37°C and 5% of CO2. After 1 hour, monocytes selectively attached to the plate 
and non-adherent cells were vigorously washed out with saline. Monocytes were cultured in 
RPMI 1640 supplemented with 1% L-Glutamine and 1% penicillin-streptomycin and 10% of 
FBS and treated as following described.  
For co-culture with MPM spheroids, after Percoll gradient, CD14+ monocytes were purified by 
using Miltenyi Biotech CD14 MicroBeads kit, for positive magnetic separation, according to 
the manufacturer’s instructions.  
In vitro generation of Monocytes-Derived Macrophages (M-DM) 
CD14+ monocytes, were seeded in complete RPMI at the concentration of 2 million cells/ml in 
low adherence plates and cultured in the presence of human M-CSF (40 ng/mL, Miltenyi) for 
6 days. Macrophage differentiation was evaluated by flow-cytometry. Cells were stained in 
0.5% FBS, HBSS solution with: anti-human CD14-FITC (clone M5E2, Bio-Legend) and anti-
human CD16-PE (clone 3G8, Bio-Legend) and analyzed by a S3 Cell Sorter (Biorad). When 
more than 90% CD14+ cells co-express the macrophage differentiation marker CD16, M-DMs 
were used as following described. 
MPM cells lines   
MSTO-211H cell line derives from biphasic MPM, harbors fibroblast-like morphology, was 
obtained from the Istituto Scientifico Tumori (IST) Cell-bank of Genoa; whereas the epithelioid 
BR-95 cell line was obtained from the biobank of the Hospital of Alessandria. All cell lines 
were routinely tested for mycoplasma contamination by PCR. Cells were grown in RPMI 1640, 
supplemented with 1% L-Glutamine and 1% penicillin-streptomycin and 10% of FBS and 
placed in a 37 °C humidified incubator with 5% CO2. 
Cell treatments 
To evaluate the effect of EZH2 inhibition on H3K27me3, MSTO-211H, monocytes, M-DMs 
were treated with EPZ-6438 (10 µM, Selleckchem) for the indicated time, then core histone 
proteins were extracted and analyzed by Western blot. Control cells were treated with the same 
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amount of DMSO (Sigma). Due to the low stability of EPZ-6438, for treatments longer than 24 
hours, cells were rechallenged with the same dose of drug or vehicle (DMSO) each 24 hours. 
To evaluate the effect of EPZ-6438 on M1-polarized activation, monocytes and M-DMs were 
treated with EPZ-6438 (10 µM) for 24 hours and stimulated with LPS (100ng/ml, Enzo Life 
Science) during the last 4 hours. Control cells were kept in culture for the entire experimental 
period. In addition, cells were treated with EPZ (10μM) for 24 hours or maintained untreated 
for 20 hours and stimulated with LPS (100ng/ml) for the last 4 hours.  
To evaluate the effect of EPZ-6438 on M2-polarized activation, monocytes and M-DMs were 
pre-treated with EPZ-6438 (10µM) for 24 hours and rechallenged with EPZ-6438 along with 
IL-4 (20ng/ml, Miltenyi) or IL-10 (20ng/ml, Miltenyi) for the following 18 hours. Control cells 
were kept in culture for the entire experimental period. Additionally, cells were treated with 
EPZ-6438 (10µM) for 42 hours, and cells were maintained untreated for 24 hours and 
stimulated with IL-4 or IL-10 (20ng/ml) for the last 18 hours.  
Production of monocytes conditional media and treatment of MPM cells 
Monocytes isolated from buffy coat were cultured in complete RPMI 1640. To induce M1 
polarized activation, cells were stimulated with h-IFNγ (20ng/ml, Miltenyi) and LPS (100 
ng/ml, Enzo Life Science). After 24 hours, medium was collected, centrifuged at 1400rpm, RT, 
10 minutes, filtered and stored at -20°C in aliquots until use. In the same way, aliquots collected 
from untreated monocytes (M0) and control RPMI 1640 medium containing the polarizing 
stimuli and left in incubator for 24 hours were stored.  
MSTO-211H and BR-95 cells were plated in 100mm-dishes in complete RPMI 1640, until 60% 
of confluence, then culture medium was replaced with fresh medium containing 50% of control, 
M0 or M1 monocytes-conditioned medium. Cells were monitored for the following 48-72 hours 
by optical microscope. To evaluate cell viability cells were harvested, proteins and total RNA 
were extracted and analyzed by Western Blot and RT-PCR respectively.  
Generation of m-Cherry MSTO-211H cells 
mCherry expressing MSTO-211H cells were generated by infecting MSTO-211H cells with a 
lentiviral vector of 3rd generation, that constitutively expressed the fluorescent reporter 
mCherry. HEK293T cells were transfected with pRRLsinPPTCherry_peo, pMDL, pREV and 
pVSVG plasmids by using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s 
instructions. After 48 hours, the medium, containing the viral particles, was collected, filtered 
and ultracentrifuged at 70.000 g, +4°C, 2 hours. The lentiviral pellet was resuspended in 
complete medium and directly added on semiconfluent MSTO-211H cells. Infected mCherry 
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MSTO-211H were selected by cell sorting (S3 Cell Sorter, Biorad), expanded and maintained 
in culture in complete RPMI 1640, in a 37 °C humidified incubator with 5% CO2.  
MPM multicellular spheroids (MCS) 
MCS were generated according to a published protocol (Manente, Pinton, et al, Epigenomics, 
2016) with light modifications. Specifically, we coated the 96-well plates with a thin layer of 
1% sterile agarose (Sigma) in water solution. Before use, the coated plates were sterilized by 
UV light for 20 min. In each well we seeded 10.000 MSTO-211H cells resuspended in 100μl 
of RPMI 1640 medium, supplemented with 1% L-Glutamine and 1% penicillin-streptomycin 
and 10% of FBS. After an overnight culture in humidified incubator, at 37 °C, 5% CO2, MSTO-
211H cells aggregate to form an MCS/well. MCS were kept in culture for 96 hours maximum, 
according to the experimental procedures following described.  
Co-culture of MSTO-211 spheroids and Monocytes  
MCS were pre-treated for 48 hours with EPZ-6438 (10µM) or DMSO then, 50.000 monocytes 
were added to each MCS and co-cultured for additional 48 hours in presence or absence of 
EPZ-6438. MCS were mechanically disaggregated and both CD14+ (monocyte-derived TAMs) 
and CD14- (tumor cells) cells were isolated by using Miltenyi Biotech CD14 MicroBeads kit, 
for positive magnetic separation, according to the manufacturer’s instructions. Both cell 
populations were analyzed for gene expression by RT-PCR.  
Monocytes were left untreated (M0) or were M1-polarized by IFNγ (20ng/ml) and LPS 
(100nl/ml) treatment for 4 hours. M0 or M1 monocytes were added to MSTO-211H spheroids 
72 hours after their formation, at the concentration of 50.000 cells/spheroid and subsequently 
co-cultured for 24 hours. MCSs were kept untreated (DMSO challenged) or treated with EPZ-
6438 (10µM) for the entire experimental period. 
Re-adherence of MSTO-211H spheroids 
MCS were pre-treated for 48 hours with EPZ-6438 (10µM) or DMSO then, 30.000 monocytes 
were added to each MCS and co-cultured for additional 24 hours in presence or absence of 
EPZ-6438. Next, MSTO-211H spheroids were plated in standard conditions and cultured for 
the last 24 hours. To evaluate the proliferating cells around the spheroid, the images were 
captured using an optic microscope (Leica MB5000B), and the area of spreading cells was 




Total protein extraction 
Cells were washed twice with cold saline solution and lysed by directly adding 1% NP-40 lysis 
buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.5 10 mM EDTA, 10 mM NaF, 10 mM 
Na4P2O7, 0.4 mM Na3VO4) with freshly added protease inhibitors (10 μg/ml leupeptin, 4 μg/ml 
pepstatin and 0.1 Unit/ml aprotinin). Cell lysates were collected and centrifuged at 13000 rpm, 
+4°C, 20 minutes.  The pellets were discarded and the supernatants, containing proteins, were 
collected and assayed for protein concentration with the Bradford method. 
Acidic Extraction of Histone Core proteins 
Cells were collected and washed twice with cold saline. Next, the pellet was resuspended in 1X 
packed bed volume of ice cold 5% perchloric acid lysis solution (5% PCA, 10mM N-
ethylmaleiamide, 10 mM NaF, 10 mM Na4P2O7, 0.4 mM Na3VO4, Cocktail α-proteasi 1X), kept 
on ice for 10 minutes and centrifuged at 13000rpm, +4°C, for 10 minutes. The extraction was 
repeated three times. The remaining pellet was resuspended in 2X packed bed volume of ice 
cold solution of HCl 0.4N, 10mM N-ethylmaleiamide and protease inhibitors, centrifuged at 
13000rpm, +4°C, for 10 minutes. The extraction was repeated three times. Supernatants were 
collected and histone core proteins were precipitated with ice-cold solution of 25% 
trichloroacetic acid (TCA) on ice for 30 minutes and collected by centrifugation at 1300rpm, 
+4°C, 20 minutes. The protein pellet was sequentially washed with 1ml of ice-cold 100% 
acetone + 0.006% HCl solution and 1ml of ice-cold 100% acetone solution.  
The dry pellet was resuspended in Tris-HCl (50mM) and quantified with the Bradford assay 
method. 
Immunoblot 
Proteins were separated by SDS-PAGE under reducing conditions, transferred onto 
nitrocellulose membrane and incubated with H3K27me3(ab6002, Abcam), H3, (ab1791, 
Abcam), PARP1, (sc8007, Santa Cruz), α-Tubulin (Sigma-Aldrich), p21 (C-19, Santa Cruz) 
antibodies. After incubation with peroxidase-conjugate Goat-α-Rabbit (7074S, Cell Signaling), 
Goat-α-Mouse (7076S, Cell Signaling) antibodies, chemioluminescent ECL reagent (Biorad) 
were added and the signals were detected at trans-illuminator Chemidoc (Biorad). 
Gene expression analysis 
Total RNA was extracted according to the manufacturer’s instructions of RNeasy Mini Kit 
(Qiagen).   
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RNA was quantified by using Nanodrop spectrophotometer. RNA quality was assessed as 
260/280 and 260/230 OD ratio >1.5, 1 μg of RNA was reverse transcribed by the Script 
Advanced cDNA Synthesis Kit (Biorad). 20ng of template was amplified using SYBER Green 
Master Mix (Biorad) and detected by the CFX96 Real-Time System (BioRad). All samples 
were run in triplicate. Expression data were normalized to β-Actin housekeeping mRNA and 
were analyzed by the 2−(ΔCt) method. Results are expressed as fold upregulation respect to the 
control cell population. The sequences of gene-specific were designed by 
using https://www.ncbi.nlm.nih.gov/tools/primer-blast/. The primers are synthetized by 
Sigma-Aldrich, the sequences are reported in Supplementary Table S1. 
Fluorescence-activated cell sorting (FACS) analysis 
1x106 cells were stained with antigen-specific antibodies. Cells were stained in 0.5% FBS, 
HBSS solution with: anti-human CD14-FITC (clone M5E2, Bio-Legend) or anti-human CD14-
BUV737 (clone MΦP9, BD-OptiBuild) and anti-human CD16-PE or-PE-Cy7 (clone 3G8, Bio-
Legend or BD-Pharmigen). Cells were acquired usiging S3 Cell Sorter (Biorad) or BD 
FACSymphony A5 (BD Bioscence) and analyzed using FlowJo (9.3.2) software. 
Time-lapse 
For time-lapse analysis, mCherry-MCS were cultured for 72 hours and followed co-cultured 
with CFSE-labeled monocytes (10.000 cells/spheroid) for 2.5 hours. After addition of 
monocytes, the plate was placed in an incubator maintained at 37°C in a humidified 5% CO2 
atmosphere and migration of monocytes towards the MCS was monitored by Leica THUNDER 
Imager 3D Live Cell microscope.  
Confocal Microscopy analysis  
Confocal acquisitions were performed on mCherry-MCS co-cultured with or without CSFE-
labeled monocytes. MCS were fixed with 4% paraformaldehyde (PFA), at room temperature 
(RT) for 1 hour and mounted with Fluoromount™ Aqueous Mounting Medium (Sigma-
Aldrich). 
MCS were acquired as z-stack of the entire sections using a Leica TCS SP8 Laser scanning 
confocal microscope, equipped with a HC PL APO CS2 10x/0.40 dry objective. Emission filter 
bandwidths and sequential scanning acquisition were set up in order to avoid any possible 
spectral overlap between fluorophores. ImageJ-win64 software package and Imaris (Bitplane) 
software were used for image analysis and 3D reconstruction. 
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Analysis of the monocyte infiltration within the MCS was performed using the macro reported 
below. Briefly, after channel separations, using the “Image Calculator” process, monocytes 
located within the MCS were selected. Subsequently, the volume of infiltrating monocytes and 
the MCS were calculated using the “Voxel Counter” plugin. 
Proliferation assay 
MSTO-211H cells were stained with CellTrace™ CFSE Cell Prolifera tion Kit (Thermo 
Fisher Scientific), according to the manufacturer’s instructions. Next CFSE-labelled MSTO-
211H were seeded in low adherence 96 well to generate MCSs and treated with EPZ (10μM) 
or DMSO for 96 hours. During the last 48 hours some MCSs were co-cultured with monocytes 
(50.000 cells/spheroids). Next, MCS were fixed with 4% PFA, RT, for 1 hour and mounted 
with Fluoromount™ Aqueous Mounting Medium (Sigma-Aldrich). Confocal acquisitions were 
performed using Leica SP8 LIGHTNING Confocal Microscope. The cell proliferation was 
quantified in term of Mean of Fluorescence (MFI), using ImageJ-win64 software. 
Statistical analysis 
Statistical significance between two groups was assessed by unpaired, Student t test and among 
multiple groups by one-way or two-way ANOVA (GraphPad Prism software). All statistical 





MSTO-211H cells form multicellular spheroids (MCS) that are sensitive to EZH2 
inhibition and capable to recruit human monocytes  
Multicellular spheroid (MCS) is increasingly appreciated as a useful in vitro model to evaluate 
drug response36–39.  
Based on this evidence, we decided to investigate the effects of TAMs on human bi-phasic 
MPM cells (MSTO-211H cell line) responsiveness to EPZ-6438 through a 3D MCS model.  
At first, we tested the effect of EPZ-6438 on MCS growth. We generated mCherry-expressing 
MSTO-211H and we cultured these MPM cells in low adherence condition, according to a well-
established protocol40.  
After 24 hours, MSTO-211H cells assemble a 3D MCS that can be kept in culture for 4 days. 
Therefore, mCherry-MCS were treated with EPZ-6438 or vehicle (DMSO) for 96 hours and 
analyzed by confocal microscopy. As compared to control (DMSO treated), we observed that 
EPZ-6438 triggered a significant reduction of MCS volume (Fig. 1A). In addition, Western blot 
analysis showed a consistent upregulation of the cell cycle inhibitor p21 in EPZ-6438-treated 
MCS (Fig.1B). These results confirm anti-tumor activity of EZH2 inhibition in our MCS model. 
Next, to go insight in the construction of an in vitro tumor model that better recapitulates TME, 
we evaluated whether human peripheral blood monocytes might be recruited into MCS.  
After 72 hours of culture, CSFE-labeled monocytes were added to mCherry-MCS and 
monitored by time lapse imaging. We observed that monocytes quickly migrated towards MCS, 
leading to their close localization around it as early as 2 hours of co-culture (Fig.1C). Next, 
confocal microscopy analysis demonstrates that monocytes were able to infiltrate the MCS after 
24 hours of co-culture and were maintained up to 48 hours of co-culture (Fig.1D).  
Moreover, FACS analysis of the MCS shows that almost the half of CD14+ monocytes 
upregulated the macrophage differentiation marker CD16 after 48 hours of co-culture (Fig. 1E). 
Collectively, these results indicate that human monocytes can be recruited into MCS, where 




Figure 1. Human monocytes infiltrate MPM MCS (A) Volume of mCherry-MSTO-211H MCS treated with EPZ-6438 (EPZ, 
10μM) or vehicle (-) for 96 hours was evaluated by confocal microscopy and calculated by ImageJ-win64 software. The results 
are shown as fold over vehicle treated MCS (-). data are shown as mean mean±SD ***P<0.001 by two-tailed t-test, N (-)=11  
and N (EPZ)=10. Representative images are shown. Scale bars: 200μm. (B) Western blot analysis of p21 expression of MSTO-
211H MCS, treated with vehicle (-) or EPZ-6438 (10μM) for 96 hours (EPZ). Total cell lysates were resolved by 10% SDS-PAGE. 
β-Actin was used as loading control. (C) Migration of CSFE-labeled monocytes towards mCherry-MCS was monitored every 
10 minutes, by time-lapse microscopy using Leica THUNDER Imager 3D Live Cell microscope equipped with an environmental 
chamber maintained at 37°C, 5% CO2 humidified atmosphere. Representative frames are shown. Scale bars: 200μm. (D) 
mCherry-MCS were cultured for 72 and 48 hours, then co-cultured with CSFE-labeled monocytes for additional 24 or 48 hours, 
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respectively. MCS were analyzed by confocal microscopy and infiltrating monocytes (CSFE+ cells) were quantified using 
ImageJ-win64. Representative confocal images after 48 hours of co-culture are shown. Scale bars: 200μm or 100μm, N (24 
hours) =4 and N (48 hours) =9.  (E) Representative dot plot of FACS analysis of monocytes (CD14+ cells) co-cultured with MCS 
co-cultured for 48 hours to check their macrophage differentiation (CD14+CD16+ cells). Data are shown as mean±SEM *P < 
0.05, ** P < 0.01 and *** P < 0.001 by two-way ANOVA N= 3.  
MCS-infiltrating monocytes acquire a functional TAM-like phenotype supporting tumor 
growth  
It has been reported that different tumor cell lines produce soluble molecules that can skew the 
differentiation of human monocytes-derived macrophages (M-DM) towards a TAM-like 
phenotype41. We evaluated whether the monocytes co-cultured with MCS underwent functional 
differentiation towards a TAM-like phenotype. After 48 hours of co-culture, MCS were 
disaggregated and CD14+ cells (monocytes-derived TAMs) were magnetically sorted and 
analyzed for the expression of selected M1 and M2 genes by RT-PCR. Untreated monocytes, 
as well as M1-polarized monocytes by LPS treatment and M2-skewed monocytes by IL-4 or 
IL-10 treatment, were used as controls. The results show a significant induction of typical M2 
genes (IL10, CD163, CD206, CD209 and CD301) in both monocytes-derived TAMs (Mo-
TAMs) and IL-4/IL-10-treated (M2-like) monocytes as compared to the untreated ones. In 
contrast, all the genes encoding inflammatory mediators (e.g. TNFA, IL1B, IL6, IL12B, COX2 
and CD80) were highly induced in LPS-(M1) activated monocytes but were not significantly 
modulated in Mo-TAMs (Fig. 2A). Overall, these results indicate that, similar to TAMs of MPM 
patients34, in vitro Mo-TAMs acquire an M2-skewed phenotype. Moreover, TAMs usually 
support their accumulation in solid tumors through the production of chemokines (e.g. CCL2 
and CXCL12) and growth factors (e.g. CSF1 and VEGF), accordingly, in our model, we 
observed a significant upregulation these chemo-attractants by Mo-TAMs, as compared to 
control monocytes (Fig. 2B).  
Next, we analyzed the expression of the major enzymes (IDO1, NOS2, ARG1) and immune 
checkpoints (CD-47/SIRPα42, PD-L1/PD143 and HLA class I/LILRB144), that respectively 
drive the immunosuppressive activity of tumor-infiltrating myeloid cells and hamper the ability 
of macrophages to eliminate cancer cells by phagocytosis (Fig. 2C-D). In comparison to control 
monocytes, Mo-TAMs showed a consistent increased expression of IDO1 and ARG1 along 
with a light upregulation of NOS2 and PD-L1 (Fig. 2C). These results along with the higher 
expression of IL10 and the low expression of the inflammatory cytokines indicate that Mo-




In addition, Mo-TAMs expressed SIRPA and showed a selective upregulation of PD1 and 
leukocyte immunoglobulin-like receptor LILRB1 (Fig. 2D), two additional inhibitory receptors 
impairing macrophage-dependent clearance of cancer cells. In parallel, MSTO-211H cells 
isolated from MCS-monocytes co-culture expressed the “don’t eat me” signal CD47 as well as 
PD-L1 and HLA molecules (HLA-A and HLA-B), that are recognized ligands for PD-1 and 
LILRB1, respectively (Fig. 2E). Overall, these results suggest that tumor cells likely escape 
phagocytosis by Mo-TAMs.  
To address the functional relevance of Mo-TAMs, after 48 hours of co-culture MCS growth 
were analyzed by confocal microscopy, then the mCherry+ tumor volume was calculated by 
ImageJ-win64 software. The results show a clear increase of tumor volume in co-culture 
condition, thus indicating that Mo-TAMs support the growth of MCS (Fig. 2F).  
Overall, these results demonstrate that MCS-infiltrating monocytes underwent a functional 
differentiation towards a TAM-like phenotype endowed of tumor-promoting activities. 
Therefore, we have generated a reliable MPM 3D model to investigate in vitro the effects of 




Figure 2. MCS-infiltrating monocytes acquire a functional TAM-like phenotype. (A-D) Monocytes-derived TAMs (Mo-TAMs) 
were isolated from MCS by magnetic cell sorting and analyzed by RT-PCR for the expression of genes encoding for selected 
(A) M1 (IL1, IL6, IL12B, TNFA, COX2 and CD80) and M2 (CD206, CD209, CD301, IL10 and CD163) molecules, (B) TAM-recruiting 
118 
 
chemokines (CCL-2 and CXCL12) and growth factors (CSF1 and VEGF) (C) immunosuppressive molecules (IDO, NOS2, ARG1, 
PD-L1) and (D) immune checkpoint receptors (SIRPA, PD1 and LILRB1). M1-polarized monocytes by a 4-hour treatment with 
IFNγ (20ng/ml) and LPS (100ng/ml) and M2-skewed monocytes by an 18-hour treatment with IL-4 (20ng/ml) or IL-10 
(20ng/ml) were used as positive controls for M1 and M2 gene expression, respectively. β-Actin was used as housekeeping 
gene. Normalized RT-PCR results are shown as fold increase over untreated monocytes (-). Data are shown as mean±SD and 
are representative of one out of three independent experiments with similar results. *P < 0.05, **P< 0.01 and ***P< 0.001 
by two-tailed one-way ANOVA or unpaired t test, N= 3. (E) MSTO-211H cells isolated from MCS co-cultured with monocytes 
were analyzed by RT-PCR for the expression of ligands for inhibitory phagocytosis receptors (CD47, PD-L1, HLA-A and HLA-B). 
β-Actin was used as housekeeping gene. Normalized RT-PCR results are shown as fold increase over MCS alone (MCS). Data 
are shown as mean±SD and are representative of one out of three independent experiments with similar results *P < 0.05, 
** P < 0.01 and *** P < 0.001 by two-tailed unpaired t test, N=3. (F) Volume of mCherry-MCS culture without (MCS) or with 
CSFE-labelled monocytes (MCS+Mo) was evaluated by confocal microscopy and calculated by ImageJ-win64 software. The 
results are shown as fold over MCS. Data shown are mean±SD ***P<0.001 by two-tailed t-test N(MCS)=7 and N(MCS+Mo)=9). 
























EPZ-6438 enhances monocyte recruitment in the MCS 
Cancer cell epigenetic reprogramming is associated with the expression of new transcriptional 
programs that impact on anti-tumor immunity through different mechanisms, including the 
upregulation of chemo-attractants that shape the composition tumor immune infiltrate45. In both 
ovarian and melanoma cells, EZH2 inhibition has been reported associated to the upregulation 
of Th1-recruiting chemokines27,28.  
We evaluated whether EZH2 inhibition in MSTO spheroids could modulate the expression of 
chemokines (CCL2, CCL5 and CXCL12) and growth factors (CSF1 and VEGF) associated 
with monocyte recruitment and survival. Western blot analysis showed that H3K27 
trimethylation of MSTO-211H cells was fully suppressed after a 24 hour treatment with EPZ-
6438 (10 M) (Fig. 3A). Therefore, tumor MCS were cultured in presence of EPZ-6438 (10 
M) or vehicle (-) for 48, 72 and 96 hours, then RNA was extracted and analyzed by RT-PCR. 
Control MCS (-) express similar levels of chemo-attractants at each time points. In contrast, 
after 48 hours (CCL2 and CSF1) or 72 hours (CCL5, CXCL12 and VEGF) of EPZ-6438 
treatment, MCS started to express increasingly amount of mRNA of the selected monocyte-
recruiting molecules (Fig. 3B). These results suggest that prolonged treatment with EPZ-6438 
might increase TAM accumulation.  
To test this hypothesis, we analyzed the recruitment of CSFE-labeled monocytes into mCherry-
MCS, by confocal microscopy. According to their time of life (96 hours), mCherry-MCS were 
treated with EPZ-6438 for 72 or 48 hours and co-cultured with CSFE-labeled monocytes for 
the following 24 and 48 hours, respectively. In both experimental conditions, confocal 
microscopy analysis showed a consistent increased infiltration of monocytes in EPZ-6438 
treated MCS (Fig. 3C).  
Besides the effects of EZH2 inhibition on MSTO cells, EPZ-6438 could also alter the 
responsiveness of monocytes to the chemo-attractants. To address this aspect, we treated 
monocytes with EPZ-6438 for 48 hours and we analyzed the expression of chemokine/growth 
factor receptors by RT-PCR. The results showed a similar mRNA level of CCR2, CCR5, 
CXCR4 and CSFR1 in both DMSO and EPZ-6438 treated monocytes, ruling out a direct effect 
of EPZ-6438 on monocytes’ ability to sense chemo-attractants (Fig. 3D).  
Overall, these results demonstrate that prolonged treatment of MCS with EPZ-6438 enhances 
the expression of monocyte-recruiting molecules in association with an increased accumulation 





Figure 3. EZH2 inhibition enhances monocyte recruitment in MCS.  
(A)  MSTO-211H cells were left untreated (-) or treated with EPZ-6438 (10μM) for 24 and 48 hours, then core histone proteins 
were extracted and analyzed by Western blot for H3K27me3 levels. Histone H3 was used as loading control.  (B)  RT-PCR 
analysis of total RNA extracted from MCS treated or not (-) with EPZ-6438 (10μM) for 48, 72 and 96 hours. Selected monocyte 
chemo-attractants (CCL2, CCL5, CXCL12, CSF1, VEGF) were evaluated. β-Actin was used as housekeeping gene. Normalized 
qPCR results are shown as fold increase over control (-). *P < 0.05, ** P  < 0.01 and *** P  < 0.001 by two-tailed one-way 
ANOVA, N= 3 technical replicates. Data shown are mean±SD from one out of three independent experiments with similar 
results. (C) MCSs were treated with EPZ-6438 (10μM) for 72 or 48 hours and subsequently co-cultured with CSFE-labeled 
monocytes for 24 or 48 hours, respectively. Infiltrating monocytes was quantified using ImageJ-win64. Representative images 
are shown. Scale bars: 200 μm. * P< 0.05  and *** P< 0.001 by two-tailed unpaired t-test; 24 hours N(EPZ)=5; 48 hours N(-)=7 
, N(EPZ)=12). (D) Monocytes were treated with EPZ-6438 (10μM) for 48 hours and analyzed for the expression of 
chemokine/growth factor-receptors (CCR2B, CCR5, CXCR4 and CSFR1) by qPCR. β-Actin was used as housekeeping gene. 
Normalized qPCR results are shown as fold increase over untreated monocytes Data shown are mean±SD from one out of 
three independent experiments with similar results.* P < 0.05, ** P< 0.01 and *** P< 0.001 by two-tailed unpaired t test N=3 
technical replicates.  
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EZH2 inhibition enhances Mo-TAM pro-tumor phenotype  
Epigenetic modulators can also directly modulate tumor infiltrating immune cells46. EZH2 
modulate gene expression programs associated with differentiation and functional activation of 
T and NK cells, therefore its inhibition has been found associated with an enhanced anti-tumor 
immunity47, but also with an increased expansion of myeloid derived suppressor cells and 
consequent suppression of anti-tumor immunity (MDSCs)48. 
Macrophages are extremely plastic cells therefore we evaluated whether the epigenetic 
reprogramming associated with EZH2 inhibition might alter the pro-tumor phenotype of TAMs. 
So far, the effect of EPZ-6438 on human monocyte/macrophage polarized activation has still 
poorly explored, hence we started by evaluating whether EZH2 inhibition might alter their 
responsiveness to either M1 (LPS) or M2 (IL-4 or IL-10) polarizing stimuli.  
Both primary human monocytes and M-DM, obtained by culturing peripheral blood monocytes 
with MCSF (40ng/ml) for 6 days, were treated with EPZ-6438 (10 M) for 24 hours and 
analyzed by western blot. In response to the EZH2 inhibitor, H3K27me3 dropped in both cell 
types (Fig. 4A and Supplementary Fig. 1A).  
Then, to analyze the effects of EZH2-dependent H3K27me3 on cell response to IL-4, 
monocytes and M-DM were treated or not with EPZ-6438 for 24 hours and subsequently 
challenged with IL-4 (20ng/ml) plus or not EPZ-6438 for additional 18 hours. Control cells 
were maintained in standard medium plus DMSO throughout the entire experimental period. 
An additional group of cells was cultured in the presence of EPZ-6438 for the entire 
experimental period, to evaluate the effects that are solely due to EZH2 inhibition. 
We analyzed the expression of typical IL-4-induced genes by RT-PCR. Consistent, the results 
obtained from monocytes isolated from different donors showed that, both control and EPZ-
6438-treated cells expressed comparable levels of the tested genes. In contrast we observed a 
little upregulation of CD206, CCL17, CD209 and CD301 along with a light downregulation of 
CCL22 in monocytes treated with EPZ-6438 plus IL-4, as compared to those activated with IL-
4 only (Fig. 4B) Similarly, in M-DM we confirmed that EPZ-6438 alone did not alter the 
expression of the selected IL-4 inducible genes, whereas EZH2 inhibition faintly modulated IL-
4-induced gene expression (Supplementary Fig.1B).  
Next, we analyzed the effects of EZH2 inhibition on monocyte response to IL-10, an 
immunosuppressive cytokine that is abundantly present in MPM microenvironment49.  
In both monocytes and MDM, we observed that EZH2 inhibition lightly increased IL-10-
induced IL10 gene expression, whereas CD163 seems to be EZH2 independent (Fig.  4C and 
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Supplementary Fig. 1C). Furthermore, in both cells type we confirmed that EPZ-6438 was able 
to induce VEGF expression either alone or in combination with IL-10 (Fig. 4C and 
Supplementary Fig. 1C). These results indicate that EZH2 contributes modulating myeloid cell 
response to selected IL-10-induced genes. 
Next, we explored whether the EZH2-dependent H3K27me3 might selectively affect the 
expression of inflammatory (M1) genes. Therefore, human monocytes and M-DM were 
cultured in presence of EPZ-438 (10μM) for 24 hours and activated with LPS (100ng/ml) for 
the last 4 hours.  
RT-PCR analysis confirmed that EPZ-6438 only did not affect gene expression, whereas 
pharmacological inhibition of EZH2 in both monocytes and M-DM sharply heightened the 
expression of selected inflammatory genes in response to LPS stimulation. Noteworthy, along 
with the anti-tumor cytokine IL12B, the other EZH2-dependent genes include monocyte 
recruiting chemokine (CCL2), pro-tumor cytokines (IL1B, IL6) and immunosuppressive 
molecules (PD-L1, IDO1, COX2) (Fig. 4D and Supplementary Fig. 1D). 
Finally, to figure out the effect of EZH2 inhibition on Mo-TAMs, monocytes were co-cultured 
with MCS in presence or absence of EPZ-6438 for 48 hours. In comparison to controls (DMSO-
treated cells), Mo-TAMs isolated from MCS exposed to the EZH2 inhibitor showed a 
significant upregulation of selective genes, in particular the pro-tumor inflammatory cytokines 
IL1B and IL6 along with the chemokines CCL2 and CCL17 (Fig. 4E) and growth factors CSF1 
and VEGF. With the exception of TNFA, the other upregulated genes also encode for pro-tumor 
(IL10, CD301, CD206 and COX2) mediators, immunosuppressive enzymes (IDO and ARG1) 
and immune checkpoints (LILRB1, SIRPA, PD1), (Fig. 4E), overall suggesting that EPZ-6438 








Figure 4. EZH2 inhibition affects human monocyte polarized activation. (A) Human monocytes were treated with 
10μM EPZ-6438 or DMSO (-) for 24hours, then core histone proteins were extracted and analyzed by Western blot for 
H3K27me3 levels. Histone H3 was used as loading control. (B, C) Cells were pre-treated with EPZ-6438 (10μM) for 24 hours 
and rechallenged with EPZ-6438 along with (B) IL-4 (20ng/ml) or (C) IL-10 (20ng/ml) for additional 18 hours. Control cells were 
maintained in standard medium throughout the entire experimental period. An additional group of cells were treated with 
EPZ-6438 (10μM) for 42 hours and M2-polarized monocytes were maintained untreated for 24 hours and then stimulated 
with (B) IL-4 (20ng/ml) or (C) IL-10 (20ng/ml) for the last 18 hours. The expression of selected (B) IL-4 (CD206, CCL17, CCL22, 
CD209 and CD301) and (C) IL-10 (IL10, CD163 and VEGF) inducible genes was analyzed by RT-PCR. β-Actin was used as 
housekeeping gene. Normalized RT-PCR results are shown as fold increase over untreated monocytes (-). Data are shown as 
mean±SD and are representative of one out of four independent experiments with similar results.  *P< 0.05, **P< 0.01 and 
***P< 0.001 by two-tailed one-way ANOVA, N=3. (D) Monocytes were pre-treated with EPZ-6438 (10 µM) for 20 hours, and 
then stimulated with LPS (100ng/ml) for the following 4 hours. Control cells were kept in culture for the entire experimental 
period. Additionally, a group of cells was treated with EPZ-6438 (10 µM) for 24 hours and a group of cells was M1-polarized 
by LPS (100ng/ml) stimulation during the last 4 hours. Monocytes were analyzed to evaluate the expression typical M1-
inflammatory genes (TNFA, IL1B, IL6, IL12B, CCL2 and CCL5) by RT-PCR. β-Actin was used as housekeeping gene. Normalized 
RT-PCR results are shown as fold increase over untreated monocytes (-). Data are shown as mean±SD and are representative 
of one out of four independent experiments with similar results. *P< 0.05, **P< 0.01 and ***P< 0.001 by two-tailed one-way 
ANOVA; N= 3. (E) Monocytes were co-culture with MCS in presence or absence of EPZ-6438 (10 µM). After 48 hours, Mo-
TAMs were purified by magnetic separation and analyzed for the expression of selected genes including inflammatory 
cytokines (IL1, IL6, IL12B, TNFA, COX2), chemokines (CCL2, CCL5, CCL22, CCL17) and M2 markers (IL10, CD163, CD206, CD209 
and CD301). β-Actin was used as housekeeping gene. Normalized RT-PCR results are shown as fold increase over Mo-TAMs 
from DMSO treated MCS (-). Data are shown as mean±SEM of three different experiments *P< 0.05, **P< 0.01 and ***P< 


















Mo-TAMs impair the efficacy of EPZ-6438  
Given that MCS treatment with EPZ-6438 enhances the recruitment of monocytes and their 
functional differentiation in pro-tumoral cells, we evaluated the impact of TAMs on MPM cell 
responsiveness to EPZ-6438.   
We analyzed the volume of mCherry-MCS treated with the EZH2 inhibitor in comparison to 
those pre-treated with EPZ-6438 for 48 hours and subsequently co-cultured with CSFE-labeled 
monocytes for additional 48 hours. Confocal microscopy analysis showed an approximately 2-
fold increase of mCherry-MCS volume in co-culture condition (Fig. 5A). These results indicate 
that Mo-TAMs impair the anti-proliferative activity of EPZ-6438. To evaluate to what extent 
Mo-TAMs affect MSTO cell responsiveness to EPZ-6438, we labeled MSTO-211H cells with 
CSFE and we then tracked their proliferation in the MCS. Confocal microscopy analysis 
confirmed that tumor cell proliferation was reduced by EPZ-6438 treatment (Fig. 5B). In 
contrast, Mo-TAMs triggered a similar tumor cell proliferation rate in both DMSO and EPZ-
6438 treated MCSs, indicating that their tumor promoting effects abolish the anti-proliferative 
activity of EZH2 inhibition. To corroborate these observations, we evaluated the expression of 
the cell cycle inhibitor p21 in tumor cells by RT-PCR and we confirmed that Mo-TAMs were 
able to fully revert the p21 induction triggered by EZH2 inhibition (Fig. 5C). These results 
definitely validate the ability of Mo-TAMs to impair the anti-tumor activity of EPZ-6438.  
Strikingly, we noted that although MCS were extremely resistant to both mechanic and 
enzymatic disaggregation, the presence of Mo-TAMs lowered spheroid firmness, allowing their 
disassembling in a viable single cell suspension. This observation prompt us to investigate 
whether Mo-TAMs might affect the migratory behavior of MSTO cells under both untreated 
and EPZ-6438 treated conditions. MCS were pretreated or not with EPZ-6438 for 48 hours, co-
cultured with monocytes for additional 24 hours and subsequently seeded in standard condition. 
After 24 hours, we evaluated the amount of MSTO cells grown around the MCS and we found 
that Mo-TAMs greatly promoted tumor cell spreading under both DMSO and EPZ-6438 treated 
conditions (Fig. 5D). Since both proliferative and migratory ability likely contribute in 
determining the extent of tumor cells around the MCS, to gather the effects of Mo-TAMs on 
tumor cell spreading behavior we isolated MSTO cells from the MCS before seeding and 
analyzed the expression of selected genes associated with extracellular matrix (ECM) 
remodeling and epithelial-mesenchymal transition (EMT). Noteworthy we found a dramatic 
upregulation of MMP9 in MSTO cells from MCS-monocytes co-culture (Fig. 5E) along with 
similar transcript levels of E-CADHERIN, N-CADHERIN, VIMENTIN, SNAIL and MMP2 
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(Supplementary Fig. 2). These results suggest that Mo-TAMs do not affect EMT but enhance 
the invasive ability of tumor cells by favoring the expression the ECM degrading enzyme 
MMP9. Overall, these findings indicate that Mo-TAMs play a key tumor promoting role in 







Figure 5. Mo-TAMs impair EPZ-6438 anti-tumoral effects (A) mCherry-MCS were treated with EPZ-6438 (10μM) for 96 hours 
and co-culture or not with CSFE-labeled monocytes for the last 48 hours. Volume of mCherry-MCS was evaluated by confocal 
microscopy and calculated by ImageJ-win64 software. Representative images are shown. Scale bars: 200 μm. Data shown are 
mean±SD ***P< 0.001 by two-tailed unpaired t test N (MCS)=4, N (MCS+Mo)=9 . (B) MCS were generated with CSFE-labeled 
MSTO-211H cells and cultured for 96 hours with 10μM EPZ-6438 or DMSO (-). As indicated, monocytes were added and co-
cultured during the last 48 hours. MCS were analyzed by confocal microscopy then CSFE mean of fluorescence intensity (MFI) 
was quantified using ImageJ-win64 software. Representative images are shown. Scale bars: 200μm Data are shown as 
mean±SD and are representative of one out of three independent experiments with similar results. **P< 0.01 and ***P< 
0.001 by two-tailed one-way ANOVA. (C) RT-PCR analysis of p21 expression by MSTO-211H cells derived from MCS co-
cultured with monocytes. β-Actin was used as housekeeping gene. Normalized RT-PCR results are shown as fold increase over 
MSTO-211H cells from DMSO treated MCS (-). Data are shown as mean±SD and are representative of one out of three 
independent experiments with similar results. *P< 0.05 and **P< 0.01 by two-tailed one-way ANOVA, N= 3. (D) MCS were 
treated with 10μM EPZ-6438 or DMSO for 48 hours, then co-cultured or not with monocytes for additional 24 hours and 
seeded in standard condition. After 24 hours, spreading cells was analyzed by optical microscope and quantified by ImageJ-
win64 software. Representative optical microscopic images are shown. Magnification: 10X. Representative data from one out 
of 6 independent experiments are shown. **P < 0.01 and *** P < 0.001 by two-tailed one-way ANOVA. (E) RT-PCR analysis of 
MMP9 expression by MSTO-211H cells derived from MCS co-cultured with monocytes. β-Actin was used as housekeeping 
gene. Normalized RT-PCR results are shown as fold increase over MSTO-211H cells from DMSO treated MCS (-). Data are 
shown as mean±SD and are representative of one out of three independent experiments with similar results. ***P< 0.01 by 




















MSTO-211H MCS neutralize the cytotoxic activity of M1-polarized monocytes  
Immunotherapeutic strategies aim to re-program TAMs in M1 effectors have been found 
effective in several preclinical models of cancers and are under evaluation in clinical studies 
for different types of human cancers50,51. Despite MPM cells are highly resistant to several 
chemotherapeutics, recent evidence indicates that LPS-activated RAW264.7 macrophages 
exert direct cytotoxic activity against MPM cells co-cultured in standard 2D condition43.  
Based on these premises, we started to evaluate the sensitivity of different types of human MPM 
cell monolayers to human M1-polarized monocytes. 
Both biphasic MSTO-211H and epithelioid BR-95 MPM cells were treated with the 
conditioned medium (M1) collected from monocytes activated with INF-γ (20ng/ml) and LPS 
(100ng/ml) for 24 hours. Similarly, tumor cells were treated with medium conditioned by naïve 
monocytes (M0) or with “control medium” obtained by incubating monocyte cell culture 
medium supplemented with LPS (100 ng/mL) and INF-γ (20ng/ml) at 37°C for 24 hours. 
MSTO-211H and BR-95 cells treated with both control and M0-conditioned medium reached 
similar confluence after 48 hours and 72 hours of culture, respectively. In contrast, the treatment 
with M1-conditioned medium led to a drastic reduction of attached cells along with the presence 
of round floating cells (Fig. 6A). These results indicate that M1 monocytes release soluble 
molecules capable of impairing survival of both biphasic (MSTO-211H) and epithelioid (BR-
95) cells.  This hypothesis was confirmed by Western blot analysis of Poly ADP-ribose 
polymerase 1 (PARP-1)52, a target of apoptotic caspases. Indeed, in both cell types we observed 
that exposure to M1-conditioned medium triggered a massive cleavage of PARP-1 (Fig. 6B). 
In agreement, RT-PCR analysis showed a consistent increased expression of genes encoding 
for the pro-apoptotic proteins BAX, BAK, NOXA, BIM and PUMA in both MSTO-211H and 
BR-95 cell monolayers (Fig. 6C).  
Overall, these results demonstrate that human M1 monocytes produce soluble factors capable 
to kill both biphasic and epithelioid MPM cell monolayers. Next, we moved to the more reliable 
MCS model in the attempt to evaluate whether the cytotoxic activity of M1 monocytes could 
synergize with the anti-proliferative effect of EPZ-6438. Monocytes were M1 polarized by 
treatment with IFNγ (20ng/ml) and LPS (100ng/ml) for 4 hours or maintained in culture 
untreated (M0). Next, untreated or EPZ-6438-treated MCS were co-cultured with M0 or M1 
monocytes for 24 hours and subsequently seeded in standard conditions for additional 24 hours. 
The results showed that both M1 and M0 monocytes similarly enhance tumor cell spreading 
and hamper the anti-tumor effect of EPZ-6438 (Fig. 6D). These results suggest that MPM cells 
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in the MCS were resistant to the cytotoxic activity of M1-polarized monocytes or were able to 
re-educate M1-monocytes in pro-tumoral Mo-TAMs. Therefore, to enhance the therapeutic 
effect of EPZ-6438, other strategies aimed to inhibit TAM accumulation rather than to re-
program Mo-TAMs in M1 effectors might be considered in combination with EZH2 inhibition.  
 
 
Figure 6. M1-polarized monocytes impair survival of MPM cell grown as monolayer but not as MCS. 
(A-B) MSTO-211H and BR-95 cells were respectively cultured for 48 hours or 72 hours with 50% of control medium (ctr), M0 
and M1-conditioned medium. (A) Representative optical microscope images are shown. Magnification: 10X.  (B) Total 
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proteins were extracted and resolved by 7% SDS-PAGE. PARP1 cleavage were analyzed by Western Blot. Tubulin was used as 
loading control. (C) Total RNA was extracted from MSTO-211H cells and BR-95 cells treated with M0 or M1 monocytes-
conditioned medium for 24 and 48 hours, respectively. Pro-apoptotic gene expression (BAD, BAK, BAX, BIM, NOXA, PUMA) 
was evaluated by RT-PCR. β-Actin was used as housekeeping gene. Normalized RT-PCR results are shown as fold increase over 
untreated cells (-). Data are shown as mean±SD and are representative of one out of three independent experiments with 
similar results. *P< 0.05, **P< 0.01 and ***P< 0.001 by two tailed unpaired t test. (D) MCS were treated with 10μM EPZ-6438 
or DMSO for 48 hours, then co-cultured or not with M0 or M1 monocytes for additional 24 hours and seeded in standard 
condition. After 24 hours, spreading cells was analyzed by optical microscope and quantified by ImageJ-win64 software. 
Representative optical microscopic images are shown. Magnification: 10X. Representative data from one out of 6 





EPZ-6438 is an inhibitor of the histone methyl transferase EZH2 that has recently entered in 
trial for MPM patients due to its anti-proliferative effects on tumor cells, however the effect of 
this epigenetic modulator on the TME and other way around the impact that TME has on MPM 
cell responsiveness to EZH2 inhibitor have never been explored.  
Macrophages represent the major population of inflammatory cells present in MPM, the driving 
force of tumor progression by exerting immunosuppressive activities34. TAMs deeply affect the 
efficacy of anti-cancer therapies. Here we provided evidence that inhibition of EZH2 enhances 
the capacity of MPM cells to recruit monocytes and to drive their differentiation towards a 
TAM-like phenotype, that in turns impair the anti-tumor effects of EPZ-6438.  
Despite studies involving research animals remain a crucial step forward the development of 
new drugs, the growing awareness of the Principles of Humane Experimental Technique, the 
3Rs, have triggered the development of new technologies and models to improve the capacity 
to address biological questions in vitro.  
In comparison to monolayer cell cultures, 3D tumor spheroids accurately mimic many features 
of solid tumors (e.g. gradients of nutrients, oxygen and pH establish over time, ECM deposition, 
cell-cell and cell-ECM interactions, cellular layered assembling) leading to a gene expression 
signature and drug resistance mechanisms that closely resemble those of patient-derived 
tumors36,39,53. 
As further improvement, we set up a 3D MPM-monocytes spheroid model, that recapitulates in 
vitro, both monocytes recruitment in tumor and their functional differentiation towards a TAM-
like phenotype endowed of tumor promoting activities. Indeed, Mo-TAMs acquire a selective 
increased expression of genes encoding M2-like receptors (CD301, CD209, CD206, CD163), 
immunosuppressive molecules (IL-10, IDO1, ARG1, iNOS, PD-L1), inhibitory immune 
checkpoints (SIRPα, PD1, LILRB1), as well as chemokines (CCL2, CXCL12) and growth 
factors (M-CSF, VEGF), that are crucial drivers of monocyte recruitment in solid tumors. 
Accordingly, CCL2 is a significantly elevated biomarker in both pleural effusion43 and serum43 
of MPM patients. Among the phagocytosis checkpoint, the EZH2-dependent expression of PD1 
by RAW264.7 macrophages has been recently reported associated with their impaired ability 
to uptake mouse MPM cells43. Here we confirmed a higher expression PD1 in Mo-TAMs along 
with a consistent upregulation of LILRB1, an inhibitory receptor that recognizes MHC class I 
complexes and impairs the ability of TAMs to clear different types of cancer cells both in vitro 
and in vivo44. In agreement with the tumor-promoting phenotype, Mo-TAMs enhance MPM 
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spheroid growth by inducing tumor cells proliferation as demonstrated by the decrease of both 
CSFE intensity (Fig. 5B) and cell cycle inhibitor p21 (Fig. 5C). Moreover, we observed that 
Mo-TAMs significantly reduced spheroid firmness, in association with a selective induction of 
MMP9 expression and tumor cell spreading abilities.  These results suggest that Mo-TAMs 
modulate the remodeling of extracellular matrix, creating a TME that is more permissive for 
tumor cells invasion. In support of this hypothesis, clinical studies have reported that high 
expression of MMP9 correlate with a more aggressive MPM phenotype associated with a 
decreased patients’ survival54,55. Hence, the molecular characterization of the potential pro-
invasive activity of Mo-TAMs warrants future studies. 
Definitely, in combination with EPZ-6438 treatment, our studies demonstrate that Mo-TAMs 
abolish the anti-tumor activity of EZH2 inhibition in MPM cells. In comparison to EPZ-6438-
treated spheroids, the presence of Mo-TAMs led to the total recover of tumor cells proliferation 
and spreading ability.  Whereas, EZH2 inhibition in glioblastoma cells was associated to the 
release of soluble factors capable to shifts human M-DM and murine microglial cells towards 
an M1 anti-tumor phenotype56. Mo-TAMs isolated from EPZ-6438-treated MPM spheroids 
showed an enhanced expression of several M2-like genes (IL-10, CD163, CD301, CD206, 
CD209, CCL17) along with a consistent upregulation of pro-tumor cytokines (IL-1, IL-6), 
chemokines (CCL2, CCL5) and faint induction of M1 anti-tumor genes (IL-12p40, TNF). 
Therefore, in MPM spheroid model, EPZ-6438 strengthens the pro-tumoral phenotype of Mo-
TAMs. This effect might be due to a modified expression of polarizing signals by MPM cells 
as well as an altered responsiveness of Mo-TAMs to the TME signals. Noteworthy, in both 
monocytes and M-DM we observed that the epigenetic reprograming driven by EPZ-6438 
weakly affect the responsiveness to both IL-4 and IL-10, but strongly enhance the expression 
of selected LPS-induced inflammatory genes (Fig.4I), including IL-1, IL-6 and CCL2. In 
addition, EZH2 inhibition in MSTO cells increases the expression of many monocyte chemo-
attractants (CCL2, CCL5, CXCL12, M-CSF, VEGF) leading to a higher accumulation Mo-
TAMs.  
Overall, our findings point out a dual activity of EPZ-6438 in MPM. Since the beneficial anti-
proliferative effects of EZH2 inhibition in MPM cells are counteracted by the accumulation of 
pro-tumoral Mo-TAMs, strategies of macrophage depletion might enhance MPM 
responsiveness to EPZ-6438. Even better, approaches of TAMs reprograming in M1 anti-tumor 
effector might work in synergism with EZH2 inhibitors leading to increased therapeutic 
efficacy. In line with previous studies with murine RAW264.7 macrophages43, we observed 
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that M1-polarized monocytes release soluble factors capable to kill different MPM cell 
monolayers. However, in the 3D spheroid model, tumor cells are highly resistant to the 
cytotoxic activity of M1 monocytes. The observation that naïve (M0) and M1 polarized 
monocytes exert comparable pro-tumor effects, suggests that MPM spheroids fully re-program 
M1 monocytes in pro-tumoral Mo-TAMs (Fig. 6D). Although strategies capable to efficiently 
enhance TAM effector capacity would be advisable, inhibition of monocytes recruitment in 
MPM or TAMs depletion represent alternative valuable approaches that could be exploited to 
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Supplementary Table 1. Real-Time PCR primers list   
Gene Forward Reverse 
ACTB cccaaggccaaccgcgagaagat gtcccggccagccaggtccag 
ARG1 ctgactggagacctcaagtgc tcgtggctgtccctttgagaa 
BAD cggaggatgagtgacgagt ccaggactggaagactcgc 
BAK aaaatggcttcggggcaag aacgtagctgcggaaaacct 
BIM agtgggtatttctcttttga gtgtccaattacgccgcaact 
CCL2 aagatctcagtgcagaggctcg cacagatctccttggccacaa 
CCL5 gtctttgtcacccgaaag gacaagagcaagcagaaac 
CCR2B gctggtcctgccgctg cacacgaagcagggttttca 
CCR5 ggagccctgccaaaaaatc tgagtagagcggaggcagga 
CD163 agacaaggagctgaggctagt acagagaccgcttccatgct 
CD206 cgatccgacccttccttgac tgtctccgcttcatgccatt 
CD47 tggactgagtctctgtattg gctagagctaagatacctcaaac 
CD80 tttcacttttgaccctaagc cctgaacagaagtgagaaag 
COX2 cccttgggtgtcaaaggtaa gccctcgcttatgatctgtc 
CSF1 ttaagaaggcatttctcctg ccttgtcatgctcttcataatc 
CXCL12 acactccaaactgtgcccttc ccacgtctttgccctttcatc 
CSFR1 tgagcaagacctggacaagga ggatgcaattcttggaagcg 
CXCR4 aacttcagtttgttggctg gtgtatatactgatcccctcc 
E-CADHERIN cccttcacagcagaactaac Cacctctaaggccatctttg  
HLA-A aaaaggagggagttacactcagag gctgtgagggacacatcagag 
HLA-B ctaccctgcggagatca acagccaggccagcaaca 
IDO gatgtccgtaaggtcttg cagtttgccaagacacag 
IL10 ttaagggttacctgggttgccaagc tcttggttctcagcttggggcatca 
IL12B cggtcatctgccgcaaa tgcccattcgctccaaga 
IL1B cctactcacttaaagcccgcc ttagaaccaaatgtggccgtg 
IL6 agaacagatttgagagtagtgaggaac ggcatttgtggttgggtcagg 
LILRB1 gcttatgcttatgacctcgaac agaacaaatctgttgtagcc 
MMP2 cacagtccgccaaatgaa cactcctgagatctgcaaac 
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MMP9 ccattcacgtcgtccttatg cgctgggcttagatcattc 
N-CADHERIN gatgaaacgccgggataaa cttcttctcctccaccttct 
NOS2 aaagaccaggctgtcgttga acgggaccggtatttcattct 
NOXA gagatgcctgggaagaagg ttctccggaagttcagttt 
P21 cagcatgacagatttctacc cagggtatgtatgtacatgagga 
PD1 cacgagggacaataggag atagtccacagagaacacag 
PDCD1 caggagggacaataggag atagtccacagagaacacag 
PD-L1 ccgaagtcatctggacaagca tctcttggaattggtggtggt 
PUMA gacgacctcaacgcacagta cacctaattgggctccatct 
SIRPA gaacggaacatctatattgtgg catgcaaccttgtagaagaag 
SNAIL gatgaggacagtgggaaa ccaaggaagagactgaagtag 
TNFA acgaacatccaaccttccca cccaattctctttttgagccag 
VEGF tacctccaccatgccaagtg atgattctgccctcctccttc 























Supplementary Figure1. The effect of EZH2 inhibEZH2 inhibition affects human M-DM polarized activation. (A) Human 
monocytes cultured with 40ng/ml of MCSF for 6 days were checked for macrophage differentiation by FACS analysis of CD16 
expression. Representative dot plot is shown (A, left). Human M-DM were treated with 10μM EPZ-6438 or DMSO only (-) for 
24 hours, then core histone proteins were extracted and analyzed by Western blot for H3K27me3 levels. Histone H3 was used 
as loading control. (B, C) Cells were pre-treated with EPZ-6438 (10μM) for 24 hours and rechallenged with EPZ-6438 along 
with (B) IL-4 (20ng/ml) or (C) IL-10 (20ng/ml) for additional 18 hours. Control cells were maintained in standard medium 
supplemented with DMSO throughout the entire experimental period. An additional group of cells were treated with EPZ-
6438 (10μM) for 42 hours and M2-polarized monocytes were cultured for 24 hours and then stimulated with (B) IL-4 
(20ng/ml) or (C) IL-10 (20ng/ml) for the last 18 hours. The expression of selected (B) IL-4 (CD206, CCL17, CCL22, CD209 and 
CD301) and (C) IL-10 (IL10, CD163 and VEGF) inducible genes was analyzed by qRT-PCR. β-Actin was used as housekeeping 
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gene. Normalized RT-PCR results are shown as fold increase over control monocytes (-). Data are shown as mean±SD and are 
representative of one out of four independent experiments with similar results. *P< 0.05, **P < 0.01 and ***P< 0.001 by two-
tailed one-way ANOVA, N=3. (D) Monocytes were pre-treated with EPZ-6438 (10 µM) for 20 hours, and then stimulated with 
LPS (100ng/ml) for the following 4 hours. Control cells were kept in culture in standard medium supplemented with DMSO 
for the entire experimental period. Additionally, a group of cells was treated with EPZ-6438 (10 µM) for 24 hours and a group 
of cells was M1-polarized by LPS (100ng/ml) stimulation during the last 4 hours. Monocytes were analyzed to evaluate the 
expression typical M1-inflammatory genes (TNFA, IL1B, IL6, IL12B, CCL2 and CCL5) by RT-PCR. β-Actin was used as 
housekeeping gene. Normalized RT-PCR results are shown as fold increase over untreated monocytes (-). Data are shown as 
mean±SD and are representative of one out of four independent experiments with similar results.  * P< 0.05, **P< 0.01 and 
***P< 0.001 by two-tailed one-way ANOVA; N= 3 
 
 
Supplementary Figure 2. Mo-TAMs do not alter EMT gene expression by MSTO-211H cells. RT-PCR analysis of EMT gene 
expression by MSTO-211H cells derived from MCS co-cultured with monocytes. β-Actin was used as housekeeping gene. 
Normalized RT-PCR results are shown as fold increase over MSTO-211H cells from DMSO treated MCS (-). Data are shown as 
mean±SD and are representative of one out of three independent experiments with similar results. ***P< 0.01 by two-tailed 
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Tumor Associated Macrophages (TAMs) are the major population of inflammatory cells 
infiltrating tumors, and the crucial orchestrators of tumor-promoting inflammation.  
Accumulating evidence indicates that TAM-centred strategies may serve as promising 
candidates for cancer therapy. Understanding the molecular determinants underlying TAM 
polarized activation represents a crucial challenge to identify new targets for more powerful 
therapeutic approaches.  
As it is well known, the biological activity of the majority of the proteins is regulated at the 
post-translational level1; in particular, the addition of phosphate groups to Serine, Tyrosine, 
Histidine and Threonine residues is a reversible modification that regulates several aspects of 
protein biology. To dissect the molecular pathways underlying the pro-tumoral activities of 
TAMs we decided to analyze the phosphoproteoma of TAMs isolated from murine MN/MCA1 
fibrosarcoma, as compared to resting (ctr), M1 (IFNγ/LPS for 30 minutes) and M2 (IL-4 for 8 
hours) activated macrophages.  
Tripartite motif-containing 28 (TRIM28) emerged as the protein that showed the most 
significant different levels of Ser473 phosphorylation (S473p) in TAMs and M1 macrophages.  
TRIM28 is a member of the Kruppel-Associated-Box Proteins that acts as a co-repressor in 
gene expression2. TRIM28 regulates multiple cellular processes, including pluripotency, cell 
growth and differentiation, neoplastic transformation, apoptosis, DNA repair, and maintenance 
of genomic integrity. Notably, TRIM28 is involved in immune responses by controlling T cells 
3and B-cells development4. Although some experimental studies suggest that TRIM28 could be 
involved in macrophage differentiation and activation5, its role in TAMs has never been 
investigated.  
In our studies we focused on the inflammatory circuits involved in TRIM28 phosphorylation, 
in order to understand whether TRIM28 could be involved in the pro-tumoral functions exerted 
by TAMs. Confocal analyses of MN/MCA1 fibrosarcoma sections, reveal that both TAMs and 
tumor cells express TRIM28 in its Ser473 phosphorylated form, suggesting that TRIM28 could 
play a role in tumor development by modulating both neoplastic cells activities and cancer-
related inflammatory microenvironment. 
In vitro, our results provide the first observation that TRIM28 pSer473 is triggered by several 
M1-inducing stimuli, including inflammatory cytokines (TNFα, IL-1β, IL-6) and plasma 
membrane toll-like receptor ligands (LPS, PAM3CSK4 and Flagellin).  
Given that TLRs play a key role in the initiation of host defense against a wide range of threats 
and can contribute to the development and progression of inflammatory and autoimmune 
diseases and cancers6, we decided to investigate the molecular mechanisms driving TRIM28 
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S473p upon plasma membrane TLRs engagement. We focused on the adaptor protein MyD88, 
which is the first crucial molecule of the transduction pathway for all TLRs, except TLR3, and 
we demonstrated that TRIM28 S473p is totally abrogated in Myd88-/- PECs, thus demonstrating 
that the Myd88-dependent pathway control TRIM28 S473p. 
Ligands of TLRs trigger several intracellular signaling pathways, such as the 
Phosphatidylinositol-3 kinase (PI3K) and the downstream serine/threonine kinases (Akts). 
Besides inflammation, PI3K/Akt dependent pathway plays an important role in the regulation 
of many cellular processes, including survival, proliferation, differentiation and metabolism7,8. 
Furthermore, several growth-factors induce the activation of this signaling pathway which are 
frequently altered in cancers9–11. Noteworthily, it was recently reported that the PI3K-related 
kinases members ATM (ataxia telangiectasia mutated)/ATR (ataxia telangiectasia and Rad3 
related) induce TRIM28 S473p in response to distinct DNA damage stimuli12. Therefore, we 
have hypothesized that PI3K/Akt signalling pathway could be involved in MyD88-dependent 
TRIM28 S473p induction. In contrast, our results reveal that TLR4- and TLR2-dependent 
TRIM28 S473p is independent of PI3K/Akt pathway. 
Another crucial protein in the MyD88-dependent pathway, is represented by p38, a member of 
the MAPKs signaling cascade, involved in the production of inflammatory mediators, including 
TNF-α and COX-213. P38 plays an essential role in regulating cellular processes, especially 
inflammation and it is activated downstream of MyD88 by stimulation of TLR2 and TLR4 14.  
In colorectal cancer cells, peroxide-induced p38 MAPK triggers phosphorylation of TRIM28 
at S473, this event is associated with a more efficient DNA repair and tumor cell survival under 
oxidative stress conditions15. Moreover, infection of human lung epithelial cells by highly 
pathogenic avian influenza virus (HPAIV) strains result in PKR-mediated sensing of viral RNA 
and p38-MSK1-dependent TRIM28 S473 phosphorylation an event that leads to exacerbated 
inflammation and tissue damage16. 
Our data demonstrated that TRIM28 phosphorylation is strictly related with the activation of 
p38 after TLR2 and TLR4 induction.  
In summary, overall in vitro studies demonstrate that TRIM28 S473p is induced by different 
pro-inflammatory signals, including cytokines and microbial products, suggesting TRIM28 as 
a novel regulator of M1-polarized activation.  
Furthermore, our Western blot analyses revealed that also immunosuppressive factor, such as 
IL-10 and PGE2, which tumor microenvironment is highly enriched, drive TRIM28 S473p.  
Finally, we demonstrated that our finding could be relevant for humans, indeed, human 
monocytes in response to inflammatory stimuli, previous studied in murine macrophages, 
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induced TRIM28 phosphorylation, indicating that our studies, in macrophage biology, could 
have translational perspectives. 
Although TRIM28 is involved in immune responses by controlling T cells17 and B-cells4 
development, its function in macrophages differentiation is largely unknown.  
To establish the role of TRIM28 in macrophages and better characterized its impact on their 
activation, we analyzed the transcriptome of murine macrophages, derived from TRIM28LysM-
Cre and TRIM28flox/flox mice, after acute and prolonged treatment with LPS, by RNA sequencing 
(RNAseq) technique. Our preliminary data suggest, as expected, that acute and prolonged 
exposition to LPS enhances the expression of different classes of genes; most of gene inductions 
are exclusively dependent by LPS treatment and only 10% of them are influenced by genotype. 
Collectively our date indicate that TRIM28 modulate macrophage response to both short and 
prolonged LPS treatment by affecting the expression of selected gene transcriptional programs 
associated to activation of adaptive immunity, modulation of multiple metabolic pathways and 
response to oxidative stress including DNA damage response.  
In future, we’re going to better characterize the pathways involved in the acute and prolonged 
inflammatory response, in order to dissect the impact of TRIM28 in macrophages phenotype 
and functional activation. In addition, given that, TRIM28 is crucial of gene transcription 
regulation, acting as a scaffold for different transcriptional factor, we’re going to perform 
analysis of transcriptional binding motifs enriched upstream of genes that are differentially 
regulated by TRIM28 during acute and prolonged exposition to LPS in order to understand how 
TRIM28 could modulate the inflammatory response in macrophages.  
In vivo, to study the circuits involved in cancer-related inflammation, we focus on DSS-acute 
colitis model and DSS/AOM CAC model. Our data showed that in DSS-acute colitis model 
TRIM28LysM-Cre mice worsens intestinal inflammation in response to the treatment, but in 
contrast, despite the increased inflammatory response, lack of TRIM28 in myeloid cells seems 
not alter tumor multiplicity in AOM/DSS-induced CRC, in order to clarify this data, we’re 
going to perform histologically analysis on CRC lesions, evaluating the colitis and dysplasia 
grade, immune infiltrated, apoptosis, proliferation, stemness, DNA-damage and EMT process.  
Given that in non-immune cells, TRIM28 has been extensively studied in different cancers, in 
which, depending on the type, it can exert pro- or anti-tumoral functions18 we explored the 
impact of inflammation on TRIM28-dependent DNA damage response and consequent 
susceptibility of intestinal epithelial cells (IECs) to undergo neoplastic transformation. Taking 
advantage of mice lacking of TRIM28 in IECs and we discovered that DSS-acute colitis model  
IEC-specific ablation of TRIM28 worsens intestinal inflammation in colitis and surprising in 
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AOM/DSS model, mice carrying IECs specific ablation of TRIM28 developed less number of 
tumor lesions in colitis-associated CRC, demonstrating that the ablation of TRIM28 in IECs 
confers resistance only under inflammatory conditions.  
Our results suggest that TRIM28 modulates CRC development in both cell-specific and disease 
stage-specific dependent manner.  
This unexpected result obtained in TRIM28VillinCre brought us to perform the single cell 
transcriptome analysis of immune infiltrated and epithelial cells during the acute phase of 
colitis, that represents the elimination phase and when tumors were formed (escape phase), 
when CRC lesions were formed.  
These preliminary results gave us an overview of the cellular population expression in the 
inflammatory condition and during tumor development, defining the difference between the 
two phenotype. In particular, in acute colitis, in TRIM28VillinCre mice had an increase in the 
percentage of NK, CD8+ and CD4+ T cells, to confirm they higher inflammatory status as 
compare to TRIM28floxflox mice. Whereas, in tumors TRIM28VillinCre mice have a higher 
expansion of B cells clusters, that could be related with a good prognostic value, as 
demonstrated by different clinical studies, in which patients whose tumors are highly infiltrated 
by B lymphocytes (CD20+) have a significantly improved disease-specific survival19,20. The 
most interesting results emerged in the distribution of myeloid clusters, indeed, in 
TRIM28VillinCre mice the presence of the tumor infiltrating neutrophils (TANs) and TAMs was 
considerably decreased in CRC lesions, as well as a reduction of colon cells expressed EMT 
genes. 
Collectively these results suggest that lack of TRIM28 in IECs impact on immune cells 
composition during the transition from colitis to cancer along with mild effects on the expansion 
of neoplastic cells with an EMThigh gene signature and accumulation of Goblet and Paneth cells 
under colitis stage.  
Further analyses are essential to better understand the mechanism involved in TRIM28VillinCre 
protection, indeed, starting from these data we’re performing gene ontology analysis (GO) and 
ingenuity pathway analysis (IPA). Moreover, by immune fluorescence analysis of γ-H2AX, a 
biomarker of double strand break damage21, we wanted to investigate if the absence of TRIM28 
could be led an increase of DNA damage focis, hypothesizing that the impair capacity to repair 
DNA double strand breaks would result in increased cell death, avoiding the surviving of 
transformed neoplastic cells. 
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Furthermore, in vitro, we’re studying the role of TRIM28 in DNA damage-repair under 
inflammatory conditions, taking advantage to MC-38, murine CRC cell line, knockout for 
TRIM28, that we have generated by using CRISP/cas-9 technology.  
In conclusion, overall our in vitro and in vivo results bring us to consider TRIM28 as a novel 
regulator of cancer-related.  
It is well known that TAMs largely express an M2-skewed phenotype, associated with 
suppression of adaptive immune functions and promotion of angiogenesis and invasion. 
However, due to the functional plasticity of macrophages, these cells can also express an M1 
phenotype associated with anti-tumor activities22. Hence, ‘re-education’ to potential anti-tumor 
effectors may represent a therapeutic approach that will hopefully increase the efficacy of 
current anti-tumor therapies. The development of TAMs-centered therapeutic strategies 
requires the elucidation of the molecular basis of their phenotype.  
Accordingly, to study the impact of TAMs on cancer-therapy, we focus our attention on 
malignant pleural mesothelioma (MPM), a rare and aggressive tumor, characterized by long 
latency period and a strong resistance to any therapeutic strategy. MPM has been causally 
associated with asbestos fiber inhalation, this process activates lung macrophages to clear this 
exogenous material, which unfortunately is impossible to phagocytize due to its big size. 
Macrophages increase reactive oxygen species production and inflammatory cytokines, leading 
to a chronic inflammatory state able to trigger a malignant transformation of cells related23. In 
first phase there is a prevalent inflammatory M1-like TAM population, while during MPM 
progression M2-like TAMs support immune escape and tumor development24–26. In vitro 
studies have demonstrated that monocyte-derived macrophages from healthy donors 
conditionated by pleural effusion of MPM patients, they upregulate the expression of IL4, IL13, 
IL10, VEGF, TGFβ, typical M2 genes and express immunosuppressive property, down 
regulating the proliferation of T cells (trough the production of PGE2)26. Clinical studies have 
showed that macrophages represent the major population of inflammatory cells present in 
MPM, and the driving force of tumor progression, to the extent that the abundance of CD163+ 
TAMs is correlated with poor prognosis in MPM patients. In addition, TAMs are central 
orchestrators of immunosuppressive TME, in particular they contribute to increase Treg 
proliferation27.  
Furthermore, TAMs play a crucial role in dictating the efficacy of different therapies, therefore, 
we decided to evaluate their impact on MPM cell responsiveness to EPZ-6438, a new epigenetic 
modulator that has recently entered in trial for MPM patients due to its anti-proliferative effects 
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on tumor cells28. To this purpose, we set up a 3D in vitro system based on spheroids of biphasic 
MPM cells (MSTO-211H) and human monocytes.  
At first, our data indicate that MPM cells are able to attract monocytes, they selectively 
increased the expression of chemokine genes, particularly CCL-2, that is a major driver of 
TAMs accumulation in solid tumor and a significantly elevated biomarker in both pleural 
effusion29 and serum of MPM patients30,31. Moreover, monocytes can efficiently migrate inside 
the MPM spheroids, where they differentiate into macrophages and acquire a TAM-like 
phenotype in terms of expression of M2 markers, immunosuppressive molecules, monocytes 
recruiting chemokines and inhibitory immune checkpoints. Overall, these results demonstrate 
that we have generated a reliable 3D MPM-monocytes spheroid model that recapitulates in vitro 
both monocytes recruitment in tumor, and the functional differentiation towards an 
immunosuppressive and pro-tumoral M2-like phenotype acquired by TAMs in the TME of 
MPM.  
The antiproliferative activity of EPZ-6438 on MSTO-211H spheroids was confirmed by 
confocal analysis, that showed a significant reduction of spheroid volume and suggested the 
correlation with senescence induction, through p21 activation, we investigated whether EZH2 
inhibition could alter the capacity of MPM spheroids to recruit monocytes.  
Our results show that EPZ-6438 treatment induces an increase in mRNA levels of chemokine 
genes, such as CCL2, CCL5, CXCL12, MCSF and VEGF, this is particularly pronounced after 
96 hours of treatment, confirming that EPZ-6438 has a significant impact on the regulation of 
genes encoding for chemokines and growth factors related with monocytes recruitment and 
maintenance. Once again suggesting that a prolonged treatment might increase TAM 
accumulation. 
To determine the chemo-attractive activity of EPZ-6438 on monocytes recruitment in MSTO 
spheroids, we evaluated the effect of TAMs on MPM cell responsiveness to this treatment. As 
many authors have described, TAMs influence tumor growth, not only creating an 
immunosuppressive TME, stimulating tumor cells proliferation and survival, but also impairing 
the effect of antitumoral therapies.  
Unfortunately, our analyses have demonstrated that this promising anti-tumor effect is 
completely reverted in the presence of TAMs, confirming in an in vitro system that the 
abundance of TAMs could impair antitumor treatment and favor tumor progression. 
TAMs enhance proliferation and consequent tumor growth, as demonstrated by the drastic 
increase of spheroid volume and the significant increase of cells proliferating rate; indeed, 
CSFE-proliferation assay have shown that TAMs are able to induce a significant decrease in 
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the CSFE mean of fluorescence of MSTO-211H spheroid cells, that is inversely proportional 
to their ability to proliferate. Furthermore, RT-PCR analysis revealed that p21 levels in TAM 
co-cultures are drastically decreased even in presence of EPZ-6438 treatment. P21 is an 
essential factor implicated in tumor suppression, but also involved in cellular senescence32. Its 
activation triggers momentary G1 cell cycle arrest or leads to a chronic state of senescence, 
acting as genome guardian33, these data confirmed TAM ability to counteract EPZ-6438 
efficacy.  
The strong pro-tumoral effects of TAMs, in presence of EPZ-6438, could also be exacerbated 
by the high number of infiltrating TAMs in EPZ-treated spheroids, as compared to control-
spheroids, that contribute to completely revert the efficacy of the treatment. 
Further, to demonstrate the key role exerted by TAMs in cancer progression, we evaluated in 
our system the ability of MSTO cancer cells to acquire a migratory phenotype.  
In general agreement with our previous findings that spheroid-infiltrating monocytes acquire a 
pro-tumoral phenotype, MSTO-211H spheroids derived from co-cultures presented an increase 
of spreading cells around the spheroid, as compared to control or EPZ treated spheroids; 
confirming once again that the presence of TAMs is able to contrast EPZ-6438 anti-tumor 
effect, favoring tumor cells migration and diffusion.   
Trying to dissect the molecular pathways involved in the acquisition of this migratory 
phenotype, we performed RT-PCR of EMT genes, this analysis revealed that in MSTO-211H 
spheroids, TAMs promote a selective induction of matrix metalloproteinase-9 (MMP-9), a 
fundamental factor for invading surrounding healthy tissues, thereby increasing cancer 
malignancy and decreasing survival in MPM patients; to the extent that it is considered a 
potential novel biomarker in mesothelioma34,35. Taken together, our data underline the 
fundamental TAMs contribution in tumor progression and diffusion and their ability to 
negatively affect anti-tumor therapy. 
Because TAMs provide a secondary source of cytokines and chemokines, which could affect 
immunosuppression, tumor growth, cell survival, angiogenesis, and metastasis, we wanted to 
investigate possible influences of the EPZ-6438 treatment on tumor promoting activities of 
monocytes. We performed RT-PCR analysis to evaluate the impact of EZH2 inhibition on M2 
and M1-polarized activation of monocytes and M-DM. EPZ-6438 in monocytes and MDM did 
not induce any relevant alterations in the expression of genes under IL-4 and IL-10 regulation.  
Indicating that EZH2 inhibition does not influence the polarization of human monocytes and 
MDM towards a cancer promoting M2 phenotype. 
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Therefore, in order to clarify the possible effect of EPZ-6438 on monocytes and MDM 
polarization, we investigated whether EZH2 inhibition could influence the capacity of 
macrophages to undergo M1-polarized activation, surprisingly, RT analysis revealed that EZH2 
inhibition in monocytes and MDM induced a significant increase in the expression levels of 
typical inflammatory genes. These results suggest that EZH2 inhibition in human monocytes 
and MDM selectively enhanced their responsiveness to M1-polarizing signals, that could 
influence/increase their pro-inflammatory, pro-immunity and anti-tumor activity.  
Furthermore, to better understand the impact of EZH2 inhibition on TAMs, we analyzed gene 
expression of monocytes derived from MSTO-211H spheroid co-cultures in presence of EPZ-
6438, and we observed an increase in chemokines levels confirming EPZ’s ability to induce 
myeloid cells recruitment and a slightly, but not relevantly, increase in typical M2 genes. 
Suggesting that the total effect of EPZ-6438 treatment will reasonable enhance the protumor 
activity of Mo-TAMs. 
Immunotherapeutic strategies aim to re-program TAMs in M1 effectors have been found 
effective in several preclinical models of cancers and are under evaluation in clinical studies 
for different types of human cancers36,37. In order to propose this strategy also for MPM therapy,  
 we started to investigate the cytotoxic activity of M1-polarized monocytes on different MPM 
cell lines, the biphasic MSTO-211H and epithelioid BR-95 MPM cells, grown in a mono-layer 
standard 2D conditions. Overall, our data suggest that M1 monocytes produce soluble factors 
able to kill both bi-phasic and epithelioid MPM cells independently of the cell subtype.  
Given that our previous results have described the antiproliferative effect of M1 monocytes on 
2D MPM cells, and that RT-PCR analysis of monocytes stimulated with LPS, previous pre-
treatment with EPZ-6438, have revealed an increase expression of M1-inflammatory genes, we 
wanted to investigate if M1 monocytes could exert a cytotoxic activity, improving the anti-
tumor effect of EPZ-6438, also on MSTO-211H spheroids. 
Although, spheroid-cocultures treated with EPZ-6438 showed a reduction in spreading cells 
area as compared to control, the presence of monocytes, whether M0- or M1-polarized, 
completely alter their antitumoral effect.  
This leads us to the conclusion that, M1-polarized monocytes do not affect MSTO-211H cell 
viability in a 3D system, and to confirm the complexity of spheroid as compared to monolayer 
cell cultures, lacking the ability to mimic many features of solid tumors. This phenomenon 
could be related to MSTO-211H cells ability to release factors in spheroids that protect cells 
inside this complex 3D system and contrast the M1 cytotoxic effect. 
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Furthermore, as in vivo, macrophages can skew their phenotype from M1 to M2, this could also 
happen in the complex structure: M1 monocytes, corrupted by tumor cells, could revert their 
cytotoxic activity and acquire pro-tumoral and immunosuppressive properties.  
This result may suggest that the 3D organization better mimics the organization of a solid tumor, 
for its complexity could contrast and revert M1-cytotoxic activity, suggesting that either the 
complete depletion of TAMs or the inhibition of their recruitment to tumor site could be the 
better strategy to improve EPZ-6438 action, as demonstrated by Miselis and colleagues in an 
orthotopic murine model of diffuse malignant mesothelioma29.   
For future development, it could be very interesting to investigate the molecular circuits 
involved in M1-monocyte reprogramming in the complex structure of the 3D spheroids, and 
how this system with its structure, metabolites could interact and affect the functions of the 
immune cells.  
Overall, our findings point out a dual activity of EPZ-6438 in MPM. Since the beneficial anti-
proliferative effects of EZH2 inhibition in MPM cells are counteracted by the accumulation of 
pro-tumoral Mo-TAMs, strategies of macrophage depletion might enhance MPM 
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